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-Foreword 
by  Commissioner Professor Pinheiro 
HIV is  one qf the major social issues  qf the end of  this  cen-
tury.  Despite a major riffort of  the developing countries, sup-
ported by the international community over the last 9 years, 
the epidemic  continues  to  spread  rapidly,  especially  in  the 
developing world. 
Already in 1987 the European  Union  launched a support 
programme  to  limit the spread of  the epidemic and mitigate 
its  social  impact.  Interventions  developed  at  both 
Community and bilateral levels si11.ce then make the Europe 
qf  the  15  the  most  important  donor  in  the field  cif 
HIV I AIDS actions  today.  In  order to  mobilize the highest political support  and  to 
improve the tjfi.cacy  of our  technical and financial support,  coordination  between  all 
mernbers  qf the Community  is  being improved and  the Council of Ministers  adopted 
an  important  resolution  on  Hl VI  AiDS actions in the developing  world.  This resolu-
tion  drjines  the European  strategies  and principles for  the next 5 years. 
One of  the priority strategies in. countries  where  the epidemic is already widespread is to 
ensure the sqfety qf blood  donations.  ince  J  987 the Community, with  its partner s,  has 
accumulated  an  experience  and  developed  an  approach which was  discussed in a first 
workshop  in  March  1991 and  reviewed at a second sqfo blood workshop  in j uly 1994. 
The results qf this workshop  are  brought together in this new edition of  the report which 
explains the strategy and shares some of  the crucial lessons from  the ongoing experiences. 
I hope that  this report will give readers  a measure of the work  already  undertaken and 
motivate many  to  organi  e further support  in  the most tjfi.cient way possible to counter 
this social and public health  threat. 
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-Brief overview 
In  the introduction to  the book  the EC's policies, strategies  and methodologies  concer-
ning saf e blood in developi11g countries  are brirfly  reviewed. 
The first  chapter proposes  how  to  best  organize saf e blood  in  a country  taking  into 
account its different components.  A  case  is  made for consideri11g  the Blood Tranifusion 
Service  as an  entity by  itself  rather than a secondary  medica./  activity. 
Chapter two shares  thoughts and experiences  about  the recruitment and  the selection 
(if blood  donors. Too  often donor  recruitment is lift to  organisations without any policy 
or capacities while it should be an  integral part of the strafe 'Y· Sometimes  blood  dona-
tions are forced or  bought but  there are numerous reasons why this should be avoided. 
The chapter  also discusses  issues  such as the right of donors to  know their  test results 
and to  be fully iriformed. Some succesiful and encouraging examples  in  the third  world 
have shown that it can  be done. 
Chapter three discusses  the concepts, dcifinition.s and parameters  for blood screening pro-
cedures for irif ectious  disease:,~ an  aspect of  blood saf ety that has very  m.uch come to  the 
foreground since  the HIV  I A IDS epidemic has eme1 ged.  In  the developed world public 
opinion and consequently, political  bodies,  are demanding foolproof blood saf ety What is 
being done in  de1 1eloping countries  ? 
Chapter four reminds the reader about  the preparation  and  the use  of blood  compo-
nents in  the context of  blood saf ety. 
Chapter five develops the main indications for the use cif blood and blood products and 
the actual rnanagement of  blood tranifusions. This chapter is a reminder to  all about the 
potential  risk  to the patient and  waste (if the donation  if precious blood  is  not  used 
appropriately Examples  cif guidelines  are included. The implementation of  those (!uide-
lines  should be monitored carefully so as not  to  be lift to form  the weakest part of the 
chain in scife  blood provision. 
Chapter six introduces  the issues around equiprnent, storage, consumables and buildings 
as related to  saf ety cif blood provision. 
--
Chapter seven  on  safe  blood  management  indicators is a new  chapter  and  has been 
developed  in  order to facilitate  monitoring and evaluation of  safe blood support in  deve-
loping countries. 
Chapter eight discusses  quality assurance  and auditing in  relation  to  safe  blood. 
Further work  on costing and financing  has  been included itt chapter nine. 
Training  and human resource  development  is reviewed in  chapter ten. 
The new, and final chapter eleven raises ethical considerations and orientations around 
blood safety, opening up  a crucial human rights  debate and discussing some of  the expe-
riences  and some rif the instruments  that can  support  the  application  of the ethical con-
text. INTRODUCTION 
In  1986,  the  international  community  reacted  to  the  new  and  then  little 
known  HIV  I AIDS epidemic  by  setting  up, under  the World  Health  Orga-
nisation (WHO), a global programme on AIDS. Around the same time, the late 
Lorenzo Natali,  Vice President of the European Comm.ission, invited all ACP 
(African, Caribbean and Pacific)  states  who had signed  the 2nd Lome Con-
vention on European aid  to developing countries, to take part immediately  in 
an ECI  ACP HIV  I AIDS programme. Almost all ACP states  responded and 6 
months later,  the programme was  extended to all  developing countries. 
Over the last years, a process  of collaboration between  the Commission and 
the EC Member States led to the development of common HIV  I AID  po]j-
cy  principles  and strategic priorities. The following policy  principles, guiding 
all  HIV  I AIDS activities, were adopted: 
l. Adaptation  to  risk  environrnents.  Interventions should  focus not only on the 
behaviour of individuals  that puts  them  at  risk, but also  on  the social and 
structural  determinants of exposure  to  risk. This  is particularly  in"lportant 
when dealing  with specific  target groups such  as  women, children, young 
people, people in high-risk situations. 
2.  Gender sensitivity and specificity.  Analysis,  planning and  intervention  must all 
show special sensitivity and specificity to gender. Long-term objectives such 
as  the  political  and  economic  empowerment, formal  education  and  legal 
protection of women must go hand-in-hand with short-term interventions 
focused on specific groups of women and men. 
3. Social  learning  and human dignity. History has  shown that m  asures  based on 
coercion  of individuals  are  counter-productive.  They  drive  epidemics 
undergound and make interventions unsustainable. So it is no use just trying 
--
I11t rodu c t io n 
to identifY  the individuals at risk or infected by H IV, and then isolating them 
from their social  environment. Instead, there  has  to  be a process  of social 
learning, the aim of which is to enable individuals and society to avoid the 
risk  of infection  wherever possible,  and  to  prevent  discrimination  against 
those already infected through respect for their human rights and dignity. 
4. Empowerrnent  and  responsibility. Most  HIV  I AIDS  activity  cannot  be  just 
administered.  It needs the motivation and support of individuals  and com-
munities. They in turn have to have the power to take responsibility for their 
own  behaviours,  risks  and  choices. Similarly, governments  and  others  in 
positions of power have to take  the responsibility for limiting the risks run 
by those over whom they  have  authority. 
5.  Integration in  a wider framework.  HIV I AIDS work  must  be  integrated  with 
other community activities, other health and education problems and other 
medical care strategies, at least where there are organisations and activities 
in these  other areas. Integration also  requires  a national  HIV  I AIDS policy 
which includes  all  ntajor participants, a multi-sectoral approach  that invol-
ves  all  the  main  departments of state,  and open  policy  dialogue  between 
public and private sectors. 
6. Adaptation  to  the stage  cif the epidemic and  rapid response. The  HIV  epidemic 
takes  time  to  spread  over  a  region, and is  at  different stages  in  different 
regions of the  world. So  responses  to HIV I AIDS also  vary  over time. But 
denial, and  political and  administrative  delays  have  often  meant that  HIV 
prevention  campaigns,  needed  before  the  epidemic  becomes  widespread, 
have  come too late. So the timelag should be shortened, and every response 
should come at an appropriate stage in the progress of the epidemic. 
The strategic priorities chosen for European action are: 
to minimize both  the spread of the epidemic and the discrimination against 
those infected 
to strengthen the health sector to cope 
to n1.easure and reduce the social and economic impact of the epidemjc 
to promote better scientific understanding, both biomedjcal and socio-eco-
noi11Jc. llltrod11ctioll 
The second strategy, to support the health sector to  cope with the epidenlic, 
includes support for safe blood interventions. 
Th  EC has  d  voted  great  efforts  to  safer  blood  supplies,  mainly  on the 
African continent, and to a Jesser extent in Latin Am.erica  and the Caribbean 
and, to date,  has  supported safe blood programmes  in a total of 29  countries, 
ranging  from  Cameroon  to  Guyana,  Mexico  and  Zimbabwe,  for  a  total 
amount of 35 million ECU. 
In industrialized countries, acquisition of  HfV infection through transfusion 
of infected  blood is now virtualJy  nil, thanks to  universal screening of blood 
before  use.  Moreover, screening adds onJy about 5 % to  the cost of a unit of 
transfused blood. 
But in the developing world, between 5 % and 10 % of HIV infections are 
stilJ  due to transfusion of  infected blood. In Afi·ica, most countries lack the type 
of Blood Transfusion Service needed  for  comprehensive  screening of blood. 
Indeed, supply  of safe  blood  has  frequently  b  en  neglected  in  developing 
countries. On the one hand, blood transfusions are often used  in an  attempt to 
save  life;  on the other hand, the blood may  not be safe, and  to  make it safe  is 
relatively more  expensive  than  in  industrialized  countries  because  it implies 
instituting a compr hensive safe blood strategy. 
However, the pressure now to make it safe  from HIV can be summed up in 
one simple statistic. The efficiency of HIV transmission through sexual inter-
course  (vagina] and anal) is between 0.1 %and 1 %. But the efficiency of  trans-
mission through blood transfusion is over 90 %. In other words, infected blood 
is lethal. 
For the m  dicaJ service, there is yet another dimension: in blood transfusion, 
the recipient often cannot individually decide and therefore the responsibility 
lies  entirely with the medicaJ services. 
So  in developing  countries,  HIV has  raised  complex issues  about strategy 
and objectives, organisation  and  management, law  and ethics,  equipment and 
financing for the provision of  safe  blood. 
A basic tenet of the safe blood policy of the Commission's  programme is that 
simple testing for F-liV  is not enough and that provision of  safe blood in itself 
is  a life saving act. Other planks to the policy are: 
blood donors need to be selected m.ore carefully, and then actively retained 
blood donors should be voluntary, not paid, to avoid (for example) infected 
people  selling  blood  under  different  names  in  different  places  to  make 
money  -I11trod11ctio11 
-
blood and blood substitutes  must be better used and available 
prevention or earlier detection of other diseases reduces  the need for blood 
transfusions and therefore the risk of infection by this route 
screening of blood for  other diseases  as  well  as  HIV is  a basic requirement: 
failure to do this could render the whole programme absurd 
sophisticated  testing laboratories  are  of little  use  if collection of blood  IS 
badly organized and produces either too little blood for testing or too many 
infected  units because  donors have  been badly selected, or fails to produce 
enough  blood  for  a reserve supply so  that, for  emergency  operations, un-
tested blood still has  to be used. LIST OF EC INTERVENTIONS 
IN THE AREA OF SAFE BLOOD 
IN DEVELOPING COUNTRIES 
The EC has  provided technical and financial support to 47 safe blood projects 
in 29 developing countries for a total amount of  35 million ECU. Support for 
safety of blood was  given in the past to: Burundi, Chad, Costa l:Uca, Djibouti, 
Dominican R epublic,  Equatorial Guinea, Gabon, Grenada,  Honduras, Mali, 
Mexico, Niger and Zaire. 
At present further safe blood interventions are ongoing in: 
Angola 
[n an initial phase EC support was given to strengthen safe  blood activities  in 
the  blood transfusion centres  at provincial  level.  Following the period of civil 
war  these  activities  are starting  up again  via  the strengthening of the  role of 
the  National Blood Transfusion Service in Luanda  as  well  as  the  services  at 
provincial level. 
Benin 
The EC supports government measures  to strengthen the facilities  and capa-
bilities  of the  public  health services  in the  southern departments of Benin. 
This includes  support for  the developn"lent of a national blood policy  of the 
Ministry of Health, the creation or upgradjng of regional  blood banks in the 
three  departments, Atlantique, Mono and Oueme, and  the  training of health 
staff in charge of blood transfusion in Benin. 
Cameroon 
Support was  given to develop a national policy and to strengthen two region-
al  blood  transfusion centres  in Yaounde  and in Douala, the  country's  main 
urban centres. These centres  were refurbished and blood collection, screening 
and storage facilities and procedures were improved. Blood donor recruitment 
was expanded  and reoriented towards blood collection  among  students and 
enterprises. 
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Congo 
The obj  ctive of EC support is to assist  the government in  the developn'lent 
of a national blood policy and to establish a regional blood transfusion centre 
in Pointe Noire, the country's second largest town, to coli  ct, test and supply 
safe  blood for  the the hospitals in town and the region around. The premises 
were  rehabilitated, staii has  been  trained, equipment and supplies  were provi-
ded. A national legislation on voluntary blood donation and blood transfusion 
was  adopted. 
Guinea  Conakry 
Th  goal ofEC support to safe blood activities in Guinea Conakry, carried out 
with the  support of the  Belgian R ed  Cross  Society, is  the  installation of a 
National Blood Transfusion Service in Conakry as  weU as  blood banks in  the 
prefectures  and the training of the personnel of these structures.  onsiderable 
eiiorts have  been made regarding the selection of blood donors among school 
students,  th  military and the private sector. 
Guyana 
With EC support, a National Blood Transfusion Service has  been set up  with 
a  blood  bank  and  testing  laboratory  for  HIV  and  other  infections  in 
Georgetown,  using  voluntary  donors. Testing is  done  on  blood  from  New 
Amsterdam, Linden and Suddie hospitals. 
Haiti 
With  the  technical  support of the  French  R ed  Cross  Society, the European 
Commission supports the safe blood activities  established by  the Haitian  R ed 
Cross Society as  well  as  by  the public hospitals in the country. 
Ivory  Coast 
Following  support given  to  the  sa fe  blood activities  of the  National Blood 
Transfusion Service in Abidjan  and  the R egional Blood Transfusion Services 
in  Korhogo and Bonake, coverage  has been extended to ali  transfusion servi-
ces in the country's  hospitals. The role played by the NETS and the RBTS in 
training and sup  rvision is crucial for this development. 
--
List  of EC  int erllentioll s  in  th e  area  of safe  blood 
Lesotho 
Support is given to the national health budget to sustain the safe blood servi-
ces which have been put in  place, with particular attention for the promotion 
of regular donations of blood by  voluntary  donors. 
Madagascar 
EC support consists  of strengthening the  National Blood Transfusion Service 
in order to  ensure  blood provision for  the  hospitals in Antananarivo  (needs 
anwunting to 8,000 blood units per year). Support is also provided to strength-
en  its  role  of supervision, training and  participation in  the  definition  of a 
national blood transfusion policy. 
Mauritius 
EC support is provided  for  essential  equipment for  blood safety,  supervision 
and quality control, and the improvement of the utilization of blood. 
Rwanda 
EC support Uoint action with Belgian Cooperation and Belgian R ed  Cross) 
has  strengthened  the  screening  capacity  of the  National  Blood Transfusion 
Service and the organisation of  counselling. Following the political conflict all 
support has  been suspended but hopefully will resun1e soon. 
Sao Tome 
The EC supports the  rehabilitation  and  reorganisation of the  blood bank of 
the nu in governm.ent hospital of Sao Tome by  training of laboratory techni-
cians and the provision of  equipment and laboratory supplies. The provision of 
safe  blood  to  health  centres  outside  the  capital  is  envisaged  for  the  near 
future. 
Uganda 
EC  assistance  enabled  the  Ugandan  government  to  develop  a  nationwide 
blood  transfusion  service.  Following  the  rehabilitation  of Nakasero  Blood 
Bank (NBB) in Kampala and the reorganisation of  donor recruitment and safe 
blood supply to hospitals in and around the capital, four regional blood banks 
and  two collecting  and  screening  centres  were  created,  operating  under  the 
direction of the Uganda Blood Transfusion Service based at NBB. The UBTS 
collects,  tests and  distributes  to  the  country's 92  hospitals all  the  blood  and 
materials  needed  for  transfusion  of patients  in  Uganda.  A  national  blood List  of EC  i11terl!elltio11s  in  th e  aJ•ea  of safe  blood 
policy  has  been  developed  and  standard  procedures for  donor recruitment, 
selection and  counselling and  for  all  blood  tests have  been  introduced in  all 
hospitals through training of health staff and quality  assurance. 
Zarnbia 
The EC supported Zambia to establish a national blood transfusion service, to 
reactivate voluntary donor recruitment and to improve safe blood facilities and 
practice throughout the country. A national blood policy has  been formulated 
within  the government's  health system reform. Th  ZNBTS is directed by  a 
core  team  and  consists  of two  central  blood  centres  serving  Zambia's  most 
populated  r  gions around Lusaka  and  the  Copperbelt, and  7  regional  blood 
centres  which  serve  the  major provincial  hospitals  and  provide  training  and 
support for the staff responsible for blood transfusion at the district hospitals in 
their area. 
Zirnbabwe 
The  Zimbabwe Blood Transfusion  Service decided  to  extend  donor recruit-
ment and the  provision of safe  blood to hospitals by  creating regional  blood 
transfusion  centres.  So  the EC assisted  to  create  new  transfusion centr s  in 
three  regions  (Gweru, Masvingo  and  Mutare),  to  improve  capacities  at  th 
Harare centre through support for staff training, transport and laboratory sup-
plies, and to develop a policy for blood use. 
-Chapt e r  1 
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Introduction 
Blood tranifusions are given in every country where there is erner gency m.edica.l care. Thus 
at least some resources  do  exist for that purpose.  However, in many developing countries, 
public health problems  are serious  and  ongoing public health  rriforms are not  taking  the 
!.pecific problems  cif saf e blood  into  account. This  is unfortunate since  by  better organi-
zing safe  blood,  higher tff ectiveness  could  be achieved. 
Key factors for  the creation  cif an  tffective  blood tranifusion service  system are: accep-
tance of tra.nifusion  medicine as a distinct sector in  the health  care systern,  establishment 
cif a nationa.l  blood policy,  well  trained and  dedicated professionals as well  as broadly 
based national  advisory  bodies. Indeed,  tranifusion  medicine  is not  only  collecting  and 
testing of  blood, it is a major therapeutic art requiring: recruitment and retention of  blood 
donors, blood  collection,  laboratory  testing,  blood processing  and  storage as  well  as  trai-
ning of  physiciam  in  appropriate  use of blood. A  discipline cif such  diversity  must  be 
recognized as a distinct  entity in  the health  system.  It  is often  lack  cif this recognition 
that contributes  to poor organisation and functioning of  blood tra.nifusion services (BTS). 
The organisation and degree of  development cif the BTS should be part of  the nation-
al  health  plan.  Ultimately,  the governrnent bears  the respomibility for  organizing and 
backing  up  the BTS system regardless  of the organisation  which is responsible for  the 
implernentation.  Safe blood  implies  the respomibility  to  be assum.ed either by  national 
health authorities  or to  be partly delegated to  a para-statal agency or NCOs such  as  the 
Red Cross  or the  Red Crescent. 
As illustrated in Figure 1A and 1B, a national blood policy has been adopted in  81  % 
cif the developed but only  in  64 % of the developing and  in  32 % of the  L east  develo-
ped countries  which  have reported  to  WHO. Since only  58 % cif the developing and 
66 % of  the L east developed countries  have  reported,  it is  conceivable that in reality even 
fewer  countries  in  the developi11g world  have  a national  blood policy.  (Figure  1A). A 
national blood tranifusion service comrnittee exists  in  47 % cif developing and  in  42 % 
of  least developed countries  reporting to WHO, and 50 % and  60 %, respectively,  have 
a national directo1c  In  48 % cif the least developed m1.d  in 46 % cif the developing coun-
tries, which  reported to WHO, the BTS are hospital based usually meaning also  lack of 
national coordination  (Figure  1B). 
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Figure  1A 
Percentage  of developed, developing  and least  developed countries  (which 
have reported to WHO), which have a national director, national pol£cy and nation-
al advisory  committee  for Blood Transfusion Service. 
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Figure  1B 
Percentage  of developed, developing and  least  developed  countries  (which 
have  reported to WHO), which have either a national,  regional  or  hospital tram-
fusion  system  or  a combination  of these. (Less  than 10 % of countries  did not 
report). 
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1. Safe blood policy and strategy 
In a safe  blood policy and strategy for a given country, several levels of  respon-
sibility and activity should be considered as  proposed and illustrated in Figure 
2. This chapter will try to propose the baselines of  an organisation likely to be 
applicable in the field in any country, and which could be helpful for decision 
makers to implement an effective safe blood strategy. The three proposed levels 
are, of  course, schematic; they represent in fact three levels of  responsibility that 
have to be adapted according to the local environment. For each level, we will 
define: the responsibility, the purpose, who is  in charge and with what means. 
-
Figure 2: Levels of  responsibility to be considered for safe blood policy 
and strategy in  developing countries. 
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1.1. Level  1:  N ational  Blood Transfusion Advisory 
Committee 
In the proposed scheme, the Ministry of Health  is responsible for the highest 
decision level  and  defines  both Safe  Blood strategy  and policy.  It  is also  the 
MOH's responsibility  to  find  financial  support. In practice,  to  achieve  these 
tasks, it is  recommended to the MOH to constitute a National Committee of 
Blood Transfusion. This National Conunittee has  to formulate the policy in a 
written document that will be integrated as  legislation, regulations or recom-
nl.endations, in agreement with the national health legislation. C hapt e r  ·t  •  Orgauisation  of safe  blood 
The members and the objectives of this National Comntittee as  well  as  the 
po]jcy content are described briefly  below: 
1. 1. 1.  National Blood Tranifusion Advisory Cornrnittee 
Mem.bers: 
1. Ministry of Health: (or representatives) 
including heads of the several health departments concerned 
2. National Blood Transfusion  ervice (representatives) 
3. Blood prescribers  (including hospital and faculty  representatives) 
4. Blood Donor Associations 
5. Others:- Press 
- Legal representatives 
- Ministry of Finance 
- Medical  or scientific associations 
- R epresentatives of the Military Medical Services 
- Ethical committee 
Objectives: 
- to formulate pobcy and design strategies  for Ministry of  Health's  approval 
- to promote voluntary non-remunerated blood donation 
- to ensure that ethical issues  concerning both the donor and the recipient 
are  respected 
- on request  of the  Ministry  as  well  as  on its  own initiative,  advise  the 
Ministry about issues  regarding safe  blood. 
1.1.2. Policy 
The main principles  on which the safe blood policy should be based must take 
into account the essential ethical principles  (informed consent, confidentiality, 
medical  secrecy  ...  )  (see  chapter  11:  Ethical  orientations  for  blood  safety)  and 
encourage  voluntary and non-remunerated blood donation. 
Provided  these  principles  are  respected,  each  government decides,  in  the 
light of  the country situation (financial, epidemiological ... ), how to best adapt 
the safe  blood policy. 
The policy content should give clear specifications and guidelines about the 
main activities of blood transfusion i.e. 
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- donor selection 
- blood collection 
- testing procedures 
- processing and storage of blood 
- use of blood 
- quality assurance 
1. 1.  3.  Instruments 
The  transfusion policy  could  be  written as  a legal  text or any other  form of 
regulation or recommendation. The  need for  legislation and/  or regulations is 
obvious, but it is a matter for the country concerned to select the most approp-
riate form. 
1.2. Level  II: Direction of Blood Transfusion  Services 
-
The expertise level (see  Figure 2), is responsible for all  technical  expertise. This 
level of responsibility can be left  either to a governmental agency, or to a spe-
cialized  department of the  MOH or to an NGO such as  R ed  Cross or Red 
Crescent. 
objective  and  tasks: 
- to organize  the Blood Transfusion Service 
- to collect, monitor and analyze data 
- to organize quality control and assurance 
- to ensure training of  staff 
- to  edit guidelines and Standard Operating Procedures  for:  blood collec-
tion, donor counselling, testing procedures and blood use 
The effective  development of the organisation of the blood transfusion servi-
ce requires  an appointed director. In countries  with a national BTS, a nation-
al director can be appointed. In large countries, regional organisation could be 
more suitable but at least a national advisory conunittee should be established. 
A  national  director or coordinator could  however play  an  important role  in 
creation of overall  consistency and coherence so  as  to ensure the provision of 
safe blood for the whole country. C hapt e r  "/  •  Orgaui satio u  of safe  b lood 
1.3. Level  III:  Organisation  of  Blood  Transfusion 
Level  III  directly  concerns all "in the  field" activities  and how they  can  be 
organized and carried  out practically. At level III, the director as  well as  staff 
members of the BTS are directly  concerned in the application of the recom-
mendations. Blood collection, testing and distribution should ideally  be stan-
dardized whatever the type of  BTS structure:  centralized, regionalized, hospi-
tal  based or m.ixed. 
1. 3. 1.  Centralized structure: 
It consists  of one national blood transfusion centre which operates the servi-
ces for the whole country, with or without regional centres. This is  m.ore feasi-
ble in small countries. 
In principle, a centralized National Blood Transfusion Service may offer bet-
ter  guarantees  for  blood safety  than hospital  based  centres  especially  in the 
areas  hereafter mentioned: 
R ecruitm.ent of  voluntary and non-remunerated blood donors: a single cen-
tralized system is less  dependent on local contingencies  or emergencies. 
R egularity in blood supply: a centralized system is more able to manage and 
to guarantee a sufficient stock in a sustained way. 
Use  of techniques  respecting minima] safety standards: a centralized system 
is more often able to  ensure  the following tninimum criteria of safety i.e. 
ABO  grouping,  compatibility  testing,  screening  for  infectious  diseases, 
record keeping and quality control. 
Improved  training  of personnel, economies  of scale  (bulk  purchase),  effi-
ciency of automation and selection of donors with rare red cell  antigens. 
In this type of system it is easier  to obtain coordination at  national level, 
which in turn results in higher cost-effectiveness. It also  increases  capacity to 
provide blood in emergencies, gives  the possibility for a balanced and uniform 
national quality assurance as  well as  standardized training of personnel. 
In a national system, it may  also  be less  difficult to create a national blood 
transfusion service centre which can provide wide expertise for clinical servi-
ce and for further development of  the BTS. National reference laboratories in 
the  field  of transfusion  medicine  (e.g.  blood  group  serology,  haematology, 
tissue  typing,  coagulation)  and  support  of scientific  research  are  easier  to 
arrange in a national centre. 
--
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It is also  easier to develop a high profile among the medical establishm_ ent, 
as  well  as  in the community at large, by  means of a national BTS than if the 
blood transfusion  service system  is  fragmented. This is  important in recruit-
nl.ent of blood donors and in creating trust and confidence in the operation. 
Need  for  good conununication (e.g. telephone  and  telefax  for  laboratory 
results) and transportation (e.g. for laboratory samples and blood products) sys-
tems are  disadvantages  of a centralized BTS organisation. There may  also  be 
delays in the provision of  laboratory results and blood components, if these are 
organized centrally. A greater distance between a national BTS centre and hos-
pitals  and  blood donors may create difficulties  in relations with the  users of 
blood as  well as  with the blood donor population. 
1. 3. 2. Regionalized system 
A  regionalized  system  is  organized  as  follows:  the  country  is  divided  into 
regions with varying degrees of autonomy, but with different mechanisms for 
achieving  national control and coordination. However, even  in this  case, the 
regulations and policy coordination should be done on a national level with 
sufficient input from the regions. 
A regional blood transfusion service system is preferred in larger countries, 
where the size of  one region may allow for the creation of  a system which cor-
responds to a national blood transfusion service of  a smaller nation. The advan-
tages  and  disadvantages  have  to  be  evaluated  taking into account the special 
conditions and political realities  in the country. 
1.  3. 3. Hospital based organisation 
Each hospital runs its own blood transfusion service with or without national 
coordination. 
Organizationally  this  system is  problematic  and coordination at  national 
level  has  been  difficult  to  reach  even  in  developed, industrialized  nations. 
Because the national supervision and regulatory role are crucial, it is in gener-
al  not recommended to leave  the  organisation of blood  transfusion services 
totally to the individual hospitals. 
However, blood banks integrated  into hospitals theoretically  present some 
minor advantages: 
hospitals are  in close  relation with patients and analyses  can  be performed 
for donors and for patients in the same laboratory; Chap t er  ·t  •  Org anisatio 11  of safe  blood 
hospital  blood banks are  closer to prescribers so  that blood indications can 
be discussed more easily. 
J.  3. 4.  Mixed organisation 
Combinations of hospital  based and national/ regional  blood centres  exist in 
28 % and  26  % of the  reporting developing  and least  developed countries, 
respectively  (see  Figure 1B). Usually, there is a national BTS, but many hos-
pitals  find  its  coverage  unsatisfactory  and  run  their  own  blood  banks. 
Sometimes the local blood centre in the capital carries the word "national" in 
its title. This organisation is not very often efficient and usually is more costly 
than national or regional blood transfusion services. 
2. Example 
2.1. Example of National Blood Policy 
Sumnurized content of the 
draft National Blood Policy of Zambia 
1. National Blood Tranifusion Advisory Committee 
Memhers:  - Ministry of  Health 
- Permanent Secretary or his representative 
-Director (head) of Clinical Services (MOH) 
- National AIDS, TB and leprosy manager 
- Chief Health Planner 
- Zambian National Blood Transfusion Service: 
- Medical director 
-Assistant director 
- Donor service nunager 
-Blood prescribers (including hospital representatives) 
- Blood Donor Associations (and R ed Cross  representatives) 
-Others:  -Press 
-Legal representatives 
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- Ministry of Finance I  Chamber of Commerce 
- Mine hospitals 
-Any medical association 
2. Specific structures  cif the Zambian  National BTS 
For each specific structure, functions and staffing are defined. 
- Core programme 
- Lusaka central blood bank 
- KJtwe central blood bank 
-Regional transfusion centre 
- District hospital and private hospital based blood banks 
3.  Collection  and processing of  blood 
- Premises: laboratory areas, donor room, phlebotomy rooms, etc. 
-Donor selection criteria:  voluntary and non-remunerated blood gift 
information, counselling of donors 
selection, minimum. medical examination 
of donors 
frequency of blood donation  ... 
- Testing procedures: required sensitivity and specificity of tests  used 
ABO and Rhesus phenotyping 
4.  Blood  Products 
- Labelling: minimum information required 
-Blood products: storage condition, expiration date, indications, ... 
- Whole Blood 
- R ed Blood Cell  concentrates 
- Fresh  Frozen Plasma 
- Platelets 
- Cryoprecipitate 
5.  Use  of Blood:  guidelines  on appropriate use  of blood and blood products. 
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6.  Import  at1d  export if  blood and blood products: MOH approval. 
7.  Quality assurance: recording and validation of documents. 
2.2. Example of BTS organigram 
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Figure 3: Organigram for the Uganda Blood Transfusion Service. 
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3. Recommendations on blood policy 
A policy framework is  supposed at least to specifY  some issues  such as: 
The objective of the blood programme 
The chain of authority from government to safe  blood services 
The advisory system 
The financial responsibility 
sources of  income 
mode of disbursem.ent 
budgeting and approval processes 
- Principles that are adopted: 
organisation of blood collection depending mainly on voluntary non 
ren1Lmerated donors, 
full  compliance with nationally approved safe blood policies as  deter-
mined by government, 
Monitoring of performance at all levels  of activity. 
4. Recommendations on the organisation 
of blood transfusion services 
Three levels cif organization  could be proposed: 
- Level I. Definition of policy and strategies by a National Committee of 
Blood Transfusion  under  the  responsibility  of the  Ministry  of Health 
through legislation, regulation and recommendations. 
- Level  II. A  National Committee designated  by  the Ministry of Health 
which has  the  responsibility for  the implementation of the legislation and 
recommendations stated at level I. The Director of the NBTS (or the board 
of directors)  would  be  the  executive  body  using  Standard  Operating 
Procedures (SOP) and quality assurance. 
- Level III.  At the "in the field level", all staff members of the BTS, under 
the responsibility of the director work and fulfil all  the activities (blood col-
lection,  testing,  distribution  ... )  according  to  the  guidelines  (Standard 
Operating Procedures) defined by level II. Chapter  2 
BLOOD DONOR INFORMATION 
AND SELECTION 
[ntroduction 
1. Blood donor motivation, recruitment and retention 
1.1.  Need for specific recruitment programmes 
1.2. There are three categories of  blood donors 
1.2.1.  Voluntary 
1.2.2. Family replacement 
1.2.3. Paid 
1.3. The aim of recruitment is to enrol "regular" blood donors 
1.4.  How to ensure blood donor loyalty ? 
2. Call  for donors and blood collection 
2.1. Standard Operating Procedures 
2.2.  Sites ofblood collection 
3. Information given to blood donors 
4. Counselling of  blood donors 
4.1. Right of blood donors to know results and responsibility 
of the BTS 
4.2. What about pretesting ? 
5. Considerations about "high risk" and "low risk" blood donors 
6. Examples 
6.1. Blood donation projects 
6.2. Information given to donors 
7.  Recommendations for blood donor recruitment 
8. Recommendations for blood donor counselling 
-C h apt e r  2  •  Blood  donor  iuformatiou  a u d  se l ectio u 
COLLECTION of  SAFE BLOOD 
It is necessary to develop systems based on: 
0  non  remunerated 
0  voluntary  blood donations 
0  anonymous 
in order to obtain: 
0  saf e blood 
0 from  selected donors 
0  in.  quantities adapted to  the need 
0  whilst preserving the donor's health 
0  whilst preserving the recipient's health 
Prerequisites are: 
0  a good organisation with regard to: 
0  iriformation.  0  blood 
0  education.  about  0  its needs 
0  sensitization  0  its risks 
0  communication  0  its hazards 
0  encouragement to: 
0  self  diferral 
0  motivation 
0  regular donations 
0  warranted confidentiality 
0  the effectiveness of  which must be proven.  and known 
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Introduction 
Everywhere  in  the  world,  tranifusion  of human blood  is  an  essential  therapeutic proce-
dure for  which  there  is  no genuine  substitute. lf  blood  can  save  human  lives  in  some 
instances,  it  can  also  transmit  inftctious  diseases  and,  sometimes,  death. The  two  main 
problems  encountered in  the field of  blood tranifusion  are: 
the  collection  cif blood in sufficient amounts 
- the  collection  cif blood  as  scife  as possible for the  recipient's  health. 
Being of  human origin, blood collection depends solely on individual decision.  Ideally, 
as  is  the  case  in  most  developed  countries,  blood should  be  collected  only from  volunta-
ry, unpaid donors and the blood gift should be anonymous. It is widely known that blood 
donors  who give  blood for cash  are  more likely  than  unpaid ones  to  be  carriers  of  infec-
tious  diseases.  Blood collection based on voluntary decision  allows for a selection of  blood 
donors, which guarantees better tranifusion scifety. The major difficulty encountered is the-
rifore  to  encourage  the  healthy population  to give  blood  and  to  become  regular  blood 
donors. 
Effective and rifficient blood donation and collection procedures are an essential part cif 
the provision  cif safe  blood in any country  or region.  In view of the HIV  I AIDS epide-
mic,  however,  screening  cif blood products for HIV has  been given  highest priority  by 
many interested parties. As a consequence, several countries  or regions  now have sophis-
ticated testing procedures for HIV, but either no  blood available  for testing,  or blood avai-
lable  that  is  highly  infected,  either  because  donors  are  wrongly  selected  or  because  the 
minimum requirements for safe  blood  are  not met at all. 
Due to  lack of  reserves  cif tested  blood and  the  need for emergency  tranifusion,  blood 
is  sometimes  given  bifore  tests  can  be  completed.  Therifore,  the  Communities' 
Programme insisted from  the beginning on the importance of  a well organized blood col-
lection service for blood tranifusion services  in general and for HIV control in particular. 
However,  when  the  programme  started  in  1987, very Jew  developing  countries  had  a 
proper blood collection  service which  usually had  to  be  built from  scratch. 
A few principles  about  blood  collection  and  donation  are  discussed.  Some  examples 
also  demonstrate  how some  countries  have  already  improved  their blood  collection  sys-
tem. 
--
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1. Blood donor motivation, recruitment 
and retention 
need for specific recruitment programmes 
three categories of blood donors: 
voluntary,  non-remunerated donors 
family replacement donors 
paid donors 
aim of recruitment: to enrol regular blood donors 
how to ensure blood donor loyalty  ? 
1.1. Need  for  specific recruitment programmes: 
In the national programme, it is in<portant that the protocol for dealing with 
blood donors and transfusion practices  is organized by a medical officer. It is 
important that  national authorities be aware of the overall  need  for a specific 
donor  recruitment programme under the direct supervision of a donor recruiter. 
In  order  to  reach  altruistic,  voluntary  donors,  low  risk  populations  such  as 
school students and  young adults in  rural populations are targeted, informed 
and educated  during  a  meeting.  Following  the  initial  meeting,  a  manager, 
sometimes  advised by a committee, determines if there is a wish of the parti-
cipants  to  invite  the  blood  transfusion service  to  collect  blood. A  session is 
arranged  usually  7-14  days  later. If  this  is  a  first  session,  a  donor recruiter 
accompanies the  collecting team. Donors are reminded that  their blood will 
be tested for HIV, hepatitis and other transmissible infections. Two weeks later, 
the same donor recruiter meets the voluntary donors by appointment to dis-
cuss  and  give  results confidentially. At this follow-up  visit, a tentative  date  is 
scheduled for the next cycle of  information, collection and counselling. O ther 
possibilities  to organise  collection also  exist, depending on the region and its 
opportunities. 
1.2. There  are  three categories of donors: 
- voluntary donors, 
- family donors 
- remunerated donors. C hapt e r  2  •  Blood  donor  information  arrd  selection 
1.2.1. Voluntary  non-remunerated  blood  donors: 
The best definition of a voluntary non-remunerated blood donor is  given by 
the EC: 
"A voluntary non-remunerated donor is  a person who gives blood, plasma 
or cellular components of ills/ her own free  will and receives no payment for 
it, either in the form of cash, or in kind which could be considered as  substi-
tute for money. This includes time off work other than that reasonably needed 
for the donation and travel. Small tokens, refreshments and reimbursement of 
direct travel costs are compatible with voluntary, non-remunerated donation". 
A blood transfusion service should aim at collecting all blood from altruistic, 
voluntary and unpaid  donors. For moral and ethical  reasons,  the  blood gift 
should remain anonymous. 
The advantages  of recruiting voluntary non-remunerated donors are  that 
lower risk populations can be targeted, services are based on ethical and huma-
nitarian principles and blood donors can be informed, counselled and n"J.oni-
tored regularly. 
1.2.2. Family  replacement donor: 
It is  admitted that in some countries,Jamily replacement  donors  continue to ful-
fil  the need for blood and blood products. Efforts must be undertaken to edu-
cate family donors so  that they are converted to regular donors, and to ensure 
that  the  standard  donor  screening  procedure  is  used  in  evaluating  their 
suitability. A staff member, or perhaps a volunteer, is responsible to ensure that 
when visitors and patients' relatives are asked to donate blood, they get infor-
mation and are adequately counselled. 
1. 2. 3.  Paid blood  donors 
In a number of countries, paid donors are still providing the bulk of the avai-
lable blood. Owing to potential danger to the recipient, this process is  undesi-
rable (but to change it will probably take years). 
--
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1.3. The aim of recruitment is  to  enrol "regular" blood 
donors 
The "ideal" blood donor is  a regular blood donor who gives  blood three to 
four times  a year,  who has  had inform.ation about risky  behaviours and who 
has  proved to take care of his health. Because they are regularly tested, regular 
blood donors constitute a population characterized by seroprevalence of  infec-
tious markers lower than that of the general population. 
1.4. How to  ensure blood donor loyalty  ? 
A main difficulty for a Blood Transfusion Service is  to encourage  the donor's 
loyalty. If the donor is accepted as  a safe blood donor, a letter can be sent three 
m.onths later, rerninding hin1./ her of  the time to return so as to increase the pool 
of regular safe  donors. Problems  in arranging for  blood donors to return on a 
regular basis arise  mainly from  lack of communication, organisational facilities 
or funds. 
In Uganda  an  average  of 2. 4 ECU is spent on  the recruitrnent of 
a first-time donor,  and  1.  5 ECU on  a returnit1g  donor. 
On the other hand, it is also important for the donor to feel his/her gift is use-
ful for the community and appreciated. He/she should  be received warmly at 
the BTS by qualified  personnel who pay attention to his/her well-being. 
It is also  possible to organize meetings  to recognize regular blood donors by a 
medal or a diploma or another small  gift. 
2. Call for donors and blood collection 
2.1. Standard Operating Procedures: 
Written procedures about how to  call  for  and  how to  manage  blood donors 
should be clearly defined and explained to nurses and/ or any people in charge 
of the donor session. They should contain essentials about how to care for the 
blood donor before, during and after donation and for referral when necessary. C hapl e r  2  •  Blood  donor  information  and  selection 
Selection criteria for blood donors should be listed and defined while taking 
into account the epidemjological characteristics of  the country for the various 
transm.issible infectious agents. 
Prior to the blood gift, a short medical exam.ination is  helpful for physicians 
to decide whether a donor can be bled or not. It should be oriented towards 
the search for the possibility of  infectious disease carrier status and would also 
aim  to  make  the physician sure  that  blood donation will  not affect  donor's 
health. 
The typical aims and contents of medical exam.inations should be defined, 
listed and included in guidelines distributed country wide. 
A  questionnaire should be constructed wruch would be completed by  all 
blood donors after they receive information focused on: the need for blood, 
blood donation, blood transm.issible diseases, risk behaviours etc  ... 
There should be a labelling system indicating that testing has been done on 
all blood units and that those units issued meet the agreed criteria. 
Records should be held containing the main data: administrative, medical 
and transfusional. A manual or computerized file  containing these data should 
always  be up-to-date. 
2.2. Sites of blood collection 
- mobile transfusion centres 
- permanent sites of blood collection 
Blood donors may be invited to donate at a nwbile transfusion centre or at 
a permanent site housing the transfusion service. In n1.ost  developing coun-
tries, the  mobile centres  organized in schools, factories  and  communities in 
general, are popular and productive. 
However, permanent sites provide for more reliable collection of  blood and 
other special blood products such as platelets, and samples for research, and also 
for improved information, and confidentiality and counselling. 
3. Information given to blood donors 
It is  the responsibility of  the Blood Transfusion Service to research and prepare 
appropriate information on two major aspects of blood donation: on the one 
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hand, the  need  for  blood in sufficient amounts,  its  therapeutic  necessity, the 
blood donation process, post-donation procedures  and follow-up, and on  the 
other hand, the absolute necessity that blood will  not transnut disease  to  reci-
pients. 
This information m.ay be provided through written, oral or electronic media 
and by person to person contact. 
This information needs to  be strengthened  at  the  predonation  stage, thus 
enabling the potential  donor to be informed fully on the donation, the tests to 
be  performed  and  the  procedures  followed  after  donation. Consent to  give 
blood under these  circumstances  ntust be obtained. 
Potential donors are to be iriformed in a full  and comprehensive way  about 
how and why some infectious diseases  are  transmissible  by  blood, about the 
n1.ain modes  of transmission of these  infectious agents,  the corresponding risk 
behaviours,  about the  tests which  will  be  performed  and  the  possibility  to 
obtain results. 
O ne of the main purposes  of the information given  to  donors is to  allow 
them to identify  their own risk factors in order to encourage appropriate self-
diferral from blood donation. 
-
Information  received  from  donors  should  be  kept completely  confidential 
and if this is not assured, names  of donors should not be recorded at all and/ or 
an alternative record  identification should be used. 
The results  of tests pe1 formed on the donor's  blood should be available for 
the donor, and for him only, provided he has  opted to  know the results, he has  been 
thoroughly  counselled  before donation and will  again be individually coun-
selled when receiving the results. 
4. Counselling of blood donors 
After the laboratory tests are performed, the service  must follow  the prescri-
bed procedure for informing donors in order to assess  whether they are suit-
able to give blood again or not. Seronegative blood donors will be encouraged 
to give  blood again (and become regular blood donors)  and informed on how 
to  continue  to  prevent infections.  Seropositive  donors will  obviously  not  be 
allowed  to  give  blood  again.  It  is the  duty of the service  to  inform them  of 
their seropositive status in compliance with local counselling procedures. These C hapt e r  2  •  Blood  dotror  itrformation  and  se / ectio 11 
may,  for  example, be  that such donors are  referred  to a doctor or approved 
counsellor or, when resources permit, the service gives  the donor the results 
with the necessary counselling support. 
Counselling may also  be  necessary  for  relatives,  at  a later stage, after  the 
donor has received the results. This is  an important and time-consuming acti-
vity which becomes difficult  to  organize in countries where seroprevalence 
among donors is  high. It is therefore a service that has to be provided progres-
sively  and  in  coordination  with  other  health  services  or structures  in  the 
regwn. 
4.1. Right of blood donors to know results  and 
responsibility of the BTS. 
When individuals are invited to give blood, (either as  an altruistic action or to 
replace blood used for a friend or relative)  the blood programm_ e authorities 
must decide whether and how they will make the test results  known to the 
donor. However, the  individual has  a right  to  have access  to  those results,  but  is  not 
required  to  be forced to  receive the  information.  Various options, the advantages and 
disadvantages of which have to be taken into account, are possible. 
4.2. What about pretesting ? 
In most cases, pretesting of  donors is  not regarded as  an appropriate method for 
selection because a similar purpose can be achieved by giving information, on 
the basis of  which a process of  self-selection is induced. 
The disadvantages of  pretesting are: an increased need for individual coun-
selling, the  inconvenience for  the  donor to return later and the risk of the 
blood transfusion service being used as  a screening centre. The cost of  pretest 
or of  improving self-selection should be estimated in view of the HIV epide-
miological situation, the type of available  tests  and the problems of ensuring 
confidentiality. Rapid tests  would avoid the necessity of returning but make 
confirmation and counselling more difficult. 
The advantages are that fewer infected units will be collected so that the risk 
of  contamination within the blood transfusion centre is reduced. However, the 
same objective can be reached by supplying appropriate information and care-
ful selection of  blood donors. 
--
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5. Considerations about "high risk" and 
"low risk" blood donors 
In nwst  developing countries, HIV is spread predorninantly  through  hetero-
sexual contacts. The high risk groups in the U.S.A. and Europe (hom.osexuals, 
intravenous drug users and blood component recipients) are therefore of  much 
less significance. Instead it is sometimes stated that all sexually active persons form 
a high risk group. Studies  need  to be carried  out to identify low  risk groups 
in the population. 
Characteristics  associated with high  HIV seropositivity need  to  be  identi-
fied at a national level in order that characteristics with a high predictive value 
for HIV  seropositivity  be  used  in  donor  selection.  Efforts  are  directed  to 
exclude donors with high risk as  determined by age, sexual activity and social 
paran1eters. For these reasons, and because of easy access, better education and 
physiological status,  blood collection strategies  presently focus on  the  17-21 
year old  senior school  and college students.  However, it is this age  group  of 
unmarried youth which is at greatest risk of acguiring infection through sex-
ual  intercourse. Increasing  attention  is  now  directed  to  retaining,  as  regular 
blood donors, those whose knowledge of HIV epidem.iology and concern for 
their own health and that of potential recipients is likely  to maintain them in 
a low risk behaviour group. Some observations illustrate the relevancy of  these 
considerations on "high" and "low" risk populations: 
1. HIV  seropositivity rate varies with age:  it increases from 17 years to 35 years (in 
son1.e Afi:ican countries, it is higher than 30 % in 30 year old  females), and 
then  declines  to  less  than  5  % in women  over  50  years and men  over  60 
years. 
2. Persons  with  itinerant  and fluctuating  activity, such  as  military  forces,  truck 
drivers,  market traders and conu11.ercial sei\.rworkers have a h.igher freguency 
of HIV than others of the same age. It can be anticipated that wars in coun-
tries  will  have  dramatic consequences  on  the spread of sexually transmitted 
diseases. 
3. The lowest rate of  infection is found in school boys between 17 and 21  years 
old, who have been informed about HIV infectivity and declare themselves 
not to have  taken any risks. 
Once a blood donor has  met the criteria of low risk and is found to be HIV 
negative, every  effort is made to encourage a risk-free life style with repeated 
blood donations every three to four months. Chapter  2  •  Blood  donor  information  and  selection 
6. Examples 
6.1. Example of blood donation projects. 
6. 1. 1. in  Guinea  Conakry 
Family  donors  were  the  only  source  for  blood  till  May  1990  when  the 
Commission's AIDS control programme started implementation of  its support. 
In May  1990,  the  programme  held  a  national  training  seminar  prompting 
blood  donor  recruiters  to  organise  a  pool  of regular  voluntary  donors  in 
Guinea Conakry for the first tin1e. Since then the activity has  been spreading 
from the capital to the rest of  the country. One year later, May  1991, blood was 
collected from 656 voluntary donors and from 1958 relatives. 85 % of the vol-
untary donors were youngsters (students and mem.bers of  youth organisations). 
This m.ade it possible to  test all blood before it was  used and since May  1990 
no HIV or HBs antigen  positive blood has been  used. All  donors have  been 
informed and counselled, and have  received some health education. 
At present the following strategies  are being developed: 
strategies  to have  donors return regularly; 
recognition of voluntary donor associations in the capital; 
elaboration of strategies  and guidelines  to  advise  seropositives  among the 
blood donors. 
6. 1. 2.  in Rwanda 
In Rwanda, blood  transfusion services  have  been  at  work for  more  then 15 
years.  Since  the  AIDS  epidemic  became  fully  evident  in  1987,  the 
Commission's  support, in cooperation with the Belgian R ed  Cross, m.ade it 
possible  to provide safe  blood rapidly. At national level, a medical  assistant in 
charge of blood donor recruitment plans and organizes blood collection. This 
person, in cooperation with the Rwandan Red Cross, also encourages  repeat, 
voluntary blood  donors. At regional level, the person in charge of the blood 
transfusion  centre  is  also  responsible  for  recruiting  as  many  donors  as  are 
necessary  to  answer  the  region's  needs. At the  local level  the  recruitment is 
organized in collaboration with the local R ed  Cross  representative who con-
tacts the voluntary donors. 
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In view of the high HIV incidence in many parts  of Rwanda and in order 
to diminish the risk for HIV transmission as  much as  possible, nearly all  blood 
collected  comes  from  campaigns  in  schools  (94  % in  1990). Other strategies 
have also  been combined to limit the risk of collecting infected blood: 
- recruitment of donors among younger people (18-25 years); 
-elimination of donors for further blood collection once found to be positi-
ve; 
- medical consultation before blood collection with questionnaire about STDs 
and AIDS; 
-
- follow up of donors to encourage them  to become regular donors; 
- change in  collection sites  (less in urban areas, more in schools). 
The results  confirmed the usefulness  of these strategies  since seroprevaJen-
ce among blood donors fell from 13.5 % in 1985 to around 3 % in 1990's. (see 
Figure 4). 
Figure 4 
The efficiency of strategies applied in Rwanda to diminish the risk for HIV 
transmission by  blood is illustrated by the continuous decrease  of HIV sera-
prevalence among blood donors between 1985 and 1990. In 1991, on account 
of a  war context  in the  country, massive  blood  collections were organized, 
making it much more difficult to select blood donors. 
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In Rwanda all blood is collected on a voluntary basis and relatives are no lon-
ger  requested  to  give  blood. AJJ  blood  is  safe  and  the  needs  are  satisfied. 
Confidentiality is assured. With regard  to HIV tests,  the donors are informed 
about the results only if they want to be. This is not an ideal solution, but the 
result of the fact that most units are  collected from donors who live far away 
from the blood transfusion centre and because  pre- and post-test counselling 
is not fully  guaranteed at the moment. 
In 1993-1994, before the war in Rwanda, a lot of  work had been produced 
to im.prove this situation which was  really progressing. It is feared that the situ-
ation after the war will be different, and will necessitate many efforts  to reach 
the level of the previous situation again. 
6.2. Examples of information given to donors 
6.2.1. Uganda programme 
Uganda 
Blood  tranifusion  service 
((saving life with safe blood" 
information for the blood donor 
Thank you for volunteering to donate blood. 
To make sure that it is safe for you to give  blood and that your blood is safe 
to give to a patient, and to safeguard  your privacy, we follow these procedures: 
1. Your name will  not be  used in registration at the  blood bank. Instead, we 
use your mother's  um11.arried name, your birthplace and your date of  birth. 
2. You  will  be  assigned  a  code  nun1.ber  which  is  placed  on  all samples  and 
records of your blood. 
3. You will be asked some questions about your health and activities  to make 
sure giving blood will  not harm you. 
4. You  will also  be asked  questions about your private life  to make sure  the 
tests we perform will more accurately determine risk. 
5. A small sample of  your blood will be taken by finger pricking and tested to 
make sure  you  have  enough blood to spare for a donation. 
6. Mter your blood donation is drawn, we ask you to remain with us for a few 
moments to rest and to take some refreshment to replace the fluids you have 
lost. We  will  also  give  you  some iron pills to help  your body replace  the 
donated blood quickly. 
--
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7. The blood you have donated will be tested for hepatitis and the HIV viru-
ses, which cause  hepatitis and AIDS, respectively. 
Note: HIV cannot be detected immediately after infection. It is possible for 
blood to  test negative for two months or more after beconung infected. 
8. T he results of these  tests will  be available to you  (and no one else) in two 
weeks, if you choose to know them. 
Please turn over for important information 
about when you should not give blood 
Uganda 
Blood tranifusion service 
"saving life with safe blood" 
information for the blood  donor 
Please do not give blood if: 
A.  In the last six months you have had sex with someone you are unsure about. 
B. In the last two months you have  had an illness  such as  a bad cold. 
C. In  the last year you have  had: 
i)  an injection except at a hospital or clinic; or 
ii)  skin scarring or cutting by a traditional healer; or 
iii) a surgical  operation. 
D. You have ever had hepatitis Uaundice causing yellow coloration of  the eyes). 
Please do give blood again if: 
A. If your blood  has  been found to be safe after testing. 
B. If you continue to practice a healthy and safe lifestyle. 
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Healthy blood donors are always needed to save lives. Patients who need blood 
can get it only if enough healthy people donate their blood. Of course,  you 
and your blood will be checked every time to make sure you are healthy and 
your blood is  safe. 
6.2.2. Rwanda programme 
RWANDA 
Information for blood donors 
BTS  uconfidential" 
Information sheet on AIDS 
Dear Blood Donor, we wish to inforn1 you that since December 1985 we test 
each blood donation for AIDS before it is  used. At present we comm.unicate 
all the results  (positive or negative)  to the donors who wish to know. 
In spite of systematic  testing  for AIDS on every  unit of blood collected, 
there still remains a nunimal risk of  transmission of  AIDS through blood trans-
fusion. Tills risk is due to the fact that the tests  that are used are made to detect 
the presence of antibodies  to the AIDS virus. Now, these  antibodies  can only 
be di  covered in the blood 2 to 6 n1.onths after infection, while the blood itself 
is contagious fi·om  the moment of contamination onwards. 
Facing this situation, the  honest contribution if  the  donors  is essential to elinuna-
te  defiiutively the risk to transnut AIDS and other infectious diseases  via  tills 
blood. 
By giving an honest  answer to the following questions you will  have  made 
your contribution. 
--
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Everything you say here will remain a  secret between 
You and the person who receives you 
YES I  NO 
1.  Are you at present in good health ? 
2.  Have  you  suffered  moments  of physical  feebleness  without  apparent 
cause  ? 
3.  Did you  have  sexual intercourse  with another person  than  your regular 
partner (your wife or husband)  during the last six months ? 
4.  Did  you  contract  any  sexually  transmissible  disease  during  the  last  12 
months? 
5.  Have  you had shingles  ? 
6.  Did you lose a lot of  weight without apparent cause  this year ? 
7.  Has  it happened  to you during the last year to have  had  drug injections 
from a Magendu ? 
8.  Were  you  subject  to  scarification practices  for  medical  treatment or for 
aesthetic reasons during the last 12 months ? 
9.  Have you received blood ? 
10.  Have  you had any skin diseases during the last  two years ? 
11.  Do you have abnormally swollen glands ? 
12.  Have you noticed anything abnornul about your state of health lately ? 
13.  Do you wish to be informed about the results of  the AIDS test performed 
on your blood ? 
Note: 
* Please,  if it  is  your  habit  to  have  frequent  sexual  relations  with  several 
people, we advise you to abstain from donating blood. 
* If you sim.ply want to have  an AIDS test performed on your blood, this can 
be  done  in all  discretion  without your having  to  donate  blood for  that 
matter. 
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7. Recommendations for blood donor 
recruitment 
There  should  be  a  National  Blood  Donor  Recruitment  Officer 
(NBDRO) who has  the overall responsibility to develop voluntary blood 
donor recruitment strategies, within the guidelines of the  National Safe 
Blood Policy and with the agreement of the National Blood Transfusion 
Advisory Conmuttee (NBTAC). 
The NBDRO, with the assistance of  trained, full-time blood donor recrui-
ters, will ensure a sufficient supply ofblood for the national requirements. 
Volunteers  to  assist  in  organisation  may  be  recruited  within  schools, 
factories,  churches and other suitable  organisations. The volunteers  will 
act as  liaison with donors within each organisation. 
A dedicated budget is  needed for donor recruitment and follow-up acti-
vities. Sufficient transport will  be provided. The BDRO's duties include 
donor and public education and the establishment of a record system  to 
provide data for donor statistics and recall procedures. 
The donor records will  be confidential and protected, as  much as  possi-
ble under national law, fron1.  disclosure to any third party. 
Procedures and donor selection methods will be made known to poten-
tial  donors  before  phlebotomy  and  conform  to  recognized  standards 
approved by the National Advisory Committee. 
Whilst every effort will be made to achieve an all volunteer donor panel, 
the value  of relatives  willingly  replacing blood used must be  recog11ized 
and supported. These donors should  benefit fiom  the same  information 
and courtesy as  volunteer donors. No cash or financial  benefit should be 
allowed. 
Counselling should be available to all donors. 
8. Recommendations for counselling 
The donation process  and post-donation procedures must be discussed 
with the donor bifore blood is  collected. 
--
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Donors must be advised bifore their next donation whether or not they 
are  acceptable  as  blood  donors. Such information is  best  given  with 
appropriate counselling support. 
The results  should be available to the donor, who should be given  the 
option of  knowing the results. 
Counselling is  essential once the results are made available to the donor. 
Counselling may also  be needed for relatives. 
Seronegative blood donors must be encouraged  to lead  a risk-free life 
and to continue to donate. Seropositive donors n1.ust be encouraged  to 
live positively with the infection. 
It  is  essential  to  protect  the  corifidentia.lity  of donor  test  results  and 
related information. Chapt e r  3 
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Introduction 
Blood tranifusion is known  to  be an  rifficient way for transmitting infectious  diseases.  It 
is  therifore important  to  screen  blood  bifore its potential therapeutic use  in  order  to  dis-
card any  blood unit capable of irifecting a recipient. 
Sornetimes, inf ectious agents can be detected directly in blood {for example: HBs anti-
gen  detection  rc]lects  directly  an HB V inf ection).  More often  blood is analyzed  in  order 
to  detect  specifr.c  antibodies.  For some  infectious  diseases,  the presence of  antibodies  may 
rc]lect  a past infection  and  does  not mean  that  the blood  is  irif ectious; in  other cases,  on 
the  contrary,  antibodies  may  rc]lect  a current  transmissible  inf ection  (for  example: anti-
HIV antibodies). 
The notion if  latency characterizing some irifections  has  also  to  be taken into  account 
for  two  main  reasons: first,  the  latent phase is  iften itif ectious; secondly,  tests  detecting 
viral antigens  bifore antibodies  become detectable are  not always available  (for example: 
HCV). 
In  many developing countries  the prevalence if  itif ectious  diseases  in  the general pop-
~tlation is  high.  For that reason,  high rates of  infected blood donors  can  be expected and, 
proportionally, a high  rate of  co-irifections. 
In  developing countries,  tranifusion of unscreened blood  is  an  important route 
of transmission for five serious irifections: HIV, HBV, HCV, syphilis and malaria. 
Laboratory  testing if  blood  donors for inf ectious  diseases  is therifore an  essential phase 
in  assessing  blood  safety. 
1. Concepts and definitions 
Populations at risk for an infectious agent can be divided into two sub-popu-
lations:  itif ected and not  itif ected. An ideal  laboratory test  would separate  these 
two sub-populations without any  possible error. This ideal  test,  which would 
be described a  100 % sensitive and 100 % specific, does not exist. 
Sensitivity is  defined as  the probability (usually expressed as  a percentage) that 
the test result will be positive when infection is present. 
Specifr.city is the probability that the test result will be negative if infection is 
--
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not present. Since an absolute standard is  rarely available, sensitivity and speci-
ficity cannot be calculated precisely. 
The predictive value of  a test is  a measure of how well the test performs in a 
given population. The preclictive value of  a positive test is  the probability (usu-
ally expressed as a percentage) that the person is actually infected when the test 
result is positive. The predictive value of a negative test is  the probability that 
the person is actually not infected when the test result is negative. 
Unlike the sensitivity and specificity, which are relatively fixed  for a given test, 
the preclictive  values change, depending on the prevalence of the marker that is 
being measured in the population. This latter parameter is  the most im.portant 
for choosing "the best test" i.e. the test best adapted to the concerned popula-
tion. 
2. Levels of screening strategy 
Laboratory testing should be considered at least at three levels,  the viewpoint 
and the consequences of each of which are different: 
- Screening  tests applied to blood units 
- Testing carried out to diagnose  an infection 
- Test results as  indicators of effective prevention of transnussion of diseases by 
transfusion 
2.1.  Screening  tests  applied  to  blood  units. To  be  useful  in the  improvem.ent of 
blood safety, screening tests  have to be applied systematically on all blood 
units in order to identifY  any  potentially dangerous blood. In this con-
text, a  positive  test  result is  by  itself  a  sufficient  reason  to  cliscard  the 
blood  unit  from  therapeutic  use. Therefore, for  the  purpose  of blood 
safety, the most sensitive test should be recommended for the screening 
of blood units. 
2.2.  Laboratory testing may acquire a role of  diagnosis when blood donors ask 
for the results obtained by analyzing their blood for infectious agents. In 
this context, the results of screening tests  have to be confirmed by con-
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cannot be concluded, and should not be announced to the donor, from 
the sole basis of  a "positive" screening assay; it must be confirmed by fur-
ther testing. 
2.3.  Test results performed in blood banks can also  be  used  as  indicators of 
the effectiveness of  the selection criteria applied to blood donors. Indeed, 
the  rate of samples  found  to  be "reactive" with the screening  test  will 
give  information about the  prevalence  in the  selected population and 
may help to revise and re-orient the criteria used in order to recruit and 
select "safer" blood donors. 
3. Parameters influencing the screening strategy 
Before dealing  with technical  considerations,  one should keep in mind  that 
environmental parameters as  well as some intrinsic characteristics of the infec-
tious agents themselves  are likely to have  an effect on the prevention of trans-
missible diseases in developing countries. 
- Ideally, any  blood for  transfusion  purposes  should be  tested  for  the  pres-
ence of  all those agents which are prellalent in a given population and, if trans-
nutted, can cause serious disease in the recipient. 
In endemic areas (for example, HBV infection in Africa), the probability for 
an  adult recipient to  have  been  infected  prior to  transfusion and to  have 
achieved immunity, depends on the prevalence of the disease in the popula-
tion. However, such  a  consideration should be  carefully  revised  as  far  as 
young children are  concerned. 
Some infectious agents are present only in cells  and are  not transmitted by 
cell-free blood components such as  plasm.a. 
On the contrary, some others will be present and infectious in either cell or 
cell-free blood components (for example, HIV infection as well as HCV and 
HBV can be transmitted by both cellular and plasma  blood components). 
Some infectious agents are killed or at least their virulence attenuated, after 
blood storage for 72 hours at 4 to 7°C (syphilis). This could be kept in nund 
if there is insufficient financial support to test for all infectious agents. 
Information given  to  blood donors in order to  teach  them  about at-risk 
behaviour and to  encourage  them  to "self-deferral" is  less  expensive  than 
--
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and probably as  useful  as  testing to  discard  dangerous  blood  units. This is 
most relevant as  far as  sexually transmitted diseases are concerned. 
- When  financial  support is lirrilted,  local  priority  should  be given  to  the 
various screening tests (e.g. HIV ~ HBV ~syphi lis~  HCV ~ HTLV) accor-
ding to  the prevalence  of the  carrier state in the  general population, the 
consequences of  infection for the recepient's  health, and the age of  the reci-
pient. 
4. Which are the best "tests" to use ? 
4.1. Screening for HIV 
Blood transfusion is an efficient mode of HIV transmission. HIV  infection is 
characterized  by  a long term asymptomatic phase.  It is common  knowledge 
that most people are likely to develop HIV antibodies within a few weeks after 
infection but individuals are very infectious immediately after contanunation. 
The tests  usually  used for HIV1 &2 antibody screeni1 1g  have a specificity and sensi-
tivity higher than  9  5 %, which is excellent in.  comparison  with  most clinical labora-
tory  tests.  imilar peiformances  were obtained in  the field. 
The characteristics  essential for screening tests  for HIV antibodies  to be used 
in safe  blood programmes  in developing  countries  are  high sensitivity, low 
cost, ease of  performance and appropriate technology. As long as  the test result 
is not used to inform the donor, a false-positive result is not a problem  other 
than  that of cost-effectiveness.  False-negative  tests have  to  be avoided when 
providing for safe blood. 
However, more and more testing procedures  are used to inform the donor. 
The  consequences, especially  of false-positive  results,  are  of extreme  impor-
tance  with regard  to the donor and his/ her environment. Confirmation tests 
with a sensitivity similar to the screening test, but with a specificity as  high Js 
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Therefore, a single positive screening test for HIV is sufficient to deterrnine 
the unsuitability for transfusion but if the donor is  to be informed, a positive 
test  result should lead  to petformance of another test  to  confirm the  first 
result. 
Diff erent testing procedures are  available that can  be classified into: 
simple tests  = imrmmo-dot screening assay  with visual reading 
EIAs  = cotwentional Enzyme Linked Immuno  Sorbant Assays 
The sensitivity of both simple  tests  and conventional EIA methods  has  been proved 
to  be similar. 
Different testing strategies  can  be proposed  (see  Figure 5): 
1. Assay A  + VI/estern  Blot  conventiona.l  algorithm 
2. Assay A  +Assay B + LIA  alternative algorithm  + a supplementary assay 
3. Assay A  +Assay B  alternative algorithm  using  two  screening assays 
[t has been shown that there is  no gain in accuracy from repeating initial reac-
tive results with the same assay  because results are generally reproducible. The 
combination of two different screening tests  (third  strategy)  has been evaluated 
and proved to  give reliable results with 100 % of sensitivity and specificity; it 
is also 5 titTles faster and 6 times less expensive than the conventional algorithm 
utilizing Western Blot. Utilization of  Line ImmunoAssay  (LIA) as a confirma-
tory method presents, compared to conventional Western Blot, the advantage 
of allowing for HIVl and/  or HIV2 diagnosis in a one-step manipulation and 
of giving a lower rate of indeterm.inate results. 
Although there  are  differences in sensitivity  between HIV antibody  tests 
when used during the seroconversion phase, these differences are small, and do 
not represent a significant threat to public health or to the blood supply. 
What about HIV1 group  0  viruses  ? 
HIV1 subgroup 0  virus, which results in antibody not detected by all EIA tests using 
synthetic peptides  or  recornbinant  antigens,  was first  dicovered in  Cameroon,  where 
estimated  0  virus  inf ections  represent  less  than  1 % of total HIV irifections. 
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Figure 5  Schematic representation of the conventional (Procedure 1) and alternative confirmatory  algorithms (Procedures 2 and 3) 
for HIV seropositivity. 
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In general, failure  to  detect HIV irif ection  is m.ore  likely  to  result from  the absen-
ce rif antibodies  in  the seroconversion window phase than from  irifectiort  with a high-
ly  divergent subgroup  0  HIV-1 strain. The existence rif subgroup 
0  HIV1  viruses  is likely  to  have little- if any - impact  on  HIV diagnosis  and 
blood saf ety  outside the area where  they are prevalent  (Cameroon).  Furtherrnore,  in 
199  5,  most  com.m.ercial  screening tests have been improved so that  they  are  able to 
detect HIV- J 0  irifections. 
4.2. Screening for  Hepatitis  B  surface antigen: HBs Ag 
Hepatitis B is an important transfusion hazard since it is established that blood 
infected with hepatitis B virus is infectious in alnwst 100 % of cases. In deve-
loping countries, the rate of people infected with HBV is  very  high and may 
reach 90% in adults. It is essential that every blood unit should be screened for 
HBsAg for  the  following  reasons:  a  great number of transfusion indications 
refer to paediatric patients who have  not been i1111nunized; besides, the conse-
quences of transfusing blood infected with  hepatitis B  to  immunized indivi-
duals are not known. 
The most reliable method for preventing HB V transmission  is to screen blood donors 
for  HB suiface  antigen  (HBsAg). The viral  suiface  antigen HBs produced  in great 
quantities  by  cells irif ected by HB Vis a good  rnarker of  current  irifection. 
The sensitivity and specificity rif screening tests are quite good and the positive pre-
dictive value  is high  when  enzyme-linked immunosorbent  assays  (EIAs)  are used. 
Other techniques  exist, e.g.  latex  a~lutinatiort, but are  less  sensitive. 
4.3. Screening for  Syphilis 
Syphilis, a  disease  caused  by  the  bacterium  Treponema  pallidurn  is  essentially 
sexually  transmitted. However, fresh  blood is potentially infectious. The mean 
cost of Syphilis tests  is  cheap, less  expensive than HIV or HBV assays. As  this 
nlicro-organism is very sensitive to low temperature, storage of blood for 24-
48 hour  at 4°C significanJy  reduces the risk. 
Although  the risk of post-transfusion syphilis is  quite low, the screening of 
infected donors may  be used  as  a marker of individuals at risk of HIV infec-
tion on account of their sexual behaviour. The screening of  blood donors can 
be performed by  using two nuin serological methods: 
--
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VDRL: search for  antibodies  against  cardiolipin,  characterized by  a low  specificity 
since  '/  % if  normal adults  produce  non-specific antibodies  which  m.ay  lead  to false 
positive  reactions. 
TPHA: allows for the  detection of  specific antibodies.  Particle agglutination tests  that 
are  cheap,  specific and sensitive have been  developed. They may  be adapted  in  micro-
well plates  technology for large  scale screening. 
4.4. Screening for Malaria 
Malaria is caused by  a protozoon. Approximately 150 m.illion individuals each 
year are infected with malaria, of whom 2 null.ion will  die.  Infection is trans-
mitted  through the  bite of an infected female Anopheles  mosquito. Hun1.ans 
themselves  are  the reservoirs of infection. Four species  of sporozoa are  causa-
tive agents of malaria:  Plasmodium  vivax,  Plasm.odium ovate,  Plasmodium  malariae 
and  Plasmodium. falciparum.  In  the course of the  life  cycle in the human host, 
merozoites  infect red blood cells. 
The best method for diagnosis  of  rna/aria  is  to  search a thick blood film for parasites 
in  the  red  blood  cells.  However, since  this  method requires  microscopic examination of 
each sample,  it is not suitable for large  scale screenit1g. 
The extent to which  transmission by  transfusion is a problem depends  on the 
incidence of malaria among the recipients.  In areas where malaria is epidem.ic, 
most recipients are likely to have been infected during childhood. Screerung for 
malaria is therefore important in countries with a low incidence of  the disease. 
4.5.  Screening for Hepatitis  C 
HCV is responsible for more than 90 % of  post-transfusional hepatitis if HBV 
has  been excluded. Estimates are that 80 % of the persons receiving a transfu-
sion with  blood infected with HCV will  seroconvert, and that probably more 
than  50 % of the persons who seroconvert will  develop chronic  liver disease 
with possible  serious  complications  10  to  20  years  after infection (liver cir-
rhosis,  hepatocellular carcinoma). 
From  1989  to  1994,  the  ifficiency  of EIA HC V serology significantly  improved: 
third gen.eration  tests are  now  available  which  are  more  sen.sitive  and  more  specific 
than.  earlier ones.  However,  the problem  related  to  the  confirmation if  EIA reactivi-Chap t er  3  •  Sc ree n i n g  .for  i u.fectio u.s  dis eas es 
ties still remains because there  is  no  true coriftrrnatory method: no viral lysate is avail-
able (such as  those used for Western  Blots in HIV coriftrm.ation) and all complemen-
tary  methods are very expensive. 
The few epidemiological data available in Africa indicate high seroprevalence 
of  anti-HCV antibodies but those data were obtained with tests of  the first and 
second generation, which gave a high rate offalse positive results and many dis-
crepancies  between screening  (EIA) and confirmation (RIBA)  results. In the 
field of HCV  serology,  as  in the  case  of HIV,  a distinction should  be  made 
between two different problems: that of  blood safety and that of  diagnosing the 
donor's HCV infection. On one hand, all  EIA reactive blood units should be 
discarded. On the other hand, diagnosis of the donor's  HCV infection should 
be referred to specialized laboratories  (as  is the case  for HIV infection). 
4.6. Screening for  HTLV-1  &  II 
The  risk  of developing  HTLV-1  disease,  adult T-cell  leukemia/lymphoma 
(ATLL) or tropical spastic paraparesis (TSP), is estimated to be 1 or 2 per 1,000 
HTLV-I positive  cases  per year after an incubation period averaging 20 years. 
The actual estimates  are  that about 60 % of the persons receiving blood con-
taining HTLV-I will  seroconvert. 
There are  three  known high prevalence  areas: Central and South America 
and the Caribbean, southern Japan and sub-Saharan Mrica  but epidenuologi-
cal  data are incom.plete. The tests (EIA test and Particle Agglutination Assay) 
give  many false  positive  results. The  available  confirmation by Western Blot 
(WB)  lacks sensitivity  for  the anti-envelope antibodies  and consequently it is 
necessary  to  use  additional  more  sophisticated  techniques  (RIPA). Actual 
screening tests do not distinguish HTLV-I and HTLV-II and it is not certain 
that HTLV-II is a pathogenic virus. 
The relevance rifscreeningfor HTLV-IIII antibodies in developing countries  remains 
questionable and needs  to  be docurnented further; at the present time,  it seems  not  to 
represent a major problem rif tranifusion safety. 
4. 7. Screening for  Chagas  disease 
Chagas  disease, also  known as American Trypanosonliasis, is caused by infec-
tion with the protozoon 1rypanosoma  cruz i. These protozoa are  transmitted to 
--
C linpl e l'  3  •  Screening for  infectious  diseases 
humans by  the bites of infected insects;  the  disease  can be  severe  and  fatal. 
Trypanosomes can  also  be acquired by  blood transfusion when  blood is col-
lected from an asymptomatic infected donor with parasitaemia. 
As  far  as  blood transmission of Chagas disease  by blood is  concerned, the 
problem  is  most serious  in South America, where  the  disease  is  endernic. 
However, migration of  people from endemic to non-endemic areas has  resul-
ted in the presence of infectious individuals in  previously non-endemic areas, 
Laboratory  testing  in  the early phase if  infection  is  by  examination if  a blood fllrn 
in order  to  detect  the protozoa,  In  the acute phase,  the  micro-organism  can be cultu-
red from  blood samples, Neither of  these  two  methods is applicable  to  the screening of 
blood  donors,  Several  serological tests  (IF,  CF, EIA, PH)  are  available for the detec-
tion  of  antibodies  that are produced in  50 %of  acute phase patients,  and  in  95 % 
with chronic  ilif ection,  but  their sensitivity and specificity remain  questionable, 
5. Example 
Serosurvey conducted in  Rwanda in  19 91 
- Blood donors tested: 
Age of  blood donors: 
- Occupation:  cultivators 
students 
n = 437 
from 17  to 29 years. 
n = 329  mean age: 21.7 ± 1.57 years 
n = 108  n1ean age: 18.8 ± 0,63 years 
Distribution of  infectious markers: 
pos  neg  tot  % 
-HIV  15  411  427  3,51 % 
- HBsAg  25  409  434  5.76 % 
-Syphilis  10  424  434  2.30 % 
-Malaria  8  426  434  1.88% 
- HCV  10  418  428  2.34% 
Total  68  434 
As  much as  16  % of blood units  colJected must be discarded  and not trans-
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Co-infections: 
HIV HBV  HCV  Syph  Malaria  N  (co)-infections  Percent 
+  - - - - 13  HIV  3.08% 
+  - - +  - 2  HIV + Syphilis*  0.47% 
- +  - - - 24  HBV  5.69% 
- +  +  - - l  HBV + HCV**  0.24% 
- - +  - - 9  HCV  2.13% 
- - - +  - 8  Syphilis  1.90% 
- - - - +  8  Malaria  1.90% 
- - - - - 357  uninfected inclividuals 
Total  422 
65  infected individuals  (15.4 %): 62  with one infection and 3 with dual infec-
tions 
* 
** 
HIV was  found with Syphilis, suggesting sexual n1.odes  of transm..ission; 
HCV was  found  alone  or in association with  HBV,  suggesting  blood 
borne contaminations. 
Distribution  of infectious  markers  among  the  two  categories  of 
blood donors: 
Occupational  Number  HIV  HBV  HCV  Syphilis  Malaria 
%  %  %  %  % 
Students  n  =  108  1.87  9.26  0.93  0.93  0.0 
Cultivators  n  =  329  4.40  4.63  2.82  2.78  2.47 
Younger people are significantly less  infected  than  older people as  shown by 
Figure 6. 
--
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Figure 6: Prevalence of infectious markers (HIV, HBV, HCV, Syphilis, Malaria) 
among  R wandan  blood  donors  (students  and cultivators)  in  1991. Younger 
people are less infected than older people. 
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6. Recommendations for testing procedures 
About screening for transrnissible diseases  in general: 
- has  to be performed taking into account epidemiological data in  the local 
population (donors and recipients) 
About screening for particular transmissible diseases: 
- HIV 
- HIV1 &2 screening tests are preferred to HIV1 only. (Most HIV tests are 
also able to detect antibodies  against HIV 0). 
- A single positive  screening  test result is sufficient to  decide to  discard 
the blood unit from  therapeutic use. 
- If the donor is to be informed, all  precautions should be taken: the posi-
tive  test  result should lead  to  performance  of an  alternative  test  (or  a 
confirmatory  test). The  choice of the  alternative  test  will  depend on 
availability and specificity. Ideally,  a second  blood sample should  be  re-
quired for HIV analysis brifore the donor is informed of his HIV status. C hapt e r  3  •  Scree 11i11 g  fo r  i11.fecti o 11 s  di se a ses 
-The choice of an appropriate screening and  testing procedure will be 
deternuned by several parameters, among which: the number of tests to 
be performed, the specificity, the sensitivity under the operational condi-
tions of the laboratory,  the (positive and  negative)  predictive  value in the 
local population and the cost of the procedures  available. 
HBV 
-The decision to test for Hepatitis B is dependent upon many factors but 
should be given a high priority. 
- If testing is adopted, it is important that a sensitive test be used and that 
all  blood donations giving a positive result be discarded. 
- HBs Ag testing is  a priority for blood transfused to non-imm.une irifants 
and children. 
Syphilis 
- Testing for syphilis is recommended. However, a positive test does not 
always  mean  that  the  blood  unit  is  infectious. Besides,  retention  of 
blood for 3 days  at 4°C inactivates  the infecting agent. 
- If the result is used  for  diagnostic  purposes, a confirmation should be 
performed with other specific tests. 
- Testing for syphilis has  advantages of suggesting intervention for donor 
health and  in suggesting  a sexually  active individual  who  might have 
increased risk of acquiring HIV infection. 
Malaria 
- In endemic areas, a medica] history seeking evidence of  recent fever and 
illness is essential. 
- ln epidemic and other areas, examination of a thick film is advised. 
-The use of  prophylactic anti-n1.alarial therapy for transfusion recipients 
remains controversial. 
- HCV 
-Epidemiological  data in Mrica  report between 2 and 20 HCV carriers 
per thousand, but need to be further documented. 
-Screening  for  HCV  antibodies  is actually  three  times  as  expensive  as 
that for HIV Financial  resources are therefore a major criterion for the 
decision on  HCV screening. 
Chagas disease and HTLV-1. 
- No systematic screening recom111.ended except in areas where the dise-
ases  are frequent. 
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Figure 7 Main blood products that can be prepared from one whole blood 
unit: R ed Blood Cells,  Plasma, Platelets  and Cryoprecipitate. C h apt e r  4  •  Preparatiorr  aud  11 se  of blood  compouerrts 
Introduction 
In developing countries, due to a lack of  equipment, blood component preparation is most 
ciften  limited to  red blood  cell  concentrates  (RBC) and plasm.a (P).  However,  some pro-
cedures  which  are simple to peiform  and which  require few means can  be carried out  to 
provide the patient with  the specific needed fraction. To  ensure optim.al  biological activi-
ty of  the tranifused products, it  is  important to  know and  to  respect their specific storage 
conditions. Separation  cif blood  components permits storage  under optimal  conditions 
which are different from  one component  to  another.  For  example, fresh frozen plasma, 
red blood  cell  concentrates  and platelets  should not be stored at  the same temperature. 
Preparation of  blood components should only be done if  and where the saf ety o f  blood 
is  satiifactory.  Indeed,  if the residual  risk for  HIV or  any  other blood  transmissible 
disease  remains  high,  preparation  of blood  components  (red blood  cell  concentrates  and 
plasma)  will multiply  twice the number of  potentially inj ected recipients. An interesting 
strategy could be to prepare blood components  only from  regular blood  donors  who  have 
been proved several  consecutive times  to  be free  of  viral inf ections. 
Moreover,  blood  components should  only  be prepared  in  sterile conditions.  In  this 
sense, multiple bag systems are prif erred to  single bag systems. 
Blood components are prepared through separation  of  elements on  the basis cif their 
different densities. Separation  is carried out  at  4 °C (except that 20 to  24 °C is  used 
when platelets are to be conserved), and can be achieved by sedimentation or,  more quick-
1)~ by  centrifugation. 
As shown in Figure 7, the basic blood components to  be considered are: 
- Whole Blood 
- Red Blood  Cells (RBC) 
- Platelets (Plt) 
- Plasma  (P): Fresh Plasma (FP)  and  Fresh Frozen Plasma  (FFP) 
- Cryoprecipitate (Factor VIII + Fibrinogen) 
--
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1. Whole blood 
Dciflnition 
One whole blood unit corresponds to approximately 450 ml (350 to 500 ml) 
volum.e of blood collected  from one blood donor, in a plastic bag containing 
an anticoagulant solution (Figure 8). 
I  1 WHOLE BLOOD UNIT  I 
- ;---
-
I  \ 
I 
PLASMA  I 
I 
RED CELLS 
I 
Figure 8  Plastic bag used to collect one blood unit 
Preparation 
ln order to prevent bacterial contanlination of the blood unit, it is of greatest 
importance to ensure skin disinfection before venipuncture of the donor. 
There is no "preparation" of whole  blood since it is  the  direct product of 
the donor's  bleeding and serves  as  raw  nuterial  for  the  preparation of blood 
components. The  acidification of whole  blood by  the anticoagulant solution 
has  a beneficial effect on the synthesis  of adenine nucleotides  which are vital 
for  the  nuintenance  of cellular  structure  and  integrity.  CPDA1  (Citrate-C hapt er  4  •  Preparation  atrd  11se  of blood  compo11ents 
Phosphate-Dextrose) is generally preferred to ACD (Acid-Citrate-Dextrose) as 
anticoagulant. The choice of anticoagulant is  important in determining the 
acceptable duration of storage of blood before  transfusion. 
Storage 
The  optimal  storage  temperature  of whole  blood  is  1  to  5  °C.  However, 
according to  the anticoagulant used, the  optimal duration of storage differs, 
longer for CPD-A (35  days)  than for ACD (21  days). 
Precautions 
Whenever possible, it is  preferable to collect whole blood into a multiple bag 
system which enables the preparation of blood components in a closed sterile 
system. 
The ABO  compatibility between donor and  recipient should be  respected 
when  transfusing  whole  blood  (see  Figure  9).  However, special  attention 
should be paid when transfusing whole blood of  the so-called universal group 
0  because of possible anti-A and anti-B high titer haemolytic antibodies (see 
below: Group  0: universal but  dangerous  donor). 
Whole  blood, because  it is  unprocessed,  is  highly  efficient  in  transmitting 
infectious diseases. 
2. Blood components 
2 .1. Red Blood Cell concentrate (RBC) 
Diftnition 
Concentrated red  blood cells  result from the removal  from whole blood of 
sufficient plasma to obtain a final concentration (haematocrit) of 60 to 70 %. 
Preparation 
Plasma can be removed from whole blood by using a closed  system  when the 
blood collection set includes one or more satellite bags. If the closed system is 
used, plasma  may be separated at any time and the red cells  continue to be 
stored at l  to 5 °C for up to the normal period for that anticoagulant/preserv-
ative  solution. A  closed  system. offers  the  important advantage  of avoiding 
microbial contamination from the environment. 
In practice, when the equipment (centrifuge, plasma extractor etc)  required 
to fractionate blood is  not available, a convenient method is  to hang the blood 
--
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ABO compatibility rules 
for transfusion of  Whole Blood and Red Blood Cells 
for transfusion of  Plasma 
Figure 9 ABO compatibility rules that have to be respected 
for Red Blood Cells and Plasma transfusions. 
bag fi.·om  its base in the blood bank, make  sure that the contents are not mixed 
before  administration  and stop  the  transfusion  when plasma  enters  the  drip 
chamber. 
Storage 
at 1 to 5 °C for no nwre than 35 days, depending upon storage conditions and 
the quality of the cold chain. 
Precautions 
The ABO compatibility between donor and recipient must be respected when 
transfusing concentrated red blood cells. 
R ed Blood Cell  concentrates  are efficient in transmitting infectious  diseases. 
Group  0  donors: universal but potentially dangerous donor 
Group  0  individuals  are generally  considered  as  universal donors,  whose  blood  can Chapt.er  4  •  Preparation  and  11se  of blood  compo11ents 
be  transfused  to  any  recipient, whatever his  own  blood group A, B or AB. However, 
some group  0  individuals possess high  titer anti-A or anti-B antibodies that can pro-
duce haemolysis in vivo. When transfused in  large amounts,  as  may  be  the case whm 
whole  blood  is  administered,  these  antibodies  are potentially  damaging for group A, 
B  or AB erythrocytes.  But when  whole  blood  is fractionated  into  concentrated  red 
blood  cells and plasma,  the  volume if  plasma  remaining  in  the  RBC concentrate  is 
much  smaller and generally  does  not entail any  adverse  ljfects  against  the  recipient's 
erythrocytes.  Therifore,  the use  of  fractionated  blood  consistently  reduces  the  risk  if 
haemolytic reaction  due  to ABO antibodies. 
2.2.  Platelets 
Definition 
One Platelet Unit is  the number of  platelets extracted from one unit of  whole 
blood = (0.6 ± 0.2) x 1011 platelets. 
Preparation 
Platelets are prepared from freshly  collected whole blood (within 6-12 hours 
from bleeding) as: 
-platelet concentrate 
- platelet rich plasma 
1. Preparation of  platelet concentrates  requires special equipment and expensive 
blood collection sets that are likely to be needed only at tertiary care facili-
ties. When adequate equipment is  available, preparation of  platelet concen-
trates requires a two step centrifugation. A  first  (low speed)  centrifugation 
allows for the separation of platelet  rich  plasma  and packed red  blood cells. 
After a  second (high  speed)  centrifugation allowing extraction of a large 
volume of plasma, the sedimented platelets  are  resuspended in a small vol-
ume of plasma (about 50 rnl). 
2. When adequate equipment is  not available, platelet  rich plasma  (PRP) can be 
prepared by allowing fresh blood to sediment with the bag supported verti-
cally for six hours at room temperature. The plasma  is  then transferred to a 
satellite bag (closed system) or to a transfer pack (open system). The red cells 
are stored refrigerated and the platelet rich plasma mixed by gentle agitation 
every four hours whilst stored for up to 24 hours at room temperature. 
Storage 
Platelet concentrates may be stored in an agitator at room temperature (RT = 
theoretically 20 ± 2 °C) for up to 72 hours from the time of the blood collec-
tion. 
--
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In  developing  countries, platelet  needs can  be  achieved  by  giving "fresh" 
blood or platelet rich  plasma (PRP) provided the whole blood has  remained 
at room temperature until separation is made. "Fresh" blood is blood that has been 
kept at room temperature for not more than 12 hours. 
Precaution 
Although it may be possible to cotnplete the required serological testing with-
in 12 hours,  it is safer to prepare platelets from blood collected  from  regular 
donors known to be negative for markers of  transmissible disease and conl.pat-
ible with the intended recipient: this does  not replace the need for screening 
and laboratory testing. 
Platelet transfusion usually includes some of the donor's red cells and there-
fore  requires  demonstrated ABO compatibility between  recipient serum and 
donor red cells. 
2.3. Fresh  and  Fresh  Frozen Plasma 
Difmition 
Plasma is the  supernatant of red  blood  cells that  contains proteins;  it  can  be 
recovered  from whole blood by centrifugation or sedimentation of red blood 
cells. One whole blood unit allows for the recovery of  approximately 250 ml of 
plasma. 
Preparation 
Plasma may be prepared  as  a byproduct of the preparation of a red  cell con-
centrate. If this is done within  6 hours of  collection it can be presumed to have 
retained labile coagulation factors (V and VIII) and can be frozen and used as 
fresh frozen plasma. Otherwise the plasma, stored either as liquid or frozen, will 
retain aU proteins except factor V and VIII. 
Storage 
The best  storage  conditions  for  plasma  are  to  be  kept frozen  at -25 °C or 
lower.  Frozen plasma can be conserved for up to 1 year. 
Liquid refrigerated  (4  to 8 °C) plasma may be  used within 35 days  of col-
lection if  separated from red cells in a closed system. 
Thawed frozen plasma must not be refrozen. 
Precaution 
The indications for the use of  plasma in developing countries are limited by the 
recognition  that  it  has  the  same  risk  of disease  transmission as  does  whole 
blood. 
Transfusion of  plasma requires ABO compatibility with recipient's red cells. C h apte r  4  •  Preparatio11  a11d  tts e  of blood  co mpo11 e 11ts 
2.4. Cryoprecipitated Factor VIII 
Diftnition 
Cryoprecipitate is a preparation of  plasma which is particularly rich in coagu-
lation factors  (fibrinogen, Factor  VIII, X  and XIII). 
Preparation. 
Cryoprecipitate is prepared from snap-frozen  fresh  plasma which  then  thaws 
slowly at 4  to  6  °C. Mter  thawing,  the supernatant plasma  is removed (cryo-
precipitate-poor plasma)  and  the precipitate is  resuspended in about 20 ml of 
plasma. 
Storage 
It can be frozen and kept for one year at -65 °C. It contains about 50 % of the 
whole blood content of fibrinogen and factors VIII, IX and XIII. 
Precaution 
Transfusion of cryoprecipitate requires ABO compatibility. 
Cryoprecipitate has  to be infused as  soon as  possible after thawing. 
3. Recommendations for preparation and 
storage of blood components 
- Whenever  possible,  a  closed  system  should  be  preferred  to  an  open 
system to avoid microbial contamination. 
Whenever possible, whole blood should be fractionated into RBC  con-
centrates  and plasma. 
For each  transfused  blood product,  there  is a  risk  of infectious  disease 
transmission, plus a risk of  immunological adverse reaction. 
Specific storage conditions (time, temperature) should be respected for each 
blood component. 
Any discoloration, sign of haemolysis, precipitate or abnormality indicates 
that the fraction must not be used. 
Conservation  of optimal  biological  activity  during  storage  of whole 
blood, red blood cells and plasma  strongly  depends on the quality of the 
cold chain.  Variation between 1 and 10 °C is acceptable for whole blood, 
provided the period above 6 °C is  no more than six  hours. 
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Blood  Main  Storage  ABO com-
Component  Indications  To  patibility 
Whole Blood  Acute blood loss  4°C  yes 
RBC concentrate  Anemia  4°C  yes 
Haemorrhage 
Plasm a  Burns  4°C  yes 
Fresh Frozen  Severe blood loss  - 25°C  yes 
Plasm a  Coagulopathy 
Platelets  Massive haernorrhage  room T
0  when possible 
Coagulation  disorders 
Cryoprecipitate  Haemophilia A  - 65°C  when possible 
Von.  Willebrand 
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Introduction 
The pattern <if blood use in developing countries is quite different from  that in developed 
countries. 
In  developing countries,  a high proportion of  blood tranifusions  are given  to  children 
and  to  women., respectively  in  relation  to  anaemia  and complications of  pregnancies. 
As an  example, a study  carried  out in  Kenya  in  1994 reports that  67 % of tranifu-
sio115  were  ordered for children  under 15 years,  27 % were for  adult women  and  6 % 
for adult  men {JR. Zucker et al.  1994). 
The risk of  viral diseases  transrnitted through tranifusion is of  great concern in gener-
al but more particularly in ch£/dren who have a potentially longer life span and are often 
otherwise  not exposed as yet.  In developing countries  with high prevalence  <if inf ectious 
diseases  (HIV, HVB  .. .),  the risk  <if transmittil1g inj ections by  blood  is high. Therifore, 
testing of  blood for serological markers  (<if HIV, HB V.. inf ection:,) is one part <if the stra-
tegy.  However,  this  is not st1.{ficient since  a rnathem.atical formula  estimated, in  199  3, 
that ... 
. . . in  a donor population incidence  of HIV of 10 %, 2 out of every  1000 tranifu-
sio115  of  blood, although tested seronegative for anti-HIV, will transmit the virus. 
Therifore,  another way to  reduce  the spread <if irifectious diseases by tranifusion is to pre-
scribe blood  or blood components  only  when they are  clearly  and strictly  indicated,  cifter 
a cariful assessment <if the relative benrifits and risks for the recipient. Ideally, every trans-
fusion  should  always be strictly  evaluated and  the decision  to  tranifuse  must take  into 
account both  the therapeutic advantages  and  the itifectious risk  encountered. 
On account of  the difficulty  to  recruit "safe" blood  donor s~ it is a priority  to  optimize 
the  use  <if blood and  blood cornponents,  to peiform  all  tests,  analyses  and manipulatio115 
so as  to  enhance  or maintain their  therapeutic benrifit. 
Other strategies  such as  those  of preventing  anaemia  in  children  and  in  pregnant 
women, or to promote administration of  blood substitutes whenever possible or to  develop 
alternative procedures  such as  autologous  tranifusions should also  be irnplemertted since 
they  are  also  likely to  reduce  the  rate  <if blood  borne ilif ections. 
j.R.  Z 11cket; E.M.  Lackritz, T K. Ruebuslt, A . W  J-Jiglll.owet; j.E.  Afhmgosi, J. B. 0. l#re and  C. C.  Campbell. 
Anaemia, blood transfusion practices, HIV and mortality among  women  of reproductive  age  in  western 
Kenya; Transac t.iot"/S  f!I the Royal  ociety ifTropical Medicit·te flttd  l-lygiene  (1994),  88;  " 173-1 76.  -C h apt e r  5  •  Use  of bloo d  a rr d  IJi ood  co m po rr e rr ls 
Another main feature if  blood  tranifusion  in  developing countries  is the absence if 
guidelines  about appropriate use  of blood. Very Jew well  designed studies  about  the  use 
cif an.d  the need  for blood  in.  developed  and  developing countries  are available. Also,  the 
bentifi.t if  blood transfi.tsion  has  always been  accepted in  rnedica.l practice  but it has  rare-
ly been  evaluated precisely,  and  data for  developing  countries  are  not  available at  all. 
Unless  more studies  become available, only current practice  and  knowledge  can  be used 
and  reported on. 
ln many developing countries mainly in Africa, there is little demand or need  for blood 
for elective surgery.  Furtherm.ore,  the rate of  blood consumption for elective surgery chiif-
ly  depends on  the degree if  sophistication if  hospitals.  Most qften, emergencies  are the 
major  indications for  blood  tranifusion. However,  in  all  the programmes  there  is  an 
important shortage  of iriforrnation  about  the real basic  needs which,  in  some instances, 
are quite different from  the demand for blood  transfi•sions. 
It is also ciften difficult for the authorities  in charge of  the tranifusion services  to obtain 
reliable data  about the  use if  blood in the hospitals.  Unlike for developed countries  elec-
tive  surgery  should  not  be  the  major  indication  governing  the  demand for  blood. 
Therifore, each country is encouraged to  convene a meeting if  a panel of  experts  to  draw 
up national guidelines for blood tranifusion indications. As a global estimatio1 1, the nurn-
ber if  blood transfi•sions  required annually in  the regions reported on is less  than  1, 000 
per 100,000 population,  which is lower than  in  developed countries  (it1  Belgium  ± 1 
per 1  0). Experience  s u~es ts that it is  between 2 and  10 transfi•sion episodes of  an aver-
age if  1. 6 units per thousand population per year. 
-
Use of  blood 
In most cases,  blood  must be immediately available to  have  an  optimal iff ect. 11-ws, as 
well as ensuring a supply of  safe blood, blood typing and compatibility testing as well as 
clinical monitoring procedures  must be simple and  not time-consumi11 g. Chapter  5  •  Use  of blood  a11d  blood  co mpo11 e 11ts 
1. Main indications for blood and blood 
components 
The major indications for  transfusion  are:  severe  anaemia  (in  children  and in 
adults,  for  example  due  to  sickle  cell  or malnutrition  ...  )  and  acute  blood  loss 
during pregnancy, delivery or accident, and the two groups most concerned as 
blood recipients are  children and  women.  However,  minor indications  such as 
elective surgery as  well  as  alternative management will also  be discussed. 
1.1. Acute Blood Loss: 
Acute blood loss  is a major indication for blood transfusion in developing 
countries. Life threatening haemorrhages  are most frequently a complication 
of pregnancy (ectopic pregnancy, delivery)  and traum.a (road accidents, war 
or weapon accidents). In some cases, acute blood loss may happen during an 
emergency or elective surgery. 
The  management  of acute  haemorrhage  relies  on  three  main  principles: 
identification of the  bleeding  site,  restoration of circulating  volume  and 
restoration of m  ..  rygen transport. 
Volume  can be restored by infusion of  crystalloid, synthetic colloid solutions 
or proteins of human origin (albumin). 
Depending upon the  patient's haemoglobin level before  haemorrhage, red 
blood cells should only be  transfused  after  25  % of volume  loss.  Indeed, 
normally, a healthy adult can  tolerate acute loss  of up  to 20 % of the  cir-
culating  blood volume without requiring  intraveinous fluid  replacement. 
Acute  blood  loss  is  a  major  cause  of female  mortality  in  developing 
countries. In a  normal pregnacy,  10  g/  dl  of haemoglobin may  be  within 
normal  range,  with  lowest  Hb  levels  at  30-34  weeks  of  gestation.  In 
pregnancy,  transfusion  is not indicated  unless  the  Hb is below 6  g/  dl, or 
below 7  g/  dl  at  the  onset of labour, and there  is evidence  of respiratory 
and/ or circulatory compromise. 
Unfortunately,  in developing  countries,  such  management of acute  blood 
loss  is  made difficult, partly due to the heavy cost of the replacem.ent crys-
talloid  solutions,  or  due  to  their  unavailability.  In  these  conditions  and 
paradoxically,  blood  is  used  as  volum.e  expander,  which  should  not  be 
recomn1ended. 
--
C hapt er  5  •  Use  of /1/ood  atrd  blood  cornpotr e trts 
1.2. Anaemia: 
Anaemia is a frequent pathology in developing countries, due to several fac-
tors:  malnutrition and  poor  dietary  intake, chronic  blood  loss  related  to 
parasitic diseases  (such  as  n1.alaria, gastro-intestinal  diseases ... ) or hereditary 
haemolytic disorders  (G6PD deficiency, sickle cell anaemia, thalassemia ...  ). 
Chronic  anaemia  is generally  well  tolerated  and  blood  transfusion is  not 
necessary  as  long  as  the  haemoglobin remains  stable. However, in case  of 
"aplastic  crisis"  or acute  haemolysis  crisis,  when  haemoglobin level  falls 
rapidly and the patient exhjbits clinical symptoms, red blood cell transfusion 
may  be indicated. Although the level and  rate of decrease of haemoglobin 
can serve as  a criterion for blood transfusion, severe anaemia associated with 
cardiac  failure is a clear indication for red cell  transfusion. Children  up  to 
age of  6 ought to have  a haemoglobin level < Sg/100 ml and show breath-
lessness  or other signs of hypoxia to justify a blood transfusion. 
For paediatric patients, in order to use  blood optimally, one blood unit can 
be divided by sterile technique into 3  units of 80 ml of packed red blood 
cells. Such blood is best collected from known HIV and HBV negative vol-
untary repeating blood donors. 
1.3. Elective surgery: 
Indications for blood transfusion as  well as  the number of  blood bags  needed 
for a given elective operation should be discussed locally and be the result 
of  a consensus between clinicians. As far as elective surgery is concerned, the 
use of autologous blood should be preferred to homologous blood transfu-
sion whenever it is possible. 
2. Alternative to homologous blood transfusion 
2.1. Prevention of anaemia: 
2. 1. 1. For pregn.an.t women. 
Prevention  of  iron-deficiency  anaerrua  by  counselling  pregnant  women C h ap t e r  5  •  Use  of  l1 l ood  atrd  IJ i ood  co m po tr e tr ts 
through  the  organisation  of open  consultation  systems  and/ or  training  of 
m.idwives.  Iron and folate supplementation and/or antimalarial prophylaxis  or 
therapy could be part of the ante-natal  care in order to reduce the risk and the 
severity of  anaemia. 
Ensuring a follow-up of  pregnant women at risk of  problem delivery in order 
to transfer them as  soon as possible to an adequate hospital environment. 
2. 1.2.  z~or infants. 
Prevention of the spread of malaria in  children by preventing mosquito bites, 
by environmental cleaning, and the use  of anti-malaria therapy. 
2.2. Autologous  transfusion 
Autologous  transfusion is  the  collection and subsequent  re-infusion of the 
patient's  own  blood  or  blood  components.  Blood  transfusion  in  general, 
whether autologous or homologous, should only be  used  when clearly indi-
cated. Autologous  blood  transfusion  is  nwst  useful  in  elective  or  planned 
surgical procedures where blood normally is needed. 
A  programm_ e  for  autologous  transfusion  requires  precise  record  keeping 
and labelling, and adequate facilities for the collection and storage of  blood; 
a  well  organized  blood  transfusion service  is  therefore  essential.  Costs  of 
these services have generally been shown to be h.igher than for homologous 
blood transfusion and should be weighed against those of long-term mor-
bidity and m.ortality of transfusion related diseases. 
In situations where homologous blood is in  short supply, expensive or carries 
a risk of transmission of  serious infection, the use of the patient's own blood 
m.ust  be  considered  before  ordering  other  blood  for  the  care  of patients 
undergoing surgery. 
Three methods exist to collect blood and reinfuse  it during or after surgery. 
1. Preoperative deposit 
2. Immediate preoperative haemodilution (perioperative collection) 
3. Intraoperative blood salvage 
2. 2. 1.  Preoperative  deposit 
Must be previously arranged with the BTS. 
Suitable for some elective procedures in which blood loss is expected to be 
greater than 30 ml/ kg. 
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- Needs  careful planning. 
- Is  at least as  expensive as  homologous blood. 
- Every  seven  days,  from  35  to  7  days  before  surgery,  10  ml/kg  can  be 
collected into CPDA1. 
Autologous blood has  to be typed (ABO &  Rhesus) and screened for infec-
tious disease according to the national policy. 
Haematinics,  such  as  ferrous  sulphate,  are  given  orally  starting  50  days 
before surgery. 
2. 2. 2.  Immediate preoperative  h.aemodilution 
10 to 20 ml/kg of blood are collected into anticoagulant and with replace-
ment of  crystalloid or colloid solution, immediately before the start of  surg-
ery.  It  is  kept in the  operating room and unrefrigerated  until  reinfusion 
within 6 hours, at the end of  surgery, or at tin1e when blood loss  is enough 
to demand replacement. 
Adequate labelling of blood bags  is  of greatest importance. 
-
Blood does  not need to be tested if it is to be given only in the operating 
room. 
If not used, it must be destroyed when the patient leaves the operating room  .. 
Suitable  for  all  elective, and  many  em.ergency,  surgical  procedures  where 
blood loss  is expected to be greater than 15  m.l/ kg. 
Contra-indications: haemoglobinopathy,  sepsis  or  severe  cardiac,  liver  or 
renal disease. 
Haemoglobin should not drop below 9 g/  dl before surgery. 
2.  2.  3. Intraoperative blood salvage 
Blood collected from a sterile uncontam.inted abdominal or thoracic cavity 
may be reinfused (after filtration if clots are  present), during or immediate-
ly after surgery. 
The most common indication is ruptured ectopic pregnancy. 
Blood  can be  collected  by  inserting  the  needle  of a  blood collection set 
through  the cavity wall before incision or by scooping and filtering blood 
after the cavity is opened. 
The cavity is examined to exclude possible contamination from bowel con-
tents, urine, bile infection or malignancy before blood is  reinfused. Chap t e r  5  •  Use  of b l ood  a11d  b l ood  components 
2.3. Blood substitutes 
It is clear that very often, substitutes could be used instead of blood products 
but that because  of their unavailability, an unknown percentage of transfu-
sions are  not indicated but still  performed. 
The rapid  administration of sufficient  volum.e  of crystalloid  solution will 
maintain circulation in most patients until the blood loss  ceases. 
Patients who need volume expanders can benefit from gelatin solution (for 
example  GelaciJ®)  which is  cheaper than other colloids like  albumin or 
Dextran, and is very effective. This would save a lot of  transfusions, especial-
ly in management of trauma. 
2.3.1.- Crystalloid solution 
A considerable proportion of  blood used in developing countries  (e.g. 20% 
in Uganda)  is  for  women with post-partum haemorrhage.  Most  of these 
patients receive less than 1 Litre of  whole blood. Experts think many patients 
could  be  managed  successfully  with intravenous saline  solution. Similarly, 
most recipients of blood following trauma get less than one litre and could 
also  be managed with saline. However, saline is not available in a lot of de-
veloping countries in sufficient supply at the time needed. 
Doctors  usually  underestimate  the  volume  required  and  the  duration of 
continued IV  fluid. For a loss  of 30 ml/ kg it is necessary  to administer 100 
nil/ kg acutely and to continue at a sim.ilar level in the subsequent 24 hours. 
2. 3. 2.- Colloid solutiom 
Colloid  solutions,  such  as  albumin  5  % or 20  %,  or substitutes  such  as 
Dextran, hydroxyethyl starch (HES), or gelatin solutions are often consider-
ed  to  manage  acute  blood loss.  However,  these  solutions are  much  more 
expensive  than  saline,  even  though  about half the  volum.e  is  needed, and 
they are therefore not included in the first priority for treatment. Compared 
with saline, Dextran is 5-10 times  (and HES 20 times)  more expensive. 
5 % albumin is very expensive. Most of the BTS programmes  have  human 
plasma  available but the  use  of untreated plasma from a population with a 
high seroprevalence of HIV and hepatitis virus is unjustified. 
--
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3. Management of transfusions 
To  respect ABO com.patibihty rules  is the  m~or  preoccupation since  transfu-
sion  of ABO incompatible  blood nuy have  adverse  effects  with potentially 
fatal  outcome for  the  recipient. In order to prevent such accidents, extreme 
care has  to be used to ensure correct identification of  patient and of specimen. 
However, it is worth noting that problems of  ABO incompatible transfusions 
are not only due to laboratory errors; most often, transfusion accidents are due 
to a mistake in the identification of patients. 
3 .1. Blood grouping 
ABO and  Rhesus  typing.  Pre-transfusion  testing  includes  blood  grouping 
(ABO and Rhesus)  of the patient. Blood samples  from patients should be 
typed  using anti-A and anti-B  (+  eventuaJJy  anti-A+B)  for  red  ceJJs  and, 
when  possible,  A  and  B  red  cells  for  serum_ typing.  Any  discrepancies 
between cell and serum grouping should be re-investigated until the correct 
group is  determined. 
AJJ  blood units are previously  phenotyped  for both ABO  (cell  and serum 
proofs)  and Rhesus (D)  systems. 
- Whenever possible, Rh negative  recipients should not be  transfused  with 
Rh positive blood.  However when the Rh negative blood is  in short sup-
ply it may be necessary to reserve it for Rh negative females with potential 
for child bearing. 
ABO  compatibility  rules  have  to  be  respected  strictly  for  transfusion  of 
whole blood, concentrated RBC and plasma (see Figure 9) 
3.2. Compatibility testing (cross-matching) 
Compatibility testing uses laboratory methods allowing verification that the 
recipient's serum does not contain any antibody likely to react with donor's 
red blood cell antigens. 
Compatibility  testing  requires  the  provision of a sample  of the  recipient's 
clotted blood  (10  ml). Patients who have  never been  transfused  nor preg-
nant  can  be  expected  to  have  only  naturally  occurring antibodies. ABO 
compatible blood is assured by an imn1ediate room temperature saline cross-
match:  the  cells to  be  transfused  are  tested  against  the  recipient's  serum. C h apt. e r  5  •  Use  of bl ood  and  blood  components 
(Compatibility testing also  serves  as  a valuable tool to  reinforce the identi-
fication of the patient and the blood unit). 
3.3. Technical  alternatives for  cross-matching 
3.  3. 1. The  Direct proof in  Sali11.e. 
Donor red cells are  added to patient's  serum and exarnined, after centrifu-
gation, for haem.olysis and for agglutination  . .if neither has occurred  the  blood is 
compatible. If  even a hand operated centrifuge is not available, red cells should 
sedim.ent through serum in a tube for 30 minutes  and then be inspected. 
In practice, a tube technique  compatibility test must be performed and found 
to  be  negative  before  transfusion. The n1.ost  convenient method is to  add 
1 drop of  5 % donor cells to 1 drop of  recipient serum in a 12 x 10 nun tube, 
at room temperature. Centrifuge for 1 minute and exam.ine by visual inspec-
tion the red cell  button as  it releases  from the tube bottom when it is gent-
ly rotated. The complete procedure can be completed within 5 minutes. 
A microscopic examination is  not required. 
Tile or slide cross-matching without centrifuging is NOT acceptable. 
3. 3. 2. Irnportance  of temperature 
The saline cross-match performed at room  temperature will avoid most problems 
of  ABO incompatibility since most ABO as  well as  cold agglutinins are more 
potent at lower temperature. However, a lot of clinically significant antibodies 
will react  only  at  temperatures  closer  to 37 °C. Therefore, cross-match per-
formed  at 37 °C  will result in enhancing the sensitivity for the detection of 
clinically significant antibodies. 
3.  3. 3.  Enhancement of sensitivity: 
Other techniques  can also  be applied in order to enhance  the sensitivity of 
the  compatibility  testing.  For  example:  use  Low  Ionic  Strength  Solution 
(LISS); use of  proteolytic enzymes  (papain, trypsin, bromelin), use of Coombs' 
reagent  ... 
The  Indirect  proof:  anti-human globulin  (ARC)  in  case  of Immunized  patients. 
Patients who have been previously transfused or who have had a pregnancy 
may  have developed allo-antibodies. Therefore, for all  recipients who might 
--
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have  been  immunized, by  pregnancy  or by  previous  transfusion, and who 
might have  produced  IgG  against red blood  cell  antigens, it is advisable to 
exclude "coating" (or  sensitizing)  antibodies. These  antibodies  have  to  be 
detected with other techniques such as  a Coombs' test (AHG). This is relia-
ble only in experienced hands. 
To  achieve  this further compatibility  analysis,  the  same  tube  used  for  the 
saline  room  temperature  test  can  be  used. The  cells  are  resuspended  by 
mixing and incubated for a minimum of 15  minutes  in a water bath or in 
an incubator at 37 °C. The tube is centrifuged and the button washed four 
times  with saline. Two  drops  of  anti-human-immunoglobulin (AHG)  are 
added  and the  tube  centrifuged  again. The  tube  is then  gently  rotated  to 
look for agglutination. 
If agglutination takes place, the blood is not compatible and should not be 
transfused. 
If agglutination is not seen, the test should be completed by adding pre-
sensitized red cells, and, after centrifuging, confirm that there are aggluti-
nates. 
3. 3. 4. Minimum alternative to  cross-matchi11g. 
A  minimum  alternative  to  cross-matching  consists  111  re-checking  the  ABO 
blood group of both  the donor and  the receiver.  Ideally, each  result of grou-
ping should be checked by two different staff members.  For example: techni-
cian A determines the patient's ABO group whereas, independently, technician 
B tests for the ABO groups of all  blood units selected. 
3. 3.  5. Type and Screen strategy. 
This strategy consists in searching  for irregular antibodies  in recipient serum 
by using standard phenotyped red blood cells as  reagents. The type and screen 
strategy  can  be  applied  with two  levels  of sensitivity: the  lowest  one  is the 
direct saline proof and the highest one, which should be reconm1ended when 
possible, with the AHG reagent. 
3.4. Transfusion reactions: 
The first 20 ml (less  for infants) of each  transfusion are the most critical.  If 
there is pain, either remote or spreading from  the site of the needle, sudden C h ap t e r  5  •  Use  of blood  a11d  blood  COIIIJJOIIellts 
fever  or  shaking  chills,  a  transfusion  reaction has  occurred. T his  must  be 
noted  in  the  patient's  chart. The patient should be  n1.oriltored  at  regular 
intervals until 12 hours after the transfusion is finished. 
Accurate records must be kept allowing identification of (1)  the transfused 
patient and (2)  the blood given. 
The  presence  of allo-antibodies  in the  serum of an  immunized  patient is 
a  finding which must  be  kept in mind and  taken  into  account in  case  of 
future transfusion. 
4. Examples 
4.1. Example of use of blood in  two African countries 
Figure 10:  Use  of  Blood in Uganda in 1993, and in Guinea in 1994. 
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4.2. Example of indications for blood transfusion 
Indications for  Blood Tranifusion  in  Uganda 
Sumnury statement of "Indications for Blood Tranifusion  in  Uganda", prepared by 
the AIDS Control Programme of the Ministry of Health of the R epublic of 
Uganda. Published July 1989. 
Blood transfusion may have  major consequences for good or bad in patient 
care. Indications and contra-indications are  different from those  in developed 
countries  and are not available in textbooks. The spread of the HIV epidernic 
in the population has  increased dramatically  the risks of transfusing blood. In 
some urban areas, more than 20 % of the blood donors have  been found to be 
anti-HIV positive. If this blood had not been tested and instead used to trans-
fuse  patients, all  recipients would have  become infected with the AIDS virus. 
In  fact, even when testing  is done  and HIV positive  blood discarded, a few 
donors will  be virus positive but antibody negative  (the window period) and 
HIV transmission will  occur. Thus severely linLiting  transfusions to  only the 
most unavoidable situations is indicated. Chapt e r  5  •  Use  of IJiood  and  blood  co mpo11 e 11 ts 
INDICATIONS FOR TRANSFUSION IN UGANDA 
prepared by 
the AIDS Control Programme of the Ministry of Health 
ofthe republic ofUganda (1989). 
1. Anaem.ia in inf ants: Transfusion may be necessary if 
- Hgb is less  than 3 g/  ell  without complications. 
- Hgb is less  than 4 g/  ell  and complicated by malaria (positive  blood smear) 
or bacterial infection, even without cardiac failure. 
- Hgb is  less  than 5 g/  ell  and is  complicated by cardiac failure (air hunger, 
increased venous pressure, hypotension= systolic BP less than 80 nm1 hg., 
tachycardia = pulse rate more than 140/minute, and general or dependent 
oedema). 
- Transfusion is NOT  necessary if  Hgb. is more than 5 g/  ell. 
2. Anaemia in pregnancy 
- Hgb levels less  than  7 g/  ell  may  need  treatment if near  term, but trans-
fusions  are  essential  only  when cardiac  failure  results from anaemia.  In 
addition, diuretics  should be concurrently administered. 
- In case of postpartum haemorrhage, blood transfusion is indicated only if 
hypotension and reduced cerebral function persist after at least 50 rnl/ kg 
of fluid has  been given intravenously, and all measures  have  been taken to 
stop blood loss. 
3. Anaemia: other 
- Blood transfusion is indicated only in cases  where symptoms of anaemia 
progress  and  Hgb. is less  than  4  g/  ell  or if haemolysis  or haemorrhage 
occurs. 
4. Haemorrhage:  the first effort is to stop blood loss. 
- Haemorrhage from any cause requires replacement of  volume rather than 
of red  cells. Initially  this should be  with crystalloid  (saline  or Ringer's 
lactate) solutions  up to  50  ml/ kg  followed by  colloid  (5  % Dextran or 
--
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5 %  hydroxyethyl-starch)  in the same amount during the  first  12 hours. 
O nly if shock is worsening or persisting after the above measures  should 
blood be given. After each 250  mls of blood the condition of the patient 
should be evaluated before the risk of more transfusion is accepted. 
5. Emergency surgery: 
- The guidelines  for haemorrhage apply. 
6. Electi11e  surgery 
- It must be an  exception  to  use  donor blood in case  of elective surgery. 
Any such instance is cause  for a full  evaluation and subsequent report to 
the District Medical  Service by the hospital  superintendant. 
7.  Other indications: 
- Chronic anaemia etc. guidelines  are being com.piled. 
5. Recommendations for the use of blood 
It is recommended that in each country a survey is performed about the 
actual use ofblood and this survey should be repeated at regular intervals 
to monitor the use ofblood. 
- Each  blood  transfusion  progranune  in a  country should also  have  an 
approximate  idea  about minimum and realistic  needs for  blood,  blood 
products and substitutes. 
In collaboration  with hospital  clinicians,  each  transfusion service should 
develop guidelines  for the best use  of blood, blood substitutes  and blood 
products and monitor the daily practice. C hapt e r  5  •  Use  of blood  aud  blood  compou eut s 
6. Recommendations 
for the use of blood substitutes 
Whenever possible,  blood transfusion  should be avoided  for infants and 
pregnant won1en and replaced by safer blood substitutes. 
Promote crystalloids as  the first choice as  volume expander. 
Facilitate the distribution and the availabiLty of  saline. 
Plasma has limited indications and must be used carefully. 
Plasma is NOT recommended for volume expansion. 
Promote autologous  transfusion for elective surgery. 
Blood  transfusion services  should  determine  the  amount of IV  saline 
required and develop procedures  to ensure supply, distribution and cor-
rect use. In Uganda it is, for example, estimated that to provide sufficient 
saline  to  treat  acute  blood  loss  by  volume  replacement  will  require 
800,000 L/year. 
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Introduction 
Equipment  required  to  provide  blood  and  blood  components for  tra.nifusion  in  a. 
tertiary care hospital in  developing countries  is much the same as would be needed in  a. 
developed country. In  a primary  care setting,  however,  emphasis should  be placed on 
providing the minimurn essential, rugged and easily maintained and replaced equipment. 
When  electrical  supply  is  available only  during  a  limited  time,  or not  at  all,  it  is 
important for the laboratory  to  be able to peif orm all  essential tasks without it. 
Storage facilities  should be equipped with  a security systern  to pre1 1 ent disappearance 
of stock  as  well  as to  protect stock from  humidity, insects,  rodents,  etc.  Another security 
measure is to  insure stock which is cheaper than it seems when looked at on a.  long-term 
basis. Reliability of  delivery  dates  is an  important issue to  take into  account. 
Monthly records of  number of  donors, collection, blood products production and distri-
bution, are necessary in  order to  organize comumable ordering and purchasing.  It is clear 
that  the best price  is not  always the lowest one and  the choice  should be made taking 
into  account the quality of the product, the quality of the service  and  maintenance,  and 
the de/i1;ery facilities, sometimes  even the tra.it1.ing facilities. 
Bulk purchasing between different programmes  is suggested to  the EC's HIV  I AIDS 
programme to get a lower price,  better standardization and better adaptation  to  the blood 
programmes  in developing countries. However,  this is usually found  to  be impossible due 
to  variation  in  imtallation, maintenance  and  delivery  requirements as  well  as individu-
al priferences. 
1. Buildings 
In  determ.ining  how  a  building  should  be  constructed  several  important 
principles  apply, including: 
selection of  suitable local materials 
integrity of electricity and water supply 
application of ergonomic principles in all areas 
donor privacy 
security 
physical separation of donor and laboratory areas 
ventilation and air-conditioning 
space requirements should be based on 8-10 square meters per donor bed, 
--
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and sufficient pre- and post-donation area should be provided to allow pri-
vacy and refreshments at interview 
planning of capital investment should be done together with that of opera-
tional costs 
all  possibilities in the construction to assure easier n1.aintenance of the work 
spaces should be applied, for example: 
the  walls  and  the  floors  should  be  easily  washable  and  covered  by 
materials not susceptible  to  be  changed  by  the  use  of detergents  (daily 
cleaning with hypochlorite solutions is necessary) 
olinths should be rounded so as  not to accumulate dust 
especially  in the  laboratory  and blood handling  spaces,  tiles  should be 
used as  much as  possible 
cupboards  should be elevated so  as  to make cleaning easier 
plumbing  and  electricity  should  not be  walled  in but they  should  be 
reduced  to  the  minimum in  the  technical  spaces  and  preferably  run 
through hallways, under the roof or outside 
washbasins should be easy to clean by non-professional people 
in climates  with heavy  rains,  rain water pipes  should be large  enough  and 
easy  to maintain. Containers can be placed to organize a water reserve for 
the dry season. 
electrical wiring, laboratorial plumbing, air-conditioning should be appro-
priate  and not  too  sophisticated  and priority should  always  be  given  to 
materials locally produced or available. 
2. Equipment 
It is essential that  equipment for  a blood transfusion service in a developing 
country be  simple,  robust  and  capable  of local  maintenance.  In selection of 
such  equipment, the availability of a locally based distributor and maintenan-
ce service  should have  a  high  priority. Within the  blood  transfusion service, 
staff members are the maintenance persons, who will look after the building, 
vehicles  and non-specialized equipment. C hapter  6  •  Eq11ipme11t,  storage,  collsllmables  a11d  b11ildi11gs 
2.1. Major equipment 
-donor beds 
- scales  for controlling the blood collection procedure 
- bench centrifuges 
- nucroscopes 
- incubators/water baths 
- refrigerators 
-freezers 
-generator 
- voltage stabilizer 
- containers 
- laboratory scales 
- autoclaves 
- still; deionizer 
- laboratory furniture 
- office furniture, equipment 
- workshop furniture, equipment 
- refrigerated centrifuge 
Major equipment should also  include vehicles for  transport. Transport of blood 
and blood products but also  transport of staff members who are in charge of 
mobile sites of blood collection. 
2.2. Other equipement needed includes: 
three or more insulated boxes for holding blood between issue and adminis-
tration. These are  very useful if  blood is required on standby for surgery 
spring balances  to  determine  the  optimum filling  of blood bags  and for 
separating blood units into smaller amounts 
tube strippers  and hand punches to clip blood tubing in segments 
strong plastic  crocodile forceps  to  occlude tubing temporarily  whilst filling 
the sample tube 
weighing scales  to determine donor's weight 
maximum and minimum thermometers 
spring loaded  and release  holders  for lancets  to pretest donors for  haemo-
globin etc. from finger prick blood samples. 
--
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3. Consumables 
"Enough but not  too  much" 
is  a rule to adapt to each item. 
The definition of a package supply for  50 donors,  which includes  everything 
necessary for recruitment, collection, treatment, etc. was discussed and seemed 
to be a good solution to organize stock management. 
(see  "List if  supplies for collecting  blood from  50 donors" as  an example at the end 
of the chapter). 
4. Storage of blood 
Ideally, blood should be stored in refrigerators having automatically  cycled, 
dual  compressors,  special  insulation,  external  maximum  and  m.inimum 
temperature recording and alarm systems. lf blood is  collected and stored 
in disposable  (closed)  plastic bags, the risk of introduced infection germ is 
minimized. This  allows  some  len.iency  on  storage  temperatures.  Blood 
may  be  safely  stored for  21  days  in a  well function.ing  domestic  refriger-
ator which is dedicated only  to  blood. The door must be  opened rarely 
and  a  maximum/m.in.imum  thernwmeter is  used  and  mon.itored  at  least 
daily. 
Variations  from  2  to  1  0°C  are  acceptable. Blood  must  never  be  frozen. 
Before  transfusion  it is  essential  that  the bag  be  carefully  inspected. Any 
discoloration  or sign of haemolysis  at  the  cell/plasm.a junction  indicates 
that it must not be given. 
The only acceptable storage system is a closed system, plastic based. 
In developing countries,  it nuy occur that electrical supply is  unreliable. 
It is therefore im.portant to  have  some notions about alternative practical 
strategies  and procedures that can be adopted. 
4.1. Electricity available  and reasonably reliable: 
Rifrigerator: a  sin1.ple  laboratory refrigerator with 60  unit capacity  can  be 
obtained  for under 200 ECU. At this price it is reasonable to reserve it for C hapt e r  6  •  Eq11ipme11t,  storage,  COIISIImab l es  a11d  b11ildi11gs 
blood bank use  only. The door should be opended for the shortest possible 
time and inventory control is less  difficult if  a lock is  fitted. 
For laboratories providing more than 50 transfusions a week, two refrigera-
tors  should be available:  one for processed and the other for  unprocessed 
blood. This is better than providing one large refrigerator for which there is 
no back up should a compressor need replacement. 
Temperature may be monitored by  a laboratory thermometer in a  water 
container  and  by  a  maximum/minimum.  thermometer.  Care  is  needed 
to  ensure  that  the  area  nearest  to  the  cooling mechanism is  insulated  to 
prevent blood from freezing. 
- Centrifuge: The blood bank needs only the simplest centrifuge. It should have 
space for twelve tubes (12 x  100 nun) and on/  off switch but no brake and 
no timer. Such a centrifuge can be obtained for less  than 200 ECU. 
4.2. Unreliable or no mains electricity service: 
Rifrigerator. Butane gas  in cylinders is  expensive and difficult  to transport. 
Paraffin has  the same problems. Solar or 12 Volt rechargeable batteries may 
be  the  best  solution. Refrigerators suitable  for  storing blood with  these 
power sources are  necessarily small  (about 12 units of blood) and must be 
well insulated and used conservatively so  the door is  opended only for the 
minimum time. An alternative as  a standby when electricity is  available at 
least part of  every 24 hours period, is  the use of  a well insulated picnic box 
with precoated ice  containers. Such a cold box will maintain 12  units of 
blood at less  than 10 °C for 48 hours. 
Centrifuge: a hand operated unit is  adequate. 
--
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5. Example 
List of  supplies for collecting blood from 50 donors. 
The following  list are  the supplies required to  collect,  process and administer blood 
from  50 donors.  The numbers  assume  20 %wastage of  collected units, and 30 % 
rf units will be used for tranifusion. of  smaller aliquots of  blood. 
Fifty of: 
0  single CPDAl blood bags  (450 rnl)  Usually 40/10 spLit 
0  double CPDAl blood bags  (450 rnJ) 
(multiple packs  for component preparation). 
0  disposable lancets 
0  sterile 5 x 5 em gauze squares 
0  hibitane 2% in  water 
0  liquid soap solution 5% in  water 
0  preprinted sets of  six identical adhesive number labels 
0  donor record cards 
0  adhesive plaster strips 
0  supplies  for donor refi:eshment 
0  thank you letters I  instructions for future blood donations 
20 mJ 
20 mJ 
0  packets of  iron tablets with instructions  40 
0  vacutainers tubes 
For reagents and analyses: 
0  test tubes 
0  anti-A, anti-B, anti-AB, anti-D; all  monoclonal 
0  anti-hum.an globulin (polyclonal) 
0  anti-HIV, HBsAg, RPR 
0  lab glassware 
0  disinfectant and detergent 
0  sharps containers 
0  protective clothing, gloves 
0  timers 
0  aspirator bottles 
For administration of  tranifusions and stationery: 
0  transfusion admjnistration sets 
0  biohazard disposable bags 
0  transfer packs 
0  blood group labels 
0  compatibility report forms in  triplicate 
0  blood transfusion  request forms in  duplicate 
0  blood crossmatched or available reports 
0  blood donor register 
0  confidential laboratory register 
0  blood donor recruiting posters and leaflets. 
10 mJ  of  each 
2m! 
75 of  each 
50 
50 
20 
60 
100 
100 
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6. Recommendations for buildings, 
equipment and consumables 
- Buildings: 
Appropriate buildings should be designed and made available for BTS. 
- Equipment: 
-Equipment should be appropriate, simple and robust. 
- Local  maintenance by  the manufacturers should be available  and the 
manufacturer should be asked to train local people for maintenance. 
Consumables: 
-It is  recommended to define  a package supply for 50 or 100 donors 
which includes everything necessary for recruitment, collection, treat-
ment etc. 
- Monthly records should be kept. 
- Bulk purchasing of products adapted to developing countries to get a 
lower price should be organized if  possible. 
- The technical assistance or programme manager appointed to the pro-
ject should be involved, at the decision stage, in the design of  buildings 
and the purchase of equipment and supplies when and if  possible. 
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THEORETICAL FRAMEWORK FOR INTERVENTION  I 
0  I  I 
Efficiency 
E  I  I 
Effectiveness 
Figure 11:  Diagram i!Justrating the various parameters and their interaction, 
to be taken into account in defining an  indicator model 
The inputs when processed using methods give a certain amount 
of output. 
This output results in iffects which  create  an  impact. The iffi-
ciency of the  health service could be  assessed  by the  propor-
tion of output to input (E1 = 0/I). 
The qfectiveness could be assessed  by the proportion of effect 
to input (E2 = E/I).  The impact could be assessed by carrying 
out cost I  benefit studies  and evaluation on a larger scale. C hapt e r  7  •  Safe  b I o o d  111  a  11 age  111 e 11  t  indicators 
Introduction 
Health  Management Indicators are variables  which  help  to  measure change in  a given 
situation. They may be a partial rrjlection  of the "real situation" because  ciften  the situ-
ation  is complex. They may  also  be only  indirect measures  of a situation. if  measured 
sequentially over time, they can indicate the direction and speed of  change. They can also 
be used to compare different geo graphical areas and different groups of  people at the same 
moment of tirn.e. 
In  summary,  indicators provide a standard  against which we can  m.easure, assess or 
show progress  in  an  activity  or objectives  where targets have been stated. 
Indicators can  only  be used in  a situation where airns  and  objectives 
have been clearly stated in  advance. 
There is some variation  in the ~trtde rs tanding  ofwhat constitutes  an indicator. The above 
difinition seems to  restrict the terrn  to  the epidemiological  and  service  coverage types  of 
information. Indicators should  not  be restricted only  to  those  which can  be drawn from 
existing  records,  but  should  include other types of itiformation  that  can  be obtained 
through observation, supervision  visits and community contacts. 
The development cif the methodology to  assure safe blood in view of  the HI  VI AIDS 
epidemic in  developing countries  is not  limited to  testing for HIV  Targeted and  better 
procedures  to  select and retain  donors and  collect blood,  as well as to  improve and m.ake 
optirn.al  use o f  blood and  blood substitutes,  are important parts of the total strategy. 
17-l.erifore,  in  all projects, the intervention  is analysed and designed in  a comprehen-
sive way. Education of  donors, counsellil1g of  seropositive and seronegative persons, ratio-
nalization  of the use of blood, training and  management are integrated components of 
the programmes  that are supported. 
1. Useful definitions 
For a better understanding of the use  of indicators and monitoring, the  dia-
gram  given in Figure  11  is useful.  ln  order to have  a clear idea of diagram, 
the following definitions are given: 
Indicator 
A  variable  which  helps  to  measure  change,  directly  or indirectly. The  mam 
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characteristic of an indicator is that it contains a well defined  numerator and 
denominator.  Indicators are not synonynwus with objectives or targets but are 
measures  of the extent to which targets  are being reached. 
Activity 
A set of actions  required to carry out an intervention. 
Activity indicator 
A measure of the extent of  implem.entation of  an activity. Monitoring of  acti-
vity indicators can show how work is progressing on the activities  needed  to 
achieve a prograrru11.e  target. 
Activity target 
Quantified goals for achievement of  specific activities  within an intervention. 
They are targets specific to target population or aspects of  activities  needed to 
carry out the intervention. The achievement of activity targets  contributes  to 
the achievement of  progranm1.e targets. 
Monitoring 
The process of  collecting and analyzing information about implementation of 
the programme. It involves  regular checking to see whether programme acti-
vities  are being carried out as  planned so  that problems can be discussed and 
dealt with. Monitoring  helps to  follow progress of planned activities, identify 
problems,  and  give  feedback  to  staff and  solve  problems  before  they  cause 
delays. 
-
Output 
The product of a given set of  service activities. 
I:_"ffectiveness 
The degree to which a plan, a programme or a project has  achieved its objec-
tives. 
Objectives 
In management terms, an objective is a statement of purpose or the condition 
desired in some stated future. A well  form.ulated objective has  criteria defining: 
-acceptable level of performance (state which is desired) 
- extent to which it is desired  (quantification) 
- when it is expected to be attained. Chapl e r  7  •  Safe  b l ood  ma~ra ge m e 11t  i11dicators 
2. Indicators 
2 .1. Categories of indicators 
Indicators can  be  classified  using  a  variety of categories. A  widely  used  ap-
proach  is  to  group  indicators  according  to  the  conventional description  of 
a progran1Jne. Thus, there are: 
- input indicators 
- output indicators 
- process indicators 
iffect indicators 
- impact indicators 
2.2. Criteria for selecting indicators 
In selecting indicators, certain qualities  should be sought: 
Validity 
An indicator has  high validity if it measures what it is supposed to measure. In 
other words, the figure obtained is the nearest reflection of the true situation. 
Reliable 
If used  under different situations, the indicator should yield consistent results 
and different observers using it should come to  the same conclusions. 
Relevant 
The indicator should relate to  the project objectives  (in  terms of time frame, 
inputs, environments etc.) 
Sensitive 
Indicators should reflect change in the situation as  soon as  it occurs. 
Specific 
Indicators should reflect changes in the situation and be free from other con-
founding variables. 
2.3. Process of indicator selection 
In  order to select indicators, a process of questioning is proposed. For exam-
ple: 
"is the nature  of the health problem clearly defined ?" 
- "is there a clear model of  service delivery ?" 
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"are there generally accepted strategies  for achieving results ?" 
"are the expected  health results clearly stated ?" 
2.4. Who  are  the  indicators for  ? 
Indicators should be developed based on the level of  the people who use these 
indicators, the level of operation of the programme they would supervise, and 
what aspect of  the programme they are concerned with. The table below gives 
a clear idea  of the  focus of  study of indicators. 
User of indicators 
Prograrrune Director 
Project Managers 
Field Managers 
Operational level 
Progranu11.e 
Projects 
Field projects 
Concerned with 
Policy I  strategies 
Objectives 
Activities 
Indicators could  be  developed to  match  the interventions. The critical  value 
for each  of the indicators could  depend on the initial status of a situation at 
the beginning of  intervention. 
With this analysis on indicators as  a background, the  interventions on "Safe 
Blood" (see Figure 12)  can be analysed. 
3. Safe blood 
There are several activities  that are  carried  out in each of these stages of the 
BTS. Each stage adds value to the unit(s) of  blood that are collected and used, 
hence the title  value  Chain of the BTS. Refer to the diagram (see Figure 12) 
which gives  a clear picture of the Value Chain of the BTS. 
The  Value Chain of  safe blood comprises  the following stages (see Figure 12): 
-
Stage 1. Blood donor recruitment &  retention 
Stage 2. Screening 
Stage 3. Storage &  stock management 
Stage 4. Distribution 
Stage 5. Use ofBlood I  SAFE BLOOD  I 
1  !Jonor recrmtlnent  Project  Managers  5 
Blood Collection 
mass 
Campaign  target  •  Field Managers  4 
Counselling  pre 
post 
Pre selection  QC 
Blood collection 
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Figure 12:  Different stages of  the 'Value Chain' 
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3 .1. Stage  1: Blood donor recruitment  &  retention  I 
Blood collection 
Effective and  efficient blood donation and collection procedures  are essential 
parts of the  Safe  Blood projects in all  the  developing countries  whjch  EC 
supports.  The  programme stresses  the  importance  of well  organjzed  blood 
collection for the BTS. A set of activities is conducted to achieve this. 
Altruistic, voluntary  donors,  low  risk  populations,  such  as  school  students 
and young  adults in rural  populations are  targeted, inform.ed  and  instructed 
during a meeting. Following the initial campaign, it is detennined if  it is a wish 
of  the attendees to invite the BTS team to collect blood. A session is arranged, 
usually 7-14 days  later. Donors are rerrunded that their blood would be tested 
for HIV, hepatitis and other transmjssible infections. Two weeks later, the same 
donor recruiter  meets the  donors,  who  have asked  for  results,  to  discuss  and 
give  results confidentially. At tlus follow-up visit, a tentative date is scheduled 
for the next cycle of  information, collection and counselling. Other possibili-
ties  to organize collection also  exist and depend on the region and its oppor-
tunities. Thus, one can see  that a recruitment cam.paign is followed by coun-
selling and preselection after which blood is  collected. 
-
This is one of the important steps of the BTS activities  and the outcome of 
these activities could be measured in terms of output and effect. For exam.ple, 
if a set of campaigns were  to be conducted in a region, the number of cam-
paigns carried out during the year could be an indicator in terms of output. 
The  effect of the  campaigns  could  be  measured  by  the increase  of altruistic, 
voluntary  donors, from  the  low  risk  population  that  are  willing  to  donate 
blood. Several indicators can thus be developed for this step in the Value Chain 
of the BTS. 
Managers could  use  these indicators for this stage of the value chain: 
Number of donors  accepted 
1 = ----------
Number of donors  assessed 
What does  this 1:ndicate? 
Many  inferences  could  be  made  from  this  indicator,  although  primarily  it 
measures  the effectiveness of the selection procedure. 
If the  number of deferred  persons is high, there  will be a need  for better 
messages to be given during the campaign for donor recruitment. C h apt e r  7  •  Safe  blood  ma11ag ement  indicators 
If the number of  deferred persons is high, it could also be that the selection 
procedure may  be required to be examined. 
On the other hand, if the number of donors accepted is high but the num-
ber of usable blood units is low, this definitely  reflects  the ineffectiveness of 
the selection procedure. 
Nurnber if  voh.mtary  donors  accepted 
2 = - - --- --- ----
Number if  donors accepted 
What does  this indicate ? 
Three  categories  of donors are recognized: voluntary donors, family/ replace-
ment donors and paid donors. A BTS should aim to collect only fron< altruis-
tic voluntary donors among the low risk population. In order to find out if  this 
aim is being reached the above indicator could be useful, provided the classi-
fication of donors is well  understood and systematically  recorded at the time 
of  blood donation. 
Num.ber of  blood units collected 
3 = ----------
Number if  donors bled 
What  does this  indicate  ? 
Needless  to say, the number of units of  blood collected is important to record. 
This third indicator helps to estimate the competence of the team involved. 
The  reporting  form.at  that  has  been  designed, generates  necessary  data to 
calculate these indicators and more if need be. Examples of reporting formats 
are found at the end of this chapter. 
3.2. Stage  2:  Screening 
At this stage of the value chain of the BTS, another set of  activities  is carried 
out. Blood units collected during blood campaigns are screened for infections. 
The essential  characteristics  for screening tests for HIV antibodies  are: highly 
sensitive, low cost and easy  to perform. Blood is screened as  per national gui-
delines prepared for the BTS. Blood is screened for HIV, hepatitis B, eventual-
ly for syphilis and others in function of the local epidemiological status. 
The danger of  false  negative  results in HIV screening is well  known. Testing 
-C /1  a p f er  7  S a J  e  b I o o d  111. a 11  a g e 111  e 11. t  i 11 d i c a t o r s 
procedures  are  used  not  only  to  screen  but  also  to  inform  the  donor  of 
the  result and  its consequences. Therefore quality  control of screening is an 
important  component  of the  BTS. There  are  several  factors  such  as  well 
trained  laboratory  technicians,  well  n1.aintained  and  equipped  laboratories, 
screening procedures adopted etc. which contribute to the success of  this stage 
of the value chain of the BTS. 
Several indicators can be developed for this stage of the value chain of the 
BTS, however  the  key  indicators have  been selected as  per the  consensus  of 
managers and given below: 
Num.ber if  units screened  'negative' 
4 = ------------ -
Num.ber of  blood  units collected 
What  does  this  indicate  ? 
The end product of the value chain of the BTS is to produce blood which is 
safe  for transfusion. This indicator measures: 
-
the effectiveness  of the BTS in terms of the adequacy in meeting the need 
for safe  blood in that region 
the  effectiveness  of the  selection  procedure  adopted  for  accepting  the 
donors 
to an extent, the health status of certain populations of the region could be 
evaluated 
if the  number of units  discarded during screening is  high, it reflects  the 
amount of resources wasted in order to produce safe  blood. 
it also  reflects the effectiveness of  the donor selection procedure in question 
which should be investigated and improved. 
Number if  units screened  'positive' for HIV 
5 = ----------------
Number of units  collected 
1/f/hat does  this  indicate ? 
Control  of HIV  transmission  v1a  blood  and  blood  products  is  one  of the 
primary aims of the comprehensive strategy of  safe blood progranm1.es. There-
fore, it is interesting to note the number of units discarded due to positivity of 
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Number of  units  discarded due  to  other inf ection 
6 = 
Number if  units collected 
What does  this  indicate  ? 
As  mentioned  earlier,  safe  blood  is looked  at  in a  comprehensive  way  and 
screening is done for infections other than HIV as  per the guidelines  adopted 
by the blood policy. It would be interesting to note the percentage ofloss due 
to this factor and the infectious agents involved. 
Number cif samples  with  right result 
7= 
Number of  sarnples  sent for  Quality  Control 
What does  this  indicate ? 
Quality Control forms an integral part of the BTS, and an indicator to meas-
ure the performance of the screening activities  of the BTS is essential.  In the 
absence of  this component of  the BTS, one is not assured of the quality of  safe 
blood that is produced and used in the region. 
Tlus indicator indirectly measures  the quality of training of the laboratory 
technicians of  the blood bank or in other words, it reflects the performance of 
the laboratories  that perform the screening. 
Screening is the heart of the value chain of the BTS. Many output indicators 
can be introduced to assess  the performances of the screening activities in the 
field according to the region and the infrastructure ofBTS. The above are the 
essential ones. 
3.3.  Stage  3:  Storage and stock management 
The principal function of the BTS is to provide the required quantity of  safe 
blood that has  been collected in sterile plastic bags and has been stored at 1 to 
6 oc. 
The above mentioned conditions require proper storage and stock manage-
ment. The fact  that blood units have  to  be stored in sterile plastic  bags  with 
anticoagulant and stored  at  1  to  6  °C makes  storage of blood an  im.portant 
component of the  BTS. This  implies  that  the  equipm.ent  used  for  storage 
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should be well maintained, the maintenance staff trained, and that there should 
be an uninterrupted supply of the goods  needed  for  proper storage. If any of 
these  conditions is not met, this would result in a high  discard  rate of usable 
blood, the value of which is high  as  the amount of effort put into the donor 
recruitment, collection and screening is  all wasted. 
On the  other  hand, assuming  the  conclitions  for  proper  maintenance  are 
n1.et, it would be a pity if  safe blood units were discarded due to excess stock 
as  blood has  limited life. At the same time, if stock is not available when it is 
needed, the purpose  of the  entire BTS is defeated. Therefore, stock  manage-
ment is also  crucial for the success of the BTS. This requires  a lot of planning 
and is directly linked to the distribution activities of  the BTS. Planning to hold 
the  right stock  according  to  the predicted demand is  important. This means 
that the planning of  blood collection has  to be scheduled in such a way that it 
does  not result in excess or shortage of stock. 
Nurnber if  units discarded 
8 = ------------
Total  Number of units produced 
What  does  this  indicate  ? 
This indicator is chosen  after a consensus  to  indicate  the  discard  rate due  to 
im.proper storage and inadequate stock management. 
Number of  saf e blood units produced 
9 = - -----------
Total  Number if  units  requested 
What  does  this  indicate  ? 
This indicator denotes  whether the supply of blood units meets  the demand, 
provided the system  of assessing the demand is  established. Even if this is not 
established there are ways and means to estimate the demand. It must be noted 
that demand does  not necessarily indicate the need for blood in that region. 
3.4. Stage  4: Distribution 
Blood has to be transported from the main blood bank to regional blood banks 
in some cases, and it has  to be further transported to the peripheral  hospitals 
where it would be used. Throughout this transportation, the cold chain has  to 
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be  maintained.  This  again implies  good  nu intenance  of the  transportation 
system and the other factors that go into it. A sound distribution network is a 
crucial function of the BTS so  that any damage in this area directly affects the 
efficiency of the BTS. 
Here again, the outcome of  this stage of  the BTS is the total number of  units 
successfully  distributed  and the  number of units discarded  due  to  bad  trans-
portation. 
Number cif units  distributed 
10 = 
Total Number cif units transfused 
What does  this  indicate  ? 
The above indicator also  n1.easures  the effectiveness  of distribution. 
3.5.  Stage  5:  Use of Blood 
This  topic  of the BTS is subject  to  a lot of discussion in the  context  that 
"demand denotes  need". Of course,  to  a certain extent this  depends  on the 
decisions  that  the  medical  officers  make  on whether or not transfusion  of 
blood could help, or what alternatives to blood could be used given a particu-
lar situation. This largely depends on the training the medical officers have had. 
For the purpose of  monitoring, a consensus is arrived to use the following two 
indicators: 
Number of  blood  units  transfused 
11 = 
Number of  units distributed 
What  does  this  indicate ? 
This indicator is an  estimate  of the  adequacy of the  demand by  blood pre-
scribers. 
Number of units cross-matched 
12 = ----- ------
Number of units  transfused 
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What does  this indicate ? 
Cross-n1atching  forms an  important activity  of the  BTS as  extreme  care  is 
necessary to ensure correct identification of the patient and specimen to avoid 
complications  due to transfusion. 
The above indicators have  been chosen based on the value chain as  shown in 
the diagram. The indicators as  can be seen are primarily activity based. 
4. Example for reporting format 
-
4.1. Blood Donors' Recruitment  &  Blood Collection 
Code 
101 
102 
103 
104 
105 
106 
107 
108 
Categories  Family
1  Voluntary
2  Total 
Donors  Donors  FD  VD 
M  F  M  F 
No. donors accepted
3 
No. donors unaccepted 
No. donors evaluated
4 
(101 +102) 
No. new donors accepted 
No. regular donors bled
5 
No. other donors bled 
Total No. donors 
(1 04+  l 05+ l 06=  1  07) 
Total No. blood units 
collected 
Family donors I  R eplacement donors I  Paid donors:  blood donors 
who are relatives ofpatients, donors donating blood either as replace-
ment or on em.ergency basis. 
Voluntary  donors: people  who  gJVe  blood  of their  own  will  and 
receive no payment either in the form of  cash or in kind wluch could 
be considered a substitute for money. Code 
109 
110 
111 
112 
113 
114 
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A donor is evaluated prior to collecting his/ her blood as  a prelinli-
nary step  to prevent collection of unsafe  blood. Several  methods of 
assessm.ent are  used  e.g.; donor interview, physical  examination etc. 
Some methods promote self-deferral. Based on this a donor is accept-
ed or not to donate blood. 
I  See footnote 3 
R egular  donors:  A  donor is  classified  as  regular  if he/she  donates 
blood two tim.es during a period of12 months and if he/she is regis-
tered. 
4.2. Screening 
Categories  Blood  Blood  Total 
units  units  units 
Family  Volunt. 
Donors  Donors 
N o. of transfusable 
Blood Units produced
1 
N o. ofBlood Units discarded 
due to HIV infection
2 
No. ofBlood Units discarded 
due to  HBV infection 
No. ofBlood Units discarded 
due to other reasons
3 
Total No. ofBlood Units 
discarded during screening 
No. ofBlood Units used 
for preparation of blood 
components 
Transfusable blood units produced: when a blood unit is  screened for 
HIV and other infections as  per the National guidelines  adopted for 
the  Blood Transfusion Service  and  found  safe  for  transf usion, it is 
called  Transfusable  blood produced. 
-·-
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Code 
115 
116 
117 
118 
119 
When there are blood units with double infection (HIV & HBV) this 
should be entered under code 110. 
Sometim.es  some blood units collected are  discarded  due  to  reasons 
other than infection e.g. air  in the  bag  etc. Units discarded  due  to 
these reasons should be entered in this  row. 
Quality Control of the screening 
Categories  Blood  Blood  Total 
units  units  units 
Family  Volunt. 
Donors  Donors 
No. of  samples  tested 
HIV positive 
sent for retest. 
No. of samples  tested 
HIV positive 
with right results 
No. of  samples  tested 
HIV negative 
sent for retest. 
N o. of sam.ples  tested 
HIV negative 
with right results 
No. ofUnits 
HIV (positive  & negative) 
with right results 
(116+118) Code 
1.20 
1.21. 
122 
123 
124 
125 
126 
127 
128 
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4.3. Stock management and distribution 
Categories  Blood Units 
Total N o. ofBlood Units requested
1 
Opening stock ofBlood Uruts as  on 1/01/19  ...... 
No. of transfusable Blood Uruts produced
2 
No. ofUnits discarded 
due to  poor storage & expiry 
N o. ofUruts discarded 
due to  poor transportation 
No. of Units discarded 
due to  other reasons 
Total Units discarded 
during  storage  & transportation 
(123 + 124 + 125) 
No. ofUruts delivered for use 
Balance stock as  on 31/1.2/19 ...... 
(121  + 122 - 126) - 127 = 128 
Blood Uruts requested: the Central Hospitals and peripheral hospitals 
would  send their requirement of Blood Units to  the Blood Banks. 
The number  of units  requested  needs to  be  recorded to  know the 
total quantity of blood uruts demanded in one year. 
This code is the same code 109. This is brought forward again under 
stock management and distribution to tally or cross  check the figures 
n1.entioned. 
~--~--------------------------------------------------- · ----
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Code 
129 
130 
Code 
131 
132 
4.4. Use of Blood 
Categories  Blood Units 
No. ofBlood Units transfused 
No. ofBlood Units cross-matched
1 
Category of Patient  No. of  Pts who 
received Tf 
Male 
Female 
Children mths - 6 yrs 
Children 7 - 13 yrs 
Total No. of patients transfused 
No. of autologous transfusions done 
Cross-matching- compatibility testing. Care must be taken to ensure 
compatibility between donor and recipient blood before transfusion. 
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5. Recommendations on the use of Process 
indicators to monitor safe blood projects 
ft is recommended that all  projects should set annual operational  targets 
in  line  with the  project  objectives. Targets for  the  activities  to  be  con-
ducted  over  a  year  period  help  to  measure  the  efficiency  of the  pro-
granune. Quantifiable  targets stated  in the  objective  are  good  tools  to 
measure the effectiveness  of the progranune. 
The management indicators of Safe Blood help to measure efficiency and 
effectiveness of  the Blood Transfusion Services. These indicators could be 
used to monitor the BTS at the national level and regional level. The use 
of these indicators is reconm1ended. 
A data collecting tool has  been designed. The proposed format could be 
used to generate data allowing to calculate the indicators for better moni-
toring. 
The concept of "value  Chain of BTS" is reconm1ended to be used in the 
field to  assess  the  performance of the Blood Transfusion  Service stage-
wise. This helps to  strengthen  the areas  of weakness  for better perform-
ance of each unit of a BTS. 
The  management  indicators  presented  here  are  not  exhaustive,  field 
managers are  urged  to  develop  related  indicators following  the scheme 
proposed in this chapter. 
Indicators measuring cost effectiveness can also be calculated. Cost details 
have  to be gathered to do this exercise. Financial managers of the Blood 
Transfusion  Services  are  encouraged  to  do  this  and  give  feedback  to 
managers in charge of the operations. 
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Standard Operating Procedures 
QUALITY ASSURANCE 
Quality control 
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Introduction 
The rnission  of any  BTS is to  provide blood  and  blood products  that  are  as safe and 
tiffective as possible, when and where they are  required for  therapy 
Not  only  blood products  (red blood  cells, plasm.a  .. .)  but  also services  (towards 
donors, recipients,  physicians, clinics  .. .)  are aff ected by  quality  assurance. The goal of 
quality  assurance  is  to  prevent,  or  to  detect  any  possibility  cif errors  in  the processes 
carried out to produce  blood or blood products from  the time of  blood donation  to  that of 
blood tranifusion. 
Quality assurance  is a concept m.ade of  a set cif measures  indispensable for guarantee-
ing saf ety  and  quality  of blood  tranifusion. In fact, this concept covers several practical 
fields such as: written guidelines  containing  detailed Standard  Operating  Procedures, 
quality control procedures, irnplementation of  an  audit,  training cif staff members,  design 
of  activity organigrarns and job  description. Other important issues  of quality assurance 
are:facilities,  equipment, testing procedures  and  record  keeping. 
The impossibility or  difficulty to  maintain  quality is generally  due to  human errors, 
misunderstanding or negligence  rather than technical problems. That is the reason why it 
is the responsibility cif the medical director of BTS and/or the managerial staff  to  inform 
and  explain  to  all  staff members at each level  cif activity, the importance  of a quality 
assurance  system.  Misunderstanding cif the importance  cif the quality assurance  is  likely 
to  make it appear as too  heavy to  apply in  the routine work and  too  expensive from  the 
financial viewpoint. 
In developing countries, BTS are more particularly concerned by  the  following aspects 
cif blood tranif usion  i.e.: recruitment and selection  cif blood donors, blood collection, sero-
logical testing for blood  transmissible diseases,  compatibility testing,  storage,  distribution 
and indications for blood products. 
-... 
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1. Definition of concepts 
Standard  Operating  Procedures. 
Written guidelines explaining in detail how a task should be conducted. All 
activities  carried out in a BTS, from the  recruitment of blood donors to the 
distribution of  tested and compatible blood products, can be divided into indi-
vidualized tasks  to which correspond proper SOP. SOP provide the means of 
compliance with generally admitted international standards. 
Record. 
Each task  carried out following its  SOP should be registered  and all  records 
should be kept in an organized manner. R ecords  are  the proof of compliance 
with SOP. 
Quality Control. 
All  techniques and activities  used to fulfil  requirements for quality. The quali-
ty  control can be external or internal or both. 
Audit. 
A  quality  audit is a  means  (internal or external)  of monitoring  compliance 
with a particular standard or guideline, allowing for a reliable evaluation of  the 
quality assurance. 
Quality Assurance. 
In<plemented systems or actions necessary to provide adequate confidence that 
a product or a service will  satisfY  given requirements for quality. For BTS, the 
objective is to give recipients the best adapted product which will be as safe as 
possible. 
2. Quality assurance implementation 
2.1. Standard  Operating Procedures 
A  manual  containing standard  operating procedures  (SOP)  should  cover all 
actions and all procedures carried out in the BTS, including: records, validation 
and  establishment of documents.  This  manual,  which  should  be  very  well 
documented from a technical point of  view, could also serve as  a management 
tool.  It allows  the BTS  to  avoid  bias  and errors liable  to  occur when  pro-
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cedures are explained or transmitted orally to staff members. It also allows for 
a more accurate evaluation of  the work produced by each staff member as  well 
as  by the whole service. Furthermore, it can serve as learning material for new 
staff members. [deally, all staff members concerned by  the application of  a SOP 
should be invited to participate in its  elaboration. 
SOP content: 
The content of SOP should answer  the following questions:  uwho  does  what, 
how,  when  and where  ?". It should cover the following items: 
a short title 
a brief description of the objectives and the basic scientific principles  used 
conditions required for staff members who will carry out the procedure 
details  concerning: materials, reagents, preparation of reagents, etc 
operating procedures  reconuTlended by the manufacturer; all manipulations 
should be described step by step and numbered 
notes  concerning how to handle safely potentially dangerous materials 
explanation on how to interpret, to record and to notify results 
what is to be done in case of  problem. 
Any  modification of SOP has  to  be  recorded, dated  and  agreed  on by  the 
person responsible for the concerned activity or process. 
2.2. Quality Control 
A  quality  control  scheme  is  conceived  to  verify  that  a  specific  activity  1s 
carried out in  agreement with SOP. BTS can adhere to internal  or external 
quality control or both. 
2. 2. 1. In practice, internal quality control samples (unrecognizable as quality con-
trol)  have to be processed by laboratory workers without special attention, by 
using the same method and the same way  as  for routine samples. R esults will 
be examined by the supervisor or by the person who is locally in charge of  the 
implementation of quality control in order to evaluate the accuracy, precision 
of the method, its reproducibility. 
2.2.2. The organisation of  external quality control at a regional or a national scale 
requires  a rif erence laboratory which  takes  charge of carrying out the relevant 
procedures  (sending out of sam.ples for testing to other laboratories  and col-
lecting the results)  and subsequently analyses  the results. Provided communi-
-... 
C h ap t e r  8  •  Quality  a s surau ce 
cation  of results is clear and informative  while preserving confidentiality, the 
external  quality control  is an  excellent tool  which  provides  each  laboratory 
with precious information about: their adherence or deviation fi:om the mean 
or norm calculated  from. the  total  results from  all  participants. The  exercise 
provides  each  participating laboratory with a  tool  which  allows it  to  detect 
and, eventually, remedy any deviation or bias in their working n1ethods so that 
that quality assurance is met. 
2.3. Training 
A  training  programme  should  be  designed  and  implemented  (see  Chapter 
'10).  It should address  all  new  employees but also, as  a matter of continuing 
education, all  staff members. 
For  each  task  workers  have  to  be  chosen  taking  into  account  not  only 
their curriculum vitae  but also  their own affinity, talents and comprehensive 
experience in the operational  and practical aspects of the system. 
It  is  important  that  each  staff member  be  fully  trained  and  motivated. 
Although good working depends upon personal characteristics and mental-
ity, motivation of personnel can also  be achieved  through information and 
recognition of individual work. 
Ideally, all  workers  should  be  convinced  that  each  working  step  of the 
activity chain  is important and that the quality of the  final product (i.e. safe 
blood)  depends on how  they  have performed their task. Managers need to 
be  familiar with the Quality assurance concept and it is their responsibility 
to transmit this approach to other staff members as well as  to motivate them. 
Therefore,  training  and  education  programmes  should  be  systematically 
planned and implemented into the BTS activities. 
2.4. Audit 
An audit is a management tool designed to monitor compliance with standards 
previously defined  by local or national authorities. It can be external or  inter-
nal, or both. An audit concerns all  factors liable to affect the quality assurance 
of a  product  or  a  service.  Ideally,  audit  should  be  realized  by  experienced 
internal people  of the BTS. However, in  developing countries,  organisations 
which  give  the  project  financial  support generally  play  the  role  of external 
audit. 
The audit concerns not only technical aspects of BTS but should also aim to 
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verify  that  blood and blood  products  are  optimally  used  for  the benefit  of 
the  patient. In  the  latter  aspect, hospital  transfusion  committees  should be 
consulted. 
3. Example 
Figure 13: Quality Control Chart for HIV EIA testing 
Quality Control Chart 
OD 
I 
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0.15  1  Run 
0  5  10  15  20  25  30  35  40  45  50  55  60 
------ OD Control  - -m +2SD  --m-2SD 
A QC graph  is  easy to perform: the Optical Density (OD) value measured 
from the control is  plotted on the vertical axis  (Y); the (X) axis indicates the 
run number or the run date. Mter testing at least  15  to  30 runs, calculate 
the mean value  (m)  and the  Standard Deviation  (SD). A  range of two 
standard deviations above and below the mean is  recommanded (m ± 2SD). 
Thus, any control OD value falling within this range will be accepted with a 
level of  confidence of  at least 95 %.Any control OD value falling outside this 
range must be rejected and the run repeated. 
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4. Recommendations on quality assurance 
The responsibilities  of a  Quality Assurance programme  should  include 
the following areas: 
Standard Operating Procedures 
Training and education with competence evaluation 
Proficiency testing with process  validation 
Record management 
Quality Assurance audit 
As  far as  the organigram of a BTS is  concerned, each function should be 
clearly defined and each  task fully described. 
At  an  individual  level,  each  staff n1.ember  should  be  fully  informed, 
motivated and conscious of the importance of his/her own work in the 
value chain of the BTS. Chapt e r  9 
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1. Cost evaluation 
Introduction 
Financial  data  are  generally  difficult  to  compare  from  one  programme  to  another. 
Therifore,  a model was  developed  to  improve reporting of  cost  data  by  non-econom.ists. 
The  lists  proposed  are  meant  to  help  avoiding  the  omission  if  relevant  cost  data,  to 
analyse what costs are  more important in  the rurming of  a BTS and  to  standardise  the 
reporting of data. 
It  is  not  the  purpose  to  go  into  "in-depth  economic jargon"  but for  the  benifit  of 
completing  the  cost  data  as  required,  some  difinitions  are  unavoidable  and  will  ensure 
the comparison if  like with like. 
1.1. Concepts and  definitions 
1. 1.1. Investments  or capital  (or equipment)  costs  are associated with the establish-
ment of  productive capacity and physical infrastructures; most of  these costs are 
concentrated at the beginning of  a project. They include the costs  of 
- construction or repairing of buildings 
- purchase of vehicles 
- installation of major equipment necessary for the function ofBTS 
- investment in human  capital  (i.e. initial  training of staff who run the BTS; 
e.g. basic training of  laboratory technicians) 
- technical assistance. 
Note that the cost related to the basic initial training of  personnel as  well as of 
its technical assistance are included in the investment. 
1.1. 2. Recurrent  (or operating)  costs  are those costs  associated with the operation 
or maintenance of  facilities or assets. These costs are likely to recur over the life 
of a project and  may even increase  at the  end of the  project as  maintenance 
costs increase. Typically, they include the costs of 
-salaries and wages (of all  personnel involved in BTS activities and addition-
al workers such as  cleaners, security guards, etc.) 
-equipment maintenance and spare parts 
- plastic blood bags 
- supplies  such  as  drugs,  dressings,  bandages  and  laboratory  reagents  and 
supplies 
-... 
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- utilities, such as  electricity, water, fuel 
- maintenance of hum.an capital  (i.e. on-the-job continuous training of tech-
nicians) 
[n practice there are  often considerable difficulties  in distinguishing between 
capital and  recurrent  costs. Their timing or periodicity is often used  to  classifY 
costs,  with recurrent costs  defined as  those which  occur with at least annual 
frequency; and  capital  costs  those  which  occur at intervals  greater  than  one 
year. 
1.1.3. Depreciation  is  the decrease in value of  a capital good because of  passage 
of tim.e, wear and tear, etc. 
For example,  a generator, being  an  essential part of BTS equipment, has  no 
eternal life.  It has  a certain life-span, depending on its quality, proper mainte-
nance and intensity of  use, estimated at between five and ten years. This means 
that every  five to ten years this equipment has  to be renewed, and for tlus pur-
pose  it is better to put son1e money aside every year. 
An allowance for depreciation may  be included as  an operating cost in the 
accounts. In the proposed format for cost-analysis ofBTS, depreciation costs 
have been included  as  part of the  recurrent costs  (recurring on an  annual 
basis). 
The  depreciation  of an  investment  will  be  considered  by  taking  into 
account, as  a recurrent cost, an annual sum equal to its initial value divided 
by  the number of years foreseen for this depreciation. 
For example, a 10,000 ECU investment redeemable over 20 years, will entail 
an annual cost of 500 ECU  (without taking intlation into account). 
1.1. 4.  Inflation  has an effect on the depreciation cost.  [t has  for example to be 
taken  into  account  that  the  lifetime  of buildings  is  generally  estimated  at 
20 years, and at 5 years for equipment and vehicles. 
Depreciation costs have to be adjusted for intlation especially in developing 
countries  were inflation rates  can be very high. 
1. 1.  5. Hidden costs.  It is important to remember that whatever activity is taking 
place in BTS, it costs somebody some money. Even if some activities, such as 
training oflaboratory technicians or salaries of  staff, have been taken care of  by 
other sources  (e.g.  the  MOH), those  costs have  to  be  reported  on  because 
without those activities the BTS would not operate. Therefore, those  activities 
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sponsored from outside and not directly represented in the budget have to be 
reported  on. Usually  these  are  salaries,  wages,  allowances,  some  equipm.ent, 
training, etc. The cost data have  to be retrieved at the source of finance, such 
as  the MOH. Basic training costs however are difficult to identifY and for those 
costs the same amount will be used for all reporting countries. Only the filled 
posts  have  to be reported on by  each country. 
1. 1. 6.  Current price is today's  cost of a certain item, that is, what it would cost 
if a  refrigerator  was  bought  today  and  delivered  to  the  blood  collection 
centre. 
1.1. 7.  Unit cost  is  the cost of one produced  unit (for example: one transfused 
blood unit).  The unit cost represents the total cost of  an activity divided by the 
number of  output units produced. This is also known as average cost. For exa-
mple,  the unit cost of a suitable blood unit is  the total cost of producing the 
yearly amount of suitable blood units (including costs  of donor screening and 
motivation, blood collection, wastage,  etc.)  divided  by  the  yearly  amount of 
suitable blood units produced. 
'Total cost of production 
Unit cost = --------------
Number of suitable  units produced 
These "Units" can  be:  collected  blood  units,  treated  blood  units, produced 
blood units, transfused blood units  ... Since there is  a progressive loss from one 
stage  to the other among  these  different items, the denonunator of the  ratio 
will differ as  well. 
1.1. 8. Maintenance  cost  is  the  cost  of maintaining buildings  and  equipment. 
For example,  the lifetime  of centrifuges  or refrigerators can  be substantially 
extended if they are properly and regularly maintained. 
These  explanations  n-llght  help  in  completing  the  reporting  format  as 
required. 
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1.2. Format for cost data  reporting of BTS 
1.Capital costs 
1.1  Capital costs of existing buildings  at current  ........ 
value: 
1.2  Costs of new planned building at current  ........ 
value: 
(remark: only complete  1.1  or  1. 2)  total  ········ 
1.3  Capital costs of major equipment 
(current price)  as  per list: 
- donor beds  ........ 
- scales for controlling the blood collection 
procedure  ........ 
- bench centrifuges  ........ 
- nucroscopes  ........ 
- incubator/ water baths  ........ 
- refrigerators  ........ 
- freezers  ........ 
- generator  ........ 
- voltage stabilizer  ........ 
- containers  ........ 
- laboratory scales  ........ 
- autoclaves  ........ 
- still; deionizer  ........ 
- laboratory furniture  ........ 
- office furniture, equipment  ........ 
- workshop furniture, equipment  ........ 
- refi:igerated centrifuge  ........ 
- any other major equipment not mentioned 
above.  .  ....... 
total  ........ 
1.4  Capital cost of transport (vehicles):  total  ........ 
... 
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1. Capital costs (continued) 
1.5  Training cost of  staff 
1.5.1 basic  in-country training: 
Number 
Medica./  doctor  ........ 
Senior laboratory  technician  ········ 
Laboratory  technician  ........ 
Nurse  ········ 
-....  ········ 
1.5.2 training outside of the country: 
Number 
Medical doctor  ........ 
Senior laboratory  technician  ...... .. 
Laboratory  technician  ........ 
Nurse  ........ 
-....  ........ 
1.6  Total amount for technical  assistance 
(foreseen.  wer project lif etime) 
Total capital cost 
Total  capital cost 
2. Recurrent costs 
2.1  Salaries, honoraria, allowances, benefits 
total costs  for 1 year: 
- adrninistrative staff 
clinic staff 
laboratory staff 
pension fund 
Medical  &  dental aid 
n1.anual staff wages 
cash in lieu of  leave 
Years 
. ....... 
........ 
········ 
········ 
.... .... 
total 
Costlyr 
........ 
. . . . . . .  . 
........ 
........ 
.  ....... 
total 
total 
- training 
+ training 
........ 
........ 
........ 
........ 
........ 
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2. Recurrent costs (continued) 
2.1  Salaries, honoraria, allowances, benefits 
total costs for 1 year: 
- training expenses  ........ 
- staff uniforms  ........ 
- other benefits  ........ 
- honoraria  ········ 
- miscellaneous  ........ 
total  ........ 
2.2  Transport: total costs for 1 year 
- allowances  ........ 
- visits, supervision  ........ 
- vehicle repair &  maintenance (1)  ........ 
- vehicle petrol, oil, lubricants (2)  ........ 
(1) + (2)  =·20% if  purchasing  cost  ........ 
- vehicle licences  ........ 
total  ........ 
2.3  Minor equipment as  per list  (m.inor equipment lasts 1 year or less) 
- don"lestic scales  ........ 
- miscellaneous equipment and surgical items  ........ 
(scissors, forceps, sphygmomanometers, 
tourniquets, stethoscopes, thermometers)  ........ 
- necessary equipment for donor refreshment  ........ 
- plasma extractors, hand sealers, tube strippers  ........ 
- plastic/ cardboard  holders for blood units  ........ 
- laboratory thermometers  ........ 
- (eventually mobile team equipm.ent)  ........ 
- other m.inor equipment  ........ 
total  ........ 
2.4  Consumables 
2.4.1  for blood coUection &  blood administration 
- disposable lancets  ........ 
- disinfectants and dressings  ........ 
- materials/supplies  for Hb concentration 
and packed cell  volume  ........ 
- blood coUection single packs  ........ 
... 
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2. Recurrent costs (continued) 
2.4  Consumables 
2.4.1  for blood collection &  blood administration 
- multiple packs  for component 
preparation  ........ 
- test tubes  ........ 
- transfusion adm.i n.istration sets  ........ 
- labels  ········ 
- supplies  for donor refreshment  ........ 
2.4.2  for laboratory 
- test tubes, slides, tiles  ........ 
- reagents + supplies  for: 
blood grouping,  ........ 
compatibil.ity testing,  ........ 
screen.ing of infections  ........ 
- lab glassware  ........ 
- disinfectant and detergent  ········ 
- sharps containers  ........ 
- protective clothing, gloves  ........ 
- timers  ........ 
- aspirator bottles  ········ 
total  ........ 
2.5  Cost of  publicity 
total  ........ 
2.6  Cost of  adrninistration 
- stationery and material  ········ 
- printing  ........ 
- postage  ........ 
- cleaning materials  ........ 
- audit fees  ........ 
- insurance  fees  ........ 
- security (e.g.  night guards)  ........ 
- bank charges  ........ 
- interest payable  ········ 
- transport charges  ........ 
- sub-contracts  ........ 
-... 
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2. Recurrent costs (continued) 
2.6  Cost of administration 
- pres  ntation & entertainm.ent  ........ 
- rentals  ········ 
- other  ........ 
total 
2.7- Utilities  for one year 
- water  ........ 
- electricity  ........ 
- gas  ........ 
- fuel  ........ 
- telephone,  fax  ........ 
- other  ........ 
total 
2.8  Maintenance for one year of 
- buildings (=  2% of capital  cost per year)  total 
- major equipment (10% of capital  cost/ yr)  total 
total 
2.9  In  service training cost per year  total 
2.10  Depreciation cost of buildings, n1.ajor  equipment 
and  vehicles: 
- buildings  total 
- major equipment  total 
- vehicles  total 
Total recurrent cost - depreciation 
Total recurrent cost + depreciation 
3. Income 
3.1  Fee for service for blood transfusion 
3.2  Fee for service for other laboratory services 
3.3  Contract services 
total 
total 
total 
........ 
........ 
........ 
........ 
........ 
........ 
........ 
........ 
........ 
········ 
........ 
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3. Income (continued) 
3.4  Funcling from: 
- Ministry of Health 
- other ministries  total  ........ 
- Hospital budgets  total  ........ 
- outside agencies  total  ........ 
- other (specify)  total  ........ 
3.5  Other sources of  income (specify)  total  ........ 
Total annual income  ........ 
1.  2. t  Specific comrnen.ts  and explanations: 
Capital costs: (see  "Forrnat for cost  data  reportil1g": 1.) 
- Capital costs of  building at current value:  (see  "Format for cost data reporting": 1.1.) 
either the original building costs can be retrieved and adjusted to current 
value by the following formula: 
c = a (1  + r)n 
c = current value 
a = previous or original value 
r = basic interest rate 
n = number of years since building was  established 
or the current cost of building a similar building can be estimated: 
c=SxP 
P = cost/ m2: can easily be obtained from any building 
S = surface area 
New building:  (see  "Format for cost  data  reporting": 1.2) 
If the current building is inadequate and plans exist to build a new building 
or renovate the existing building, the costs of the new building can be used 
for capital cost. 
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Ma jor equipment:  (see  "Format for cost  data reporting":  1.3) 
capital costs of major equipment (current price)  as  per list:  (rnajor  equipment = 
equipment that normally lasts  5 years or longer; this list is not meant to be 
exhaustive but major cost items have been identified; other items can be put 
under "any other main equipment" not mentioned above) 
The current price of  an iten1 is the price which would  have  to be paid today to 
get this item installed at the BTS (e.g. cost of a refiigerator + cost of eventu-
al transport, freight, insurance, customs clearance); the easiest way of knowing 
those  prices  is to  enquire  at local companies/shops or to  use  the  UNIPAC 
price-list (available at UNICEF's Country Office). 
Training  cost  cif staff (see  "Forrnatfor cost  data  reporting": 1.5) 
basic in-country training: (see  "Format for cost  data  reporting": 1.5.1) 
Costs are calculated on the basis of  internationally accepted average costs 
to train specific  managers; the same  costs will  be  used  for  all countries. 
The  only information required  is the number  of staff in  each  category 
and the number of  years initial training takes in the reporting country; for 
example, it might take 3 years to train a laboratory technician, but 5 years 
to train a technologist; (primary  /secondary school education is not taken 
into account). 
It  should be  clear  that  often these  training  costs  are  taken  care  of by 
Ministry of Health  (MOH) or Ministry of Education (MOE), but have 
to be taken  into account because  without trained staff blood transfusion 
services would  not function up to required standards. 
training outside of the country: (see  "Format for cost  data  reporting":  1.5.2) 
If staff get  their basic  training  as  part of the  project  costs  (e.g. staff are 
trained in Europe during a specific period), annual cost estimates  of this 
training should be submitted separately. 
The technical assistance is considered a capital investment. The total cost over 
the project lifetime will be spread over a period of ten years. Note that there 
is no depreciation applicable to technical assistance cost. 
Recurrent cost:  (see  "Format for cost  data  reporting": 2) 
Hidden  cost related to work and services  done  free of charge should  also  be 
evaluated and considered as a recurrent cost. The corresponding benefit should 
also be considered under the "other sources of income" section  . 
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Minor equipment: (see  "Format for cost  data  reporti11g": 2.3) 
lasts one year or less; may  differ by country and the lists presented are  only a 
fram.ework. 
- Maintenance  for one year of (see  "Format for cost data  reporting":  2.8) 
buildings  (2 % of capital cost per year) 
- major equipm.ent (10% of capital  cost/ year) 
2. Financing 
The  cost  data  are  useful  tools  to  finalize  a  budget  for  a  gJVen  programme. 
Frequently, in developing countries, the budget is divided in  two parts: the first 
one dedicated to buildings and investment and a second one for recurrent costs 
(functioning, salaries ...  ). Mter the exercise  of cost evaluation, it is necessary to 
proceed  to  an  exhaustive  listing  of all  inputs. These  latter  include:  external 
financing  by international grants,  bilateral  financial  support, budget  fi:om the 
local Ministry of  Health etc. 
2.1. External financing 
International  financing  of Blood Transfusion  Programmes  can  either  be 
dedicated  to  investments  (heavy  equipment,  buildings ... )  or  to  outside 
training. T his  can be  help  given  once  as  a  whole,  or  alternatively, it can 
be  allocated over a longer period of time. In this latter  case, it provides  a 
financial support for the function and/ or technical assistance. 
Financing  support  to  Transfusion  Programmes  originating  from  the 
Ministry of Health should be subnutted  to  the same  management rules  as 
the whole Public Health budget. The diversity of  financial support to trans-
fusion progranunes explains why "cost recovery" has  to be discussed. 
2.2. Cost recovery 
If the  technical implementation of a Safe  Blood Progranune is of greatest 
importance from a practical viewpoint, it is also as  important to determine 
accurately  the  costs of such  programmes  in order to  evaluate  their cost-
effectiveness. At the end of this chapter, an  example of calculation of cost-
effectiveness, that could  be considered as  a model, will be illustrated. 
-... 
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Possibilities  for cost recovery mechanisms n1.ay  be different from one count-
ry to another, depending on the local econorrtic, financial  and organisation-
al  set-up, and on  po]jtical  acceptabi]jty  of the  idea of cost-recovery. It is 
therefore impossible to work out an all-round solution and the meeting as 
well  as  the report only discussed some of the possibilities.  Practical opera-
tional  solutions  will  have  to  be  developed  for  specific  countries. 
Nevertheless,  in  terms  of sustainability  of BTS  services,  it  is  extremely 
important to develop local mechanisms of cost-recovery. 
The four important questions on recovery of costs are: 
what to  charge for  ? 
who  and who  not  to  charge  ? 
how to  charge  ? 
how m.uch  to  charge  ? 
2.  2. 1. What and who  to  charge for ? 
Which services should, or could, be charged for and which not ? 
First, only those BTS activities directly related to blood transfusion are con-
sidered. 
Producing  a  suitable  and safe  blood  unit costs money.  Although  blood is 
given free, there are the costs of recruitment, collection, screening, testing, 
production,  distribution, health education, etc. As a  matter  of fact,  blood 
transfusion has  an "externality": transfusing  infected  blood  (e.g., HIV  in-
fected)  would not only affect the consumer (the patient who has been trans-
fused), but also  the conummity (spreading the infection). This could be an 
argument not to charge  for blood transfusion. On the other hand, the ac-
tivities that are essential for ensuring suitable safe blood are the activities that 
increase  substantially  the  cost of production. Somebody has to  pay  for  it, 
whether it be the MOH, the  hospital budget, the patient, the community, 
donor aid, etc. 
From an  ethical point of view it would  be  defendable  not to  charge  the 
individual  patient, as  blood is given free by the donor and is only transfused 
to  a critically ill patient, carefully selected  and in need of blood. Whether 
this means that a patient could  not even be charged a nominal fee is open 
to debate.  In terms of cost-recovery, it would be defendable to charge the 
individual patient a  nominal fee  for  this  activity  (as  compared with other 
charges for X-rays, surgery, etc.), or to earmark part of  the in-patient fee for 
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blood transfusion activities. However, if  patients pay for blood transfusion it 
should be made d ear to them  that they do not pay  for the blood (that was 
given  fi:ee)  but for the whole service or process  ensuring suitable blood. 
There are of course other methods of cost recovery than charging the indi-
vidual  patient. Depending on the specific situation of each  country, some 
m.ight be more feasible, more acceptable and/ or more effective: 
- private patients could be charged  for all services  (and could  be charged at 
a price  higher than the economic price) 
- public patients  could  be  charged  for  blood  transfusion services,  but at  a 
price lower than the economic price. 
The full  costs could be shared by: 
- charging the hospital budget directly 
- charging  the  total  number of patients adm.itted  over one year  (cost  of all 
blood un.its/number of  in-patients per year) 
- idem, but charging adults only 
- charging the user (the patient transfused)  only; this would be inequitable, as 
the user is the one in need. 
Other mechanisms could be: 
- cross-subsidization by charging private in-patients 
- cross-subsidization from other activities  carried out by BTS (e.g. HIV and 
other laboratory testing) 
- local insurance mechanisms  such as pre-paym.ent schemes 
- conununity financing 
- donor aid. 
Which m.ix of  sources would be acceptable, feasible and efficient, and what 
would be the extent of their relative contribution, is  a question that has to 
be looked into by  the individual countries  and by  community authorities 
and experts. 
Another issue is, who should be exempted from payment if  a fee were to be 
introduced  ? Would it  be acceptable  to  charge children in need  for  blood 
transfusion ? What about poor people,  and  on the  basis of which criteria 
would persons be exempted ? 
In countries  where the most common indication for transfusion would be 
anaem.ia in infants/  children, and where the decision would be taken not to 
charge  children, the price of a blood un.it  charged  to adults directly  could 
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be high, and a better solution could be to charge the hospital directly or the 
total of  adult in-patients instead of the individual patient. 
An interesting  method  of cost-recovery  is  cross-subsidisation of the  cost 
of blood transfusion by the profit made on contract services. Some labora-
tories in developing countries run a reasonably lucrative business by, for exa-
n1.ple,  testing blood for  Syphilis or for HIV One national BTS engages  in 
private laboratory activities  during njght-time and by so doing makes  some 
money for cross-subsidizing more essential  activities  such as  blood transfu-
sion. The feasibility and efficiency of tills  cost-recovery mechanism  should 
be looked into by the individual countries' authorities. 
2.2.2. Proposal. 
A  possible  and  maybe  feasible  way  for  cost  recovery of BTS  111  developing 
countries  could be to combine the following sources: 
the Government, by charging the hospital budget directly 
the international communjty,  through  donor aid, by  asking  for continuous 
support for some operational costs of the national BTS, and 
... 
the patient,  by charging the  collectivity of in-patients, excluding children, 
for the service of having a continuous availability of  safe blood. 
Exemption from paying  would follow  the  national  exemption criteria  for 
in-patient hospital services. 
2. 2. 3.  How much  to  charge for  ? 
In determining the cost-recovery formula, the cost per unit needs to reflect 
the  number  of units  (including components)  used, rather than collected. 
Herein lies  a problem. - an efficient and effective service will have minimal 
outdating,  and  so  the  difference  in  cost  determined  by  total  operating 
costs/number collected and total operating costs/number used will not be 
great, whereas in an inefficient service there will be a significant difference. 
Whatever  the  formula,  it  should  take  into  account both inflation  and  a 
provision for future capital outlay, if MOH is in agreement. 
The first step would be to define what the full economic price of a blood 
unit is in a specific  country. The full  economic price would be  the  total 
recurrent costs  (including depreciation costs)  divided by the total number 
of units transfused  over one year, increased  by a mark-up to cover  inflat-
Ion  . 
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This would  be  the  cost  to  be  recovered  over,  for  exam.ple,  the  3  sources 
mentioned above. How nwch to charge each of the three sources would be 
a decision to be taken nationally. A possible way of deciding this could be: 
What is reasonable and fair  to  charge the adult patient for having the security cif having 
blood available for  hirnlher and  the family  at any  time? 
This is extremely  difficult  to  answer, but one could  com.pare  with other 
charges  or costs of services, for exam.ple: 
The cost/ charge of a chest X-ray ? 
The cost/ charge of a delivery ? 
The cost/ charge of an in-patient day  ? 
The cost/ charge of  a hernia  operation ? 
The local daily wage of an agricultural labourer ? 
If  5  %  of all  adult  in-patient  fees  (or  maybe  5  %  of the  total  hospital 
budget  ?)  would  be  earmarked  for BTS, how much  of the  cost of having 
safe  blood available would be covered ? 
If a  hospital  budget  for  blood  transfusion services  exists,  how  much  of 
the total need could be covered by  this budget ? 
Countries  that have  no hospital charges and are reluctant to introduce  them, 
would  have  to  focus  on hospital  budgets,  the  international conununity and 
possible cross-subsidization from private to public patients. 
3. Example 
Cost-Effectiveness  of  Uganda Blood Programme 
Background: 
Uganda  has  a population of 16  million and a gross  national product of 170 
USD per capita. Total  health  budget is about 2  USD per capita per annum. 
More than 25 % of  young adults have antibodies to HIV1 and 6 %are carriers 
of Hepatitis B  virus. 
Blood  donors: 
volunteer blood donors recruited + patients' relatives  as  replacem.ent donors. 
-... 
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All  blood units are tested for H fV  and HBs Ag. The mean seroprevalence was: 
5.5 % for  HfV  and 6.3% for HBs Ag. In  1993, out of32,100 unjts collected, 
26,194 (81.6 %) were transfused and distributed in 92 hospitals. 15.6 % of  blood 
units collected were discarded because of  HIV, HBV or any  other reason. 
Cost tdfectiveness: to answer 4 questions. 
1. How many  patients' lives  were saved  by blood transfusion ? 
Children  Adults  Total 
Number transfused  11515  8641  20156 
Expected to die without  5758 (50 %)  3898 (45  %)  9656 
Die despite transfusion  3801 (33 %)  2592 (40 %)  6393 
Number cif deaths prevented  1957  1296  3253 
¢  Half of  the children who met the cnteria  (Hb < Sg/  dl  + respiratory con<-
promise) would die liatn the primary illness. 
2.  How many  HIV infections are  prevented by screening blood ? 
Children  Adults  Total 
Infected if 16.1 % donors are carriers  1854  2226  4080 
Of  above recipients already infected  167  (9  %)  890 (40 %)  1057 
Non-surviving infected recipients  562 (33 %)  401 (30 %)  963 
Infected if 0.8% donors are carriers*  92  105  197 
Total corrections to be su bstracted  821  1396  2217 
HIV irifections prevented  1033  830  1863 
*i.e. donors during the window period of HIV infection. 
c:>  1863  new infections  were  prevented  in  the  survivors of the  episode  for 
which blood was  given. 
3. How many HBV infections are prevented by  screening blood ? 
Children  Adults  Total 
Infected if 5.7 % donors are carriers  656  747  1403 
Of  above recipients  already  infected  66 (1 0 %)  635 (85  %)  701 
Non-surviving infected recipients  197 (33  %) 
Total corrections to be substracted  263 
HB V irifections prevented  393 
c:>  471  new HBV infections were prevented . 
34(30 %) 
669 
78 
231 
932 
471 
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4. What is the cost of each prevention ? 
Total cost of  BTS in 1993 
R ecruiting, counselling and care of 18,297 donors 
HIV sere  ning of 32,100 units 
HBs Ag screening of 32,100 units 
Cost of supplies  &  staff for  J 782 HIV positive  units 
Cost of supplies  &  staff for 2025 HBs Ag positive units 
USD  USD 
929,900 
167,300 
J  30,800 
103,100 
21,794 
24,766 
-447,760 
Cost to transfuse  26,200 units if  screening was not done  482,140 
Adclitional cost of HIV screening  319,894 
Additional cost of HBV screening  127,866 
c:>  The cost of HIV screening was  319,894 USD (10 USD per unit collected) 
c:>  The cost of  HBV screening was 127,866 USD (4  USD per unit collected) 
Conclusions: 
Number  Cost  cost/case 
USD  USD 
Deaths prevented by transfusion  3253  482,140  148 
HIV infections by  transfusion prevented  1863  319,894  172 
Hepatitis B infections by  transfusion prevented  471  127,866  271 
c:>  148 USD per prevented death IS cost-effective health care 
c:>  172 USD per HIV infection prevented is the most cost-effective of  AIDS 
prevention interventions 
c:>  271 USD per hepatitis B infection prevented is good value. 
1 ECU  = 1.2 USD 
-... 
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4. Recommendations on cost analysis 
An effective  safe  blood progranm1e  will have  an impact on the health 
of the population as  well  as  on the  health system in general. Although 
they are difficult to evaluate with accuracy, these  benefits exist and have 
to be considered as  well. 
Reporting of cost data  is useful  in order: 
- to determine the total  cost ofBTS in a specific country; 
- to  identify  the  major cost  components in  the  total  cost.  In  trying  to 
reduce the overall cost of  a BTS it is  important to focus on these cost 
components. 
- to evaluate the cost-iffectiveness  of the BTS; 
- to  monitor the cost of  the service on the basis of  standardised reporting 
of yearly cost data; 
- to compare the BTS if  different  countries  in terms of the importance of 
different cost components as  parts of  the overall costs, and to determi-
ne  cheaper strategies  (and in combination with indicators of effect-
iveness, more cost-effective strategies); 
- to facilitate  the  decision  on which costs or which part of the total costs 
one wants to recover by, for example, cost-sharing. 
5. Recommendations on cost recovery 
·- The first step is  to determine the actual cost of one blood unjt. 
·- Once this cost has  been determined, decisions should be taken as to how 
much of the cost of this service  the individual and/  or the community 
are able to bear. 
·- Additional revenue can be generated through testing for patients and by 
selling by-products such as  test sera ... 
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Introduction 
The succesiful implernentation of  a safe blood strategy will largely  depend on  the know-
ledge,  skills and  commitm.ent of the people  working in  every  Blood Tranifusion  Service 
and/or Hospital Blood  Bank. 
To  be  ifficient,  training  strategies  should  be integrated  as  much  as  possible  into  a 
human  resources  policy  which  is  appropriate  to  the  country~· public  health  policy  and 
more particular!) ',  to  the  blood policy 
Training  if  personnel for  blood  tranifusion  services  (BTS)  is  required  to  ensure, 
improve and sustain ifficien.t functioning of the  services. 
1. Training modules 
should be addressing persons at  different stages if  experience: 
- personnel with many years  of  service  at a BTS who need to refresh and  upgra-
de their knowledge and often re-orient their practices; 
new staff members, entering the service after having just completed their pro-
fessional training, who need a proper introduction into the operations of  the 
BTS and into their own tasks. 
Appropriate and professional  training has  to  be provided  for all  staff of BTS, 
i.e. the doctors in charge, nurses and paramedical staff, the laboratory techni-
cians,  the  donor recruitment officers,  the  nuintenance  technicians  and  the 
counsellors. 
2. Training: a regular and continuous activity 
The training of personnel must be conceived and carried out as  a regular and 
continuous activity for a BTS. 
It must be based on: 
an analysis  of the BTS operations and functions 
a detailed job description for each task 
an assessm.ent of the individual training needs of each staff member 
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the definition of priorities  for the training 
identification of appropriate training methods, facilities  and timing 
sufficient funds  on  a sustained  basis 
T he  training  programme  should include  a  regular  evaluation of its r  suits in 
terms  both of improved  qualification  and  skills  of the  staff member  and  of 
in'lproved  functioning of the BTS as  a whole. 
3. Organization of training 
different kinds (if training can  be organised 
locally at the BTS (using  appropriate support wher  necessary)  or 111  other 
institutions in the country; 
in  appropriate training  centres  or institutions in  the region; 
in blood transfusion (training)  services out of the region; 
through  Distance Learnir1g  Material (see Annex 1). 
.Ill 
It is demonstrated to be more effective in  developing countries if  training starts 
with  in-service training, organised at the BTS - with  external  technical assi-
stance  if  required - related  to  the  day-to-day  practice  of the  staff. Training 
courses  outside, in specialised institutions or in-s  rvice training in  comparable 
services in  the  country or abroad should  be organised  only after a reasonable 
period of working experience after the initial in-service training. 
4. Specific training 
]}aining for  the different functions  of the staff of  blood  tranifusion  services: 
4.1. Medical  Director 
Sound  knowledg  of all  aspects and techniques  of blood transfusion services 
is the first priority. Management and administrative  tasks are frequently under-
estimated  and  often the  doctors  selected  for  this  function  do  not  have  any 
training  in  this  6eld.  Competence  in  all  relevant  aspects  of organisation, 
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management and adnunistration of  a blood bank are equally important for the 
medical  director. 
4.2. Donor Recruitment Officer 
Donor recruitment requires, in particular, social  and conununication skills. 
A  university  training  in  psychology  or social science may  be  a good basis 
but it is stressed  the  function depends essentially  on  personality, reliability, 
charisma  and orgatusationa.l  capabilities. It is agreed  that  any  training  for 
such officers in BTS n1ust be carried out in an appropriate environm.ent. 
For  example,  WHO and  FRCR CS  developed  such  a  training  course  for 
donor recruitment officers in Harare for Anglophone candidates. 
4.3. Administrator 
BTS administration involves  a specific  mix  of organisation and control of 
supplies  and  stocks,  financial  management  and  accounting,  personnel 
admitustration, transport, etc.  The  administration  of several  facilities  in a 
large region requires  more nunagerial skills than  for one blood bank only. 
[nitial  in-service  training  must  introduce  and  adapt  adnunistrators  who 
should  have  a  traitung  obtained  in  other  sectors  of public  or  business 
adnunistration.  It is  usually  possible  to  find  training  opportunities  in the 
country.  T here are some institutions in Europe offering appropriate courses. 
4.4. Chief Technologist  I  Laboratory Technicians 
[t is often  possible to  organise  refresher and upgrading trai1ling for laboratory 
technicians  in  the  country  or  in regional  training  institutions. T he  training 
should address all relevant techniques of  serological analysis and testing and the 
proper handling of technical equipment. 
4.5. Nurses  I  Phlebotomists 
Nurses/phlebotomists  are  the  officers  with  most  contact  with  the  donors. 
T hey need training not only in the technical  aspects and organisation ofbleed-
ing,  but also  regarding  an  appropriate  behaviour towards  the  donors. Their 
social skills are very important for donor retention and must be developed. 
-... 
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4.6. Maintenance Technicians 
Good maintenance of the laboratory equipment, vehicles, etc. is a backbone 
of an efficient BTS. Training of maintenance technicians must develop also 
skills for minor repairs. 
[n case of  absence of  local servicing facilities  for laboratory and other equip-
ment,  training  for  maintenance  technicians  should  be  organised  at  the 
manufacturing companies. 
5. Technical assistance 
Technical assistance and inter-institutional support and cooperation are very 
often  needed  to  develop and  support safe  blood  initiatives  in developing 
countries. However, worldwide, very few exp  rts and institutes are available 
with the necessary expertise, the managerial and programming skills, and the 
developmental experience to  take  up  this task  in an  effective and  approp-
riate way. 
Discussion revealed that more regular expert meetings  organised to exchan-
ge and  analyse  experiences, set up guidelines, and  elaborate checklists etc., 
are beneficial and could be supported by organisations such as  the European 
Community  jointly with  the  fnternational  Federation of the  Red Cross. 
This  would  greatly  benefit  the  strengthening  of the  blood  transfusion 
services  for the sake of  public health and as  a means to improve HIV-AlDS 
prevention. 
6. Example 
Experiences  of the  EC  H IV I AIDS  Programme  in  supporting  safe  blood 
initiatives in Developing Countries  have  highlighted the need for a training of 
BTS professionals which addresses  the  specific  problems  of establishing safe 
blood  transfusion services  under  conditions  of developing  countries  where 
little organisation exists. Training in blood transfusion in industrialised  coun-
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tries  generally does  not address  these aspects. These skills can best be acquired 
through a training progranune based on the actual experiences of  a developing 
country  that faces  such  problems and  has  im.plemented  a successful  national 
safe  blood program_ n'le. 
The creation of the Uganda Blood Transfusion Service  (UBTS) was  a major 
project of the  safe  blood  programme  supported  by  the EC Since  its  start 
in 1988, with the  rehabilitation of Nakasero  Blood Bank in  Kampala,  the 
development of UBTS has  passed  through  the  different stages  of building  a 
comprehensive nationwide blood transfusion service and developing a nation-
al  safe  blood policy. 
Based  on  the  experiences  cif the  UBTS, a training programme for BTS staff  from 
English-speaking  developing  countries  is  being  01;ganised  at  Nakasero  Blood  Bank 
starting  in  1996. 
Two  specific  training  progranunes  will  be  developed  and  conducted,  in 
English, by  the  UBTS, one for  senior BTS  staff and one for technicians from 
developing countries. 
J. Training course for senior BTS staff 
Tlus  10  weeks  training  course  is  for  those  expected  to  be  the  prof essionals 
acting as leaders in the National Blood Transfusion Progranune or in Regional 
Blood Transfusion Centres. It will be conducted ideally for teams from different 
countries  including the medical  director, cruef technologist, aclnuJustrator and 
se1uor donor recruiter and/ or nurse  in charge of such progranunes. Each  will 
have the general and professional education required to be employed in a seni-
or position, and will have  had at least two years experience in blood transfusion 
practice or in a leaderslup role in the adnunistration or provision ofhealth care. 
The training will  provide s  nior BTS professionals with the  knowledge  and 
ability to: 
- Write N ational Guidelines  and Policies 
Develop a blood donor recruitment programme 
Organise  a  core  group  responsible  for  the  management of the  different 
aspects of the BTS 
Deternune needs and arrange tenders and purchase of all  blood transfusion 
related supplies 
Train blood bank and other hospital staff in efficient safe  blood transfusion 
practice 
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Plan a s  cure record  system and data analysis  programme 
M.onitor and  provide  quality  assurance  for  the  various  elements of a  safe 
blood progranu11e 
This training course  will  consist of: 
A six  week course  of lectures, senlinars and group work based on practical 
case  studies  covering  the  relevant  subjects  of donor  recruitm.ent,  blood 
transfusion medicine and the technical organisation, management and adnu-
nistration  of a  national  or  regional  blood  transfusion service.  Participants 
wilJ  at the end develop policies  for im.plem.entation in their own country. 
A  four week training attachm.ent for  doctors and  technologists,  including 
two weeks providing extensive experience of  actually pe1 form.ing laborato-
ry  testing of blood with both manual and automated n1.ethods, a one week 
training attachment at  a major hospital  focusing on blood use procedures, 
record systems and evaluation of  need for blood, and a one week attachment 
in a R egional Blood Bank where participants will actually perform the roles 
of their respective counterparts. 
T his training course wilJ  be given once a year. 
2.  Training  course for Technicians 
This  12  week  training  course  IS  for  technicians  in  charge  of larger  blood 
transfusion laboratories serving more than one hospital and responsible for the 
collection,  testing, storage,  compatibility  testing  and  issuing  of blood  for  a 
patient. These  need  a  complete  knowledge  of the  essentials  of blood  bank 
practice  and  the ability  to teach  these  essentials to others and to train junior 
staff to improve the quality of blood transfusion medicine in their hospitals. 
... 
Candidates  must have completed at least a two year structured professional 
training in a school of medical laboratory technology. 
The training will consist of theoretical courses and practical exercises. It wilJ 
cover  all  relevant subjects  of blood  transfusion laboratory procedures,  blood 
screening and  grouping techniques, blood bank organisation, data  recording, 
personnel management, quality assurance and control, and training methods. 
At least  60 % of the  time  will  be  spent gaining  practical  experience  at  a 
regional blood bank or a hospital blood transfusion service. 
This training will  be given twice a year. 
3. Other training 
In  addition to these  two training courses, a short information and study visit 
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programme on safe blood policies, strategies, and organisation of blood trans-
fusion services will be developed by  the UBTS for senior health sector policy 
makers and planners of developing countries. 
This programme  will provide  such  national  decision makers and planners 
with the  inforn1ation to  determine  the  needs,  the  options and  the  resources 
and measures required to establish a National Blood Policy and effective blood 
transfusion services in their country. 
This short (approx. 3-5 days)  information programme will  be organised by 
UBTS upon request. It can be tailored to the specific needs and interests of  the 
participants. 
Address:  Uganda Blood Transfusion Service 
Nakasero Blood Bank, Director UBTS 
P.O. Box 1772, Kampala, Uganda 
F~'< Nr. (256-41) 257484 
4. '1i'ainin' in  Blood Tranifusion  in  the Ti·opics 
A three month training course in  blood transfusion for medical staff and labo-
ratory technicians fiom francophone countries in Mrica and the Indian Ocean 
has  been  developed  by  the  French R ed  Cross  (FRC) in collaboration  with 
specialists in blood transfusion fi:om Afi:ica  and France. 
This training course, consisting of theoretical lectures  and practical  labora-
tory and blood bank training, aims at providing the key medical staff and labo-
ratory technicians with the knowledge and skills in blood donor recruitment, 
blood transfusion medicine, laboratory techniques  and blood bank practice to 
enable them  to improve the organisation and quality standards of their blood 
transfusion and to train  their colleagues  and junior staff. 
Pilot courses  were organised by the FRC in  Yaounde in collaboration with 
the  Medical  Faculty  of the  University  ofYaounde/Cameroon in  1991  and 
1992. They were supported  by  the  French government, the EC, WHO and 
the  International R ed  Cross and R ed  Crescent Societies. It is envisaged  that 
future courses  will be held in Abidjan / Ivory Coast. 
Address:  Croix  R ouge  Franc;:aise 
1 Place Henry Dunant 
75008 Paris, France 
Fax (33-1) 44.43.11.01 
-... 
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7. Recommendations on training 
Training within a National Blood Service  must involve an assessment of 
existing hum.an resources and of existing skills. 
Annual planning must necessarily include a mapping of  the training acti-
vities directed at the various professional  groups as  well  as  the  resources 
to be allocated. Planning must also take into consideration the pronwtion 
of the most adequate use  of blood and its components. 
At each level of blood transfusion practice  (local, national and regional) 
the presence of a specialist in Transfusion Medicine remains a key requi-
site. 
Training  must  involve  measures  of enhancement of qualifications  and 
skills as well as  operational improvements. 
Training activities  should preferably be carried out in  the blood transfu-
sion services  or in  the  hospital  blood banks, if necessary  with technical 
assistance fi:om  abroad. R egional exchanges of  personnel for courses  is to 
be encouraged. 
Training activities  on the spot should only be carried out after a reason-
able period of practice by  the staff involved and the setting up of realistic 
priorities. 
Technical assistance should be called in whenever necessary.  lt is recom-
n1.ended that it should be carried out by experts in blood transfusion  . 
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8. Annex 
8.1. Distance Learning Material (DLM): a WHO project. 
WHO  has  developed  a  set  of Distance  Learning  Materia]  (DLM)  for  Safe 
Blood and Blood Products. The  aim~  of this project  is to  contribute  to  the 
global preventive  strategy  on HIV and  AIDS  through  the  provision of safe 
blood  and  blood  products.  DLM  has  been  specifically  designed  to  make 
training n1.ore accessible and effective for laboratory technicians. 
Background: 
It is essential  that all  those  involved  in the  collection, processing and  use  of 
blood and  blood products use  all  possible means to  ensure its  safety,  particu-
larly in relation to HIV and other infectious agents. The training of  laborato-
ry technicians  is a particular priority, especially since in many countries a large 
proportion of  them work under limited supervision.  World-wide, the need for 
the training  and  continual updating of technicians  is so  great  that it will be 
impossible to meet it within the foreseeable future using existing approaches. 
The  distance  learning  approach  is  designed  to  help  overcome  some  of the 
practical  problems that trainers throughout the world are currently facing by 
offering a practical and cost-effective means of  making the best possible use of 
limited training resources. 
Evaluation if  the distance  learning project: 
The  DL project  started  in  1991  and was  completed  111  1994. The  pnmary 
audience will be laboratory technicians and  the secondary audience  will  be 
blood transfusion technologists who have  responsibility for training. In order 
to  ensure regional evaluation, two participants from each WHO region were 
invited to attend an evaluation course in 1992. The evaluation formed part of 
the project and will form the basis  of continuing evaluation and modification 
where necessary. 
The Distance  Learning Materials comprises: 
Study Guide (for trainees) 
Three modules  of  learning material 
Module 1: Safe Blood Donation 
-... 
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Module 2: Screening for  HIV and other infectious agents 
Module 3: Blood Transfusion Technology 
Trainers' Guide 
Trainers  will  be able  to provide  uniformly high  guauty training to all  techni-
cians in  their countries  because  they  will  ali study the same learning material 
prepared  by  international experts.  Ti- ainees  will  have  control  over the pace  at 
which they  work on the  n"laterials;  this means that those who are slower lear-
ners  or who are less  knowledgeable or experienced can spread their study over 
a longer period than  those  who are more familiar with the subject. The  dis-
tance learning approach is interactive. As the trainees study, they should be able 
to relate their theoretical knowledge directly to their own work. 
Module contents and learning objectives: 
Module 1:  Safe Blood Donation 
section  1  Identification of  safe  blood donors 
section  2  Education, motivation and recruitment 
section 3  Selection of donors 
section  4  Organising donor sessions 
section  5  Care for  the blood donor 
section  6  Blood donor retention 
Module 2:  Screening for HIV and other infectious agents 
section  1  Introduction to transfusion nucrobiology 
section  2  The Human  Immunodeficiency Virus 
section  3  HIV screening assays  and factors affecting their use 
section  4  HIV-Ab screening of donated blood 
section  5  Quality assurance 
section  6  Screening for other transnl.issible infectious agents 
Module 3:  Blood Transfusion Technology 
Part  1: Blood group serology 
section  '/  Immunology 
section  2  ABO blood grouping 
section  3  Rh blood grouping 
section  4  Compatibility testing 
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section  5  Techniques in blood group serology 
Part  II: The storage, transportation and stock control 
of blood and blood products. 
section  6  Storage and transportation 
section  7  Stock control 
8.2. Distance Learning Material 
- Transfusion M.edicine; A European course  in blood transfusion: 
Coordinators: B. Genetet & WVan Ak:en. 
Edited by Centre Nationale d'Enseignement a  Distance, 
supported by: Ministere de !'Education Nationale, Vanve , France. 
This bilingual English/French European course  was initiated by  the Blood 
Transfusion Expert Committee of the Council ofEurope.A system. of written 
tutorials  leads  to  a  certificate  issued  by  the  Louis  Pasteur  University  of 
Strasbourg following written examination. 
Address:  Centre Nationale d'Enseignement a  Distance 
60, boulevard  du Lycee 
92170 Vanves  Cedex 
France 
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ETHICAL ORIENTATIONS FOR 
BLOOD SAFETY 
Introduction 
1. Rights and obligations within the context of blood safety 
1  .1.  Basic ethical principles: universal  rights 
1.1.1. Confidentiality 
1  .1.2. Medical secrecy 
1.1.3. Non-discrimination 
1.1.4. Honest and clear information 
1.1.5. Free and informed consent 
1.1.6. Hum.an dignity 
1.2.  Specific rights and obligations 
1.2.1. The donor: rights and obligations 
1.2.2. The recipient: rights and obligations 
1.2.3. The population: rights and obligations 
2. Commitment of  all  those responsible for blood safety 
2.1.  Public and national authorities 
2.2.  The medical profession and health system 
3. Instruments of  application and ethical context 
3.1.  Legislative texts and/ or regulations 
3.2.  Committee on Ethics 
3.3.  Judiciary system 
3.4.  Operational strategies 
3.5.  Official structures 
3.6.  Associations 
3.7.  Ethical charter 
4. Example: Code ofEthics for blood donation &  transfusion (ISBT) 
5. Reconu11endations on ethical issues 
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Blood safety 
Who is responsible 
* National authorities 
*Health  system 
*Medical professionals 
~._ 
r(Q hts  ·€3  ob/igatio115 
Instruments  Ethical principles 
* Legislation  & regulation  , ~ Hurnan dignity 
* Cowunittee  on Ethics 
~ Non discrirnination 
,~ Hones t & clear iriformation  * Operational strategies  , ~ Free & inforrnerl  consent 
* Bloor/  Policy  . ~ Co t~rlentiality 
-> Me  ical secrecy 
... 
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Introduction 
The quality of blood saf ety  in  a country or a region  will  be determ.ined by  several fac-
tors. High among those  factors  is the broad acceptance rf  a civic and medical ethic to guide 
action  around safe  blood.  It  is our viewpoint that without this  ethic  at all  levels  concer-
ned, frictions and  tensions related to  priorities, rights,  responsibilities  and  costs  will  not 
be resolved appropriately 
The ethical framework  we propose  with  regard  to  saf e blood  is a step  towards recog-
nition.  of basic va.lues  and principles,  related  to  solidarity  between potential  and  actual 
donors  and recipients,  which  are guiding medical practice and ensured by state rules  and 
regulations on  a blood policy. A lthough  this is true for a lot of  other topics,  blood safety 
is here especially  considered. 
We wish to  draw  the reader's  attmtion to  three  essential points: 
1. At this stage,  we present only  a reminde:- rf  rights and obligations and give orienta-
tions as  to  how these could be taken into consideration and respected. The text has neit-
her the pretentio11 nor the mandate to  represent an  qfficial or regulatory viewpoint. 
2.  Furtherrnore,  the  text does  not  have the  i11tention  to  regulate blood  safety,for exa-
mple,  it  does  not give indications  (it  is not meant  to  do  that)  as  to  structure  (private or 
public), who  will be responsiblefor blood  collection,for tranifus1 :on,  who  will communi-
cate  test  results,  etc  ... 
3. The proposals concern.  all countries  although we know that realities  are  different from 
one country  to  a  no the~: Howe1 Je1 ; the goal  and general  rules  are similar and  are focused 
upon  here. 
The two  main partners in saf e blood are the donor and the recipient with between thern 
the blood  (product)  and the  facilitators, the medical personnel and the health system. The 
total sum rf  interactions  take place  in  a district, state, and  international context. 
All partners  in  the  interaction  have  rights and  responsibilities  in  order  to  ensure  the 
safety rf  blood  tranifusion  as  a medical, lif e saving  act. Those mponsibilities  and  rights 
can  be difin.ed  through  consideration  of  civic, moral and ethical  rules  and principles. 
I11 this  chapter  we  try  to  difi.ne the most  important of these  ethical principles, rules 
and responsibilities. We further discuss som.e of  the instruments and conclude that a char-
ter at national and international  [e,;e/ for blood saf ety could  be a step forward  to  clarify 
ethical principles  and guide policy practice for safe blood initiatives. 
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1. Rights and obligations within the 
context of blood safety 
1.1. Basic ethical principles: universal rights 
Some basic ethicaJ  principles  in relation to safe  blood are hereby enumerated 
in  order to enunciate  and encourage  conunitment to  core  values  concerned 
with the quality of safe blood and blood transfusion within medical practice, 
and strengthen the sense of common responsibility at all  levels of  society. 
'I. 1. 1. Confidentiality. 
Obligation for aJJ  personnel (not only medical and paramedical) not to disclo-
se  any  data  on the  health and  private  life  of the  individual  obtained  fi~om 
questionnaires and/or m.edicaJ examinations, which he/she has  come to know 
in the context of his/her duties. 
1. 1. 2.  Medical secrecy. 
Ethical  obligation of the  medical  and  paramedical  staff not  to  disclose  any 
medical and personal data concerning  his/her patient in the context of their 
mutual relationship. 
1. 'I. 3. Non-discrim.ination. 
Equitable treatment, irrespective of race, nationality, religion, illness, sex, social 
and financial  status of the person. 
· t. 1. 4.  Honest and  clear iriformation. 
Accurate,  comprehensive explanations given  to the person concerned  on the 
reasons for,  and the method and consequences  of, an administrative or medi-
cal act (questionnaire to be completed, test to undergo etc  ...  ) 
... 
1. 'I .  5.  Free  and iriformed consent. 
Clear and  full  agreement by the person concerned  to undergo a medical act, 
having previously  received honest and clear information concerning this act . 
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1. 1. 6. Respect of Human dignity 
Accomplishment of the  medical  or administrative  act  while ensuring  moral 
and physical  respect for the individual. 
1.2. Specific rights and  obligations 
Firstly,  rights  and  duties  are  almost  entirely  defined  in  terms  of the 
relationship  between people and governments. We believe  that it is crucial 
to tlunk about rights and duties  in broad terms when discussing safe blood 
because  of the  great  interdependence  of all  partners. This means  that  all 
citizens,  as  individuals and as  members of groups and associations,  should 
recognize and help protect the rights of others. 
Secondly, the  rights need  to be paired  with responsibilities.  Over the long 
run, in relation to safe  blood, the rights of the recipient are the obligation 
of the donor, and  roles  are interchangeable. 
1.2. 1. The  donor 
Rights: 
to be informed of the use  made of the blood donated 
to refuse  the conm1.ercialization of his/her donation 
to  be  accepted  as  a  donor and screened with respect  to  the  basic  ethical 
principles  given earlier 
to receive test results, orientation, advice, follow-up and care 
to respect the anonynuty of his/ her donation 
to  a  professional  environment and  to  a  (para)medical  supervlSlon  when 
donating blood, which is a medical act. 
Obligations: 
to give blood without remuneration (by  refusing any financial reward) 
to be honest with respect to personal information given at interview 
to  only  use  the  official  circuits,  established  and  supervised  by  the  health 
authorities, when giving blood. 
-... 
CIt a pI e r  '/  1  •  E I IIi c a/  or i e 11 tat i o 11  s  J or  b I o o d  safety 
1.2. 2. The recipient 
Rights: 
to  receive  a  blood  transfusion  when it  is  deemed  necessary  on  n1.edical 
grounds 
to receive transfusion of safe  blood (knowing that it is not possible to ens-
ure 100 % safety) 
to a professional enviroru11.ent and to (para)medical supervision when recei-
ving a transfusion, which is  a medical act 
to receive blood collected, stored and supplied in accordance with the appli-
cable safety standards 
to  receive  a transfusion irrespective  of race, nationality, religion, sex, social 
and financial status 
Obligations: 
to use the official circuits established and supervised by the health authori-
ties  for receiving blood 
to inform the doctor responsible  for  the blood transfusion of any reactions 
the recipient may have  noticed after the transfusion. 
1. 2 .3. The population 
Rights: 
to  the  existence  of a public  health system which  takes  into account blood 
safety 
to obtain information on blood safety (donation or reception) 
to have access to blood of the qua]jty and in the quantities  required 
to  have  access  to  a blood supply, stored  and transfused  in ethical  and  safe 
conditions 
Obligations: 
to encourage the population to participate actively in voluntary non-remu-
nerated blood donations 
to  make  the population aware of the fact  that donating blood is an act of 
human solidarity and moral responsibility 
to  participate  in  the  implementation  of a  safe  blood  policy  (screening, 
transfusion, therapy,  research etc.)  in order to  protect  the  members  of the 
population 
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to resist and protest against ethical misconduct 
not to create unofficial and  conm1ercial circuits,  either for blood donation 
or for blood transfusion 
to circulate to its n1.embers information on blood safety 
2. Commitment of all those responsible 
for blood safety in a  country 
2.1. Public authorities and national authorities of the 
state  concerned. 
The public and national authorities of the state concerned are responsible for 
recognizing the rights and obligations of the population. 
2.2. The medical profession and  the health system. 
The medical  profession in the  country  concerned  is  responsible  for  taking 
into account the rights and obligations of donors and recipients and must be 
willing to implement these. 
Blood  collection  and  transfusion  organisations,  together  with  all  health 
structures in the country concerned, have a responsibility to ensure that every-
one within the organisation (staff, donor, recipient  ...  ) is  fully informed about, 
and respects, the rights and obligations of donors and recipients. 
3. Instruments to ensure the ethical context 
of blood safety 
The following instruments can help to ensure the development of the ethical 
context of blood safety  within countries  and unite people  around common 
rights and shared  responsibilities  which would provide  the moral foundation 
for constructing and watching over an  effective system  of blood safety.  Over 
time, those principles, rights and responsibilities  can be developed into national 
and international charter(s)  for blood safety  that could provide guidance. 
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3 .1. Legislative  texts and/  or regulations adopted by 
the  public authorities  to  define  a  coherent blood policy 
within the framework of a public health policy. 
These texts  should, in particular, establish: 
the conditions governing safety of blood, particularly through defining and 
attributing the roles and responsibilities of  the health system and the profes-
sional and medical  nature of such interventions 
the  conditions  governing  blood  safety,  particularly  by  setting  parameters 
measuring the transfusion risks  and the  n1.argins beyond which  transfusion 
is not authorized 
the obligation of voluntary non-remunerated, non-commercialised, anony-
mous blood donation 
the obligation of  no n-discrin~na tion regarding blood distribution 
the obligation to distribute 'non perishable' blood products 
selection criteria of blood donation (age, frequency, etc) 
the  intervention  of official  bodies  and  non-profit  making  organisations 
entitled to carry out blood collection and transfusion 
a supply policy (self-sufficiency or imports with the appropriate guarantees) 
a policy  on blood collection, storage  and delivery meeting the ethical  and 
safety requirements for everyone and in everybody's interest 
a policy aiming at rationalizing the use  of blood donations so  as  to prevent 
waste 
means  (notably  financial  and  structural)  allowing  implementation  of the 
above mentioned policies. 
3.2. Committee on Ethics and the protection of human 
rights  established by the public authorities with 
consultative  status  (binding opinion). 
This  comn~ttee brings  together all  those  concerned in a  multidisciplinary 
partnership  (recipient, donor, the  medical profession, health authority repre-
sentatives,  national  authority  representatives,  ethicists, etc)  and  through  the 
diversity of its membership, guarantees its impartiality and thereby its effecti-
veness. 
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3.3. An independent judiciary system which must guarantee 
rights and obligations of the various parties as  regards 
transfusion safety. 
3 .4. Operational strategies devised and applied by the 
medical profession to  take action in an area in which 
legislative texts and regulation are often still lacking. 
The operational strategies  must take better account of the  rights and  obliga-
tions of the donor and the recipient, particularly  by: 
systematically  using appropriate methods and means to ensure reliable results 
forwarding results to the donor and systematically taking care of  donors dis-
covered to be HIV infected (orientation, follow-up, counselling, care) 
strengthening and creating a protection system for data which are conside-
red  confidential  (protection  of private life, ]jnlited access  to  data of indjvi-
dual, non-disclosure of medical  results, etc). 
All these operational strategies are essential, as they must be the driving force 
behind the adoption oflegislative texts and regulations, by providing the tech-
nical, scientific and ethical basis. 
3.5. Blood policy for official structures entitled to collect 
and/ or to transfuse blood. 
These structures should adopt a blood policy in order to ensure recognition of 
the operational strategies  and the ethical principles. 
This blood policy  should be elaborated  with the assistance of the medical 
profession and through consultation with associations  of people  concerned 
(donors, recipients, patients, staff, etc). 
This policy  should be  applicable  to  everyone  and by  everyone  (staff and 
patients)  witrun the organisation. 
3.6. Associations established within the society by and 
for people with a  common interest (recipients, donors, 
haemophiliacs, HIV-infected people, patients etc). 
Through such associations, the population and society are  taking steps to en-
sure that they  are properly  represented and will be recognized  as  responsible 
partners for the public authorities. 
-•.  ,. 
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3.  7. Ethical charter for blood safety: declaration of 
intention 
Within the context of  actions supported by the European Commission in the 
nutter of blood safety, it seems opportune as  n1.uch for the Commission as  its 
partners,  the  beneficiary countries,  to  recognize the ethical guidelines in the 
matter of  blood safety. 
Over a certain time period and after further discussion a charter could be 
developed. This charter could be a national and international  moral commit-
ment for all parties  concerned by blood safety. 
4. Example 
Code of  Ethics for blood donation and transfusion (1980). 
International Society of Blood Transfusion 
The object of this code is to define the principles  and rules  to be observed in 
the field of Blood Transfusion: these should form the basis of national legisla-
tion or regulation. 
I. The Donor 
1.  Blood donation shall, in all  circumstances,  be  voluntary: no pressure  of 
any kind must be brought to bear upon the donor. 
2.  The donor should be advised of the risks connected with the procedure: 
the donor's health and safety must be a constant concern. 
3.  Financial  profit must never be a motive either for the donor or for those 
responsible  for  collecting  the  donation.  Voluntary  non-remunerated 
donors should always  be encouraged. 
4.  Anonymity between  donor and recipient must  be  respected  except in 
special cases. 
5.  Blood donation must not entail discrimination of  any kind, either of  race, 
nationality or religion. 
6.  Blood must be collected under the responsibility of  a physician . 
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7.  The frequency  of donations and  the total volume of the blood collected 
according to the sex and weight of  the individual, as well as  the upper and 
lower age limits for blood donation, should be defined by regulations. 
8.  Suitable testing of each donor and blood donation must b  performed in 
an attempt to detect any abnormalities: 
a)  that would make the donation dangerous for the donor, 
b) that would be likely to be harmful to the recipient. 
9.  Donation  by plasmapheresis should  be the subject of special  regulations 
that would specify: 
a) the nature of additional tests to be carried out on the donor, 
b) the maximum volume of plasma to be taken during one session, 
c)  the nunimum tin"le  interval between two consecutive sessions, 
d)  the maximum volume of plasma to be taken in one year. 
10.  Donations ofleukocytes or platelets by cytapheresis should be the subject 
of special regulations that specifY: 
a)  the information to be given to the donor about any drugs injected and 
about the risks connected with the procedure, 
b) the nature of  any additional tests to be carried out on the donor, 
c)  the number of sessions within a given time frame. 
11.  Deliberate immunisation of donors by any foreign antigen with the aim 
of obtaining  products  with a  specific  diagnostic  or  therapeutic  activity 
should be the subject of special  regulations that would specifY: 
a)  the information to be given to the donor about the substance injected 
and  the risks involved 
b) the nature of any additional tests which have  to be carried out on the 
donor. 
N.B.: The purpose of the special regulations in items 9, 10 and 11  above is to 
safeguard  the donor. After being  told about the  nature  of the operation 
and the  risks involved, a statement of informed  consent must be signed 
by  the donor.  For donors immunised  against red  cell  antigens,  a special 
card should indicate the antibodies  and specific details as  to  the approp-
riate blood to be used in case the donors need to be transfused. 
12.  The  donor  must  be  protected  by  adequate  insurance  against  the  risks 
inherent in the donation of blood plasma or cells as  well  as  the risks of 
inun unisation. 
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II. The Recipient 
13.  The object of transfusion is  to ensure for the recipient the most effective 
therapy compatible with m.aximum. safety. 
14.  Before any  transfusion of blood or blood products, a written request, sig-
ned by a physician or issued under his responsibility must be made, which 
specifies  the identity of the recipient and the nature and quantity of the 
substances to be administered. 
15.  Except for  the  emergency  use  of the  type  0  blood  or red  blood cells, 
every red cell transfusion necessitates preliminary blood grouping tests on 
the  recipient, and compatibility  tests between  the  donor and the  reci-
pient. 
16.  Before administration, one must verify that blood and blood products are 
correctly  indentified and that the  expiry date has  not been  passed. The 
recipient's identity must be verified. 
17.  The actual transfusion must be given under the responsibility of  a physi-
c1an. 
18.  In case of  a reaction during or after the injection of blood or blood pro-
ducts,  appropriate investigations may be required to ascertain the origin 
of the reaction and to prevent its recurrence. A reaction may require the 
interruption of the transfusion. 
19.  Blood and blood products must  not be given  unless  there is a genuine 
therapeutic  need. There must be  no financial motivation on the part of 
either the prescriber or of the establishment where the patient is treated. 
20.  Whatever their financial  resources,  all  patients  m.ust  be  able  to  benefit 
fi·om  the administration of human blood or blood products, subject only 
to their availability. 
21.  As far as  possible the patient should receive  only that particular compo-
nent  (cells,  plasma,  or plasma  derivatives)  that  is  needed.  To  transfuse 
whole blood into a patient who requires only part of  it may deprive other 
patients of  necessary components, and may  carry some additonal risks to 
the recipient. 
22.  Owing to the human origin of blood and to the limited quantities  avai-
lable, it is important to safeguard the interests ofboth recipient and donor 
by avoiding abuse  or waste. 
23.  The optimal  use  of blood and blood products requires  regular contact 
between the physicians who prescribe and those who work in blood tran-
fusion centres . 
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III. Controls 
24.  Appropriate controls should be required by the Health Authorities to ver-
ifY  that  blood transfusion practices  meet internationally  accepted stan-
dards and that the guidelines or regulations issued in accordance with this 
code are effectively respected. 
25.  The following should be regularly checked: 
a)  the proficiency of the staff, 
b)  the adequacy of the equipment and premises, 
c)  the quality of  methods and reagents, source material and finished pro-
ducts. 
5. Recommendations on ethical issues 
In all national safe blood programmes supported by the EC, it has also been 
recommended to the national authorities: 
to  pass  legislation  and  regulation  to  ensure  the  concept of voluntary, 
non-remunerated  and anonymous donation of blood, of voluntary and 
informed testing, and of the protection of  personal information 
to set up a legal statute for Blood Transfusion Services 
to take into account the blood transfusion scheme and then to define the 
function and the operational rules of  this structure at each level 
to ensure optimal blood collection, processing, storage and distribution 
under  safest  conditions possible. This latter strategy is  seen as  a medical 
responsibility and dealt with as  such 
to inform all  personnel on matters related  to ethical principles such as: 
confidentiality, anonymity, protection of personal information 
to  create  an  ethics  committee  to  watch  over  the  application of these 
ethical principles. 
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MEANING OF ABBREVIATIONS 
ABO 
ACD 
Agglutination 
Agglutinin 
AHG 
AIDS 
Album.in 
Anaemia 
Antigen 
Asymptomatic 
ATLL 
Human blood group system  comprising 4  main 
blood groups: A, B, AB and 0. 
Acid  Citrate  Dextrose: preservative  and  antico-
agulant solution used to conserve blood in plastic 
bags. 
Immunological reaction between cellular antigens 
(for  example,  those  at  the  surface  of red  blood 
cells)  and antibodies  (in  serum or plasma)  brin-
ging cells close together (agglutinates). 
another name for "antibody". 
Anti-Human Inmmnoglobulin. 
Acquired  Immune Deficiency Syndrome due to 
HIV infection. 
The most abundant plasmatic protein the role of 
which is to retain plasmatic water in blood vessels. 
Insufficient  number  of red  blood  cells  (under 
3,000,000/mL)  due to a blood loss or to a lack of 
erythrocytes production 
Substance able to induce antibody production. 
In transfusion practice, a donor is  called "asymp-
tomatic" when he/she is infected while presenting 
no clinical sign of this  infection (for example: in 
the course of HIV and/ or HCV infections). 
Adult T-cell Leukemia Lymphoma. 
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Audit 
Autologous transfusion 
Blood grouping 
Blood and blood products 
Blood substitutes 
Blood Unit 
BTS 
CF 
Chagas  disease 
Coagulation 
Cold Chain 
Compatibility 
Coombs reagent 
Counselling 
CPD 
Cross-Matching 
Cryoprecipitate 
Procedure  carried  out within a quality  assurance 
programme  in order  to  depict  problems  and  to 
find  solutions 
donor giving blood for him I  herself. 
Generally  designates  the ABO and  Rhesus phe-
notyping of red  blood cells. 
These  terms  include  alJ  therapeutic  substances 
derived  from  whole  blood  i.e.  cellular  compo-
nents (red blood cells, platelets, white blood cells) 
and plasma  derivatives. 
Any substance which can  replace  blood or blood 
products. 
l  Blood Unit = 450 ml of whole blood colJected 
by venipuncture. 
Blood Transfusion Service 
Complement Fixation 
A disease  transmissible by blood, due to Trypano-
soma cruzi and frequent in  South America. 
Phenomenon  resulting in  the  transformation  of 
blood from a liquid to a solid phase  (clot). 
A way to designate the optinu l storage cons  rva-
tion  (2  to  10 °C) of whole blood units collected; 
the cold  chain should never be disrupted. 
A  laboratory  test  (cross-match)  which  aims  to 
make  sure  that  compatibility  rules  are  respected 
between  antibodies  (natural  or irregular)  in reci-
pient  serum. and  antigens  at  the  surface  of the 
donors' red celJs. 
Anti-human immunoglobulin reagent. 
OveralJ  information  and  advice  given  to  blood 
donors  about one  particular  subject  such  as,  for 
example, HIV seropositivity. 
Citrate  Phosphate  Dextrose; anticoagulant  solu-
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Product of plasma obtained  by  freezing and  tha-
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coagulation Factor Vlll. 
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VeneraJ  Disease  Research  Laboratory: a  method 
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Genetic  disease  due  to  a  coagulation  disorder 
(abnormality  of Factor VIII). 
Western Blot (Immuno Transfert): a method used 
to confirm the specificity of (HIV)  antibodies. 
World Health Organization. 
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